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Abstract 
Isotope-dilution liquid chromatography-tandem mass spectrometry (ID-LC-MS/MS) is 
emerging in the field of clinical chemistry and laboratory medicine as an alternative to 
immunoassays and is acknowledged as the MS “gold standard” for small biomolecule 
quantification. Hepcidin-25, a key iron-regulatory peptide hormone discovered in 2000, 
has revolutionized the understanding of iron disorders and its quantitative determination in 
biological samples should advance the management of iron related pathology (diagnosis, 
prognosis and treatment). This study applied LC-MS/MS, using the triple quadrupole 
(QqQ) mass spectrometer, in a rapid and robust analytical strategy for the quantification of 
hepcidin-25 in human serum, to be implemented in routine laboratories. For this purpose, 
two sample preparation strategies and two complementary chromatographic separation 
conditions were investigated, where the use of acidic mobile phases (0.1% trifluoroacetic 
acid) was compared with a novel approach involving solvents at high pH (containing 0.1% 
ammonia). The application of these LC-MS/MS methods to human samples in an intra-
laboratory comparison, using the same hepcidin-25 calibrators, yielded a very good corre-
lation of the results. The LC-MS/MS employing trifluoroacetic acid-based mobile phases 
was selected as a highly sensitive (limit of quantification LOQ of 0.5 µg/L) and precise 
(coefficient of variation CV<15%) method and was recommended as a reference method 
candidate for hepcidin-25 quantification in real samples (in the dynamic range of 0.5-40 
µg/L). One of the novel aspects of the methodology was the use of amino- and fluoro-
silanized autosampler vials to reduce the interaction of the 25-residue peptide to laboratory 
glassware surfaces. Moreover, this LC-MS/MS method was used for an international round 
robin study, applying a secondary reference material as a calibrator. By determining the 
degree of equivalence between the results of the ten participating methodologies, the per-
formance of the method developed in this study was found to be in the optimal range as 
defined by the International Consortium for Harmonization of Clinical Laboratory Results 
(ICHCLR). In this work, the formation of hepcidin-25 complexes with copper(II) was in-
vestigated. The first reversed-phase chromatographic separation of hepcidin-25/Cu2+ and 
hepcidin-25 (copper “free”) was achieved by applying mobile phases containing 0.1% of 
ammonia (pH 11). LC-MS/MS and high-resolution mass spectrometry (Fourier-transform 
ion cyclotron resonance (FTICR) MS) were applied for the mass spectrometric characteri-
zation of the formed hepcidin-25-Cu(II) species at pH values of 11 and 7.4 respectively. A 
new species corresponding to hepcidin-25 complexed with two copper ions was identified 
at high pH. 
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Zusammenfassung 
Die Isotopenverdünnungs-Flüssigkeitschromatographie-Tandem-Massenspektrometrie 
(ID-LC-MS/MS) entwickelt sich auf dem Gebiet der klinischen Chemie und Laboratori-
umsmedizin zu einer Alternative zu Immunoassays und gilt als "Goldstandard" für die 
Quantifizierung kleiner Biomoleküle. Hepcidin-25, ein 2000 entdecktes Peptidhormon, das 
eine Schlüsselrolle im Eisenstoffwechsel spielt, hat das Verständnis von Eisenerkrankun-
gen revolutioniert.  Es ist zu erwarten, dass dessen quantitative Bestimmung in biologi-
schen Proben die Diagnose, Vorhersage und Behandlung von Eisenstoffwechsel-Krankhei-
ten vorantreibt. In dieser Studie wurde Flüssigchromatographie gekoppelt mit einem 
Triple-Quadrupol (QqQ) Massenspektrometer (LC MS/MS) in einer schnellen und robus-
ten analytischen Strategie zur Quantifizierung von Hepcidin-25 in menschlichem Serum 
verwendet, welche letztlich in Routine-Laboratorien genutzt werden soll. Zu diesem Zweck 
wurden zwei Probenvorbereitungsstrategien und zwei komplementäre chromatographische 
Trennbedingungen untersucht, wobei eine saure mobile Phase (0,1% Trifluoressigsäure) 
mit einem neuartigen Ansatz unter der Verwendung einer basischen mobilen Phase (0,1% 
Ammoniak) verglichen wurde. In einem laborinternen Vergleich beider LC-MS/MS Me-
thoden wurde Hepcidin-25 in humanen Proben unter Verwendung der gleichen Hepcidin-
25-Kalibrierstandards quantifiziert und eine sehr gute Korrelation der Ergebnisse ermittelt. 
Hierbei wurde die Analysestrategie mit saurer,mobiler Phase  als hochsensitiv (Bestim-
mungsgrenze (LOQ) von 0,5 μg/L) und präzise (CV <15%) befunden und als Kandidat 
einer Referenzmethoden für die Hepcidin-25 Quantifizierung in realen Proben empfohlen 
(im dynamischen Bereich von 0,5-40 μg/L). Einer der neuartigen Aspekte der Methodik 
war die Verwendung von Amino- und Fluor-silanisierten Autosampler-Fläschchen, um die 
Adsorption des 25 Reste umfassenden Peptids an Oberflächen zu reduzieren. Darüber hin-
aus wurde diese LC-MS/MS-Methode in einer internationalen Ringversuchsstudie einge-
setzt, bei der ein sekundäres Referenzmaterial als Kalibrierstandard verwendet wurde. In 
dieser Ringversuchsstudie wurde gemäß des International Consortium for Harmonization 
of Clinical Laboratory Results (ICHCLR) die hier präsentierte Methode im Vergleich mit 
neun anderen Methoden als optimal bewertet. In dieser Arbeit wurde die Bildung von 
Hepcidin-Komplexen mit Kupfer(II) untersucht. Die erste Umkehrphasen-chromatographi-
sche Trennung von Hepcidin-25/Cu(II) und Hepcidin-25 (Kupfer "frei") wurde unter Ver-
wendung von mobilen Phasen mit 0,1% Ammoniak (pH 11) erreicht. LC-MS/MS und 
hochauflösende Massenspektrometrie (Fourier-Transformations-Ionenzyklotronresonanz 
(FTICR) MS) wurden für die massenspektrometrische Charakterisierung der gebildeten 
Hepcidin-25-Cu(II)-Spezies bei pH-Werten von 11 bzw. 7,4 verwendet. Eine neue Spezies, 
Hepcidin-25 komplexiert mit zwei Kupferionen, wurde bei hohem pH identifiziert. 
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Introduction 
The discipline of clinical chemistry, earlier known as chemical pathology, arose from the 
attempts to apply chemistry into medicine [1]. A clinical chemist perceives the patients as 
“black boxes”, complex metabolic machines that utilize molecules to generate energy and 
to defy entropy. Clinical diagnosis, at its very core, represents important data collection 
from this “box”, separation of signal from noise and eventually assigning an interpretation 
to this signal. This implies that the information acquired from a body fluid sample can be 
processed to deduce knowledge about the state of the individual that it came from [2]. 
With the publication of the first comprehensive textbook in this field by R. J. Henry in 
1964, the ground stone for the application of analytical chemistry in the framework of la-
boratory medicine was set. Together with other relevant concepts in the field, such as ac-
curacy, precision, control charts, significant figures, and normal values, this book covered 
one of the first breakthroughs in clinical pathology represented by photometry. In addition, 
analytical methods were described for various proteins and peptides found in biological 
fluids, inorganic ions, blood pH and gases, electrolytes, enzymes, carbohydrates and me-
tabolites, vitamins, lipids and others [3]. This was followed by the successful introduction 
in clinical chemistry of antibody-based ligand binding assay (“immunoassay”) in the 1960s 
and of the gas chromatography-mass spectrometry in the 1970s. However, it was the intro-
duction of non-disintegrating soft ionization techniques as atmospheric pressure ionization 
in the 1990s that ultimately made most of the biologically important analytes (endogenous 
metabolites as well as xenobiotics) amenable to highly specific mass spectrometric anal-
yses [4]. Nowadays, liquid chromatography-electrospray ionization-tandem mass spec-
trometry (LC-ESI-MS/MS) is accepted as the “gold standard” for quantification of many 
biomolecules in clinical chemistry and laboratory medicine [5]. 
Going back to the metaphoric context of the “black box”, the disorders of iron metabolism 
exhibit significant contribution to its unresolved puzzles. According to the World Health 
Organization (WHO), iron deficiency affects more people than any other condition, consti-
tuting a public health condition of epidemic proportions [6]. The diagnosis of iron-related 
pathology assumes the evaluation of the players involved in iron homeostasis. By such, the 
present study intends to focus on the clinical assessment of the primary iron regulator using 
LC-ESI-MS/MS. By putting it in a very concise manner, one could say that this research 
work is devoted to find a connection between life and the test tube. 
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1. Theoretical background 
1.1. Iron 
Iron (Fe) is the most frequent element on Earth after oxygen and silicon, contributing to the 
composition of all its three main layers: crust, mantle and core [7, 8]. Due to its high reac-
tivity, iron is rarely found in its elemental state. In this respect, the divalent, ferrous iron 
and the trivalent, ferric iron are the oxidation states of highest importance. However, iron 
appears in a variety of other states, for example the hexavalent ferrate [9]. 
This element presents a vast diversity of functions in the biosphere. All organisms with rare 
exceptions among bacteria need iron from the environment to meet their metabolic needs 
[10]. In humans, iron is an essential nutrient used by iron-containing proteins for oxygen 
transport and storage or as a catalyst for redox reactions [11]. 
In order to establish a good understanding of the factors involved in maintenance of iron 
balance and the mechanisms resulting in pathological states, iron metabolism and its regu-
lation in the human body will be discussed in detail in the following section. 
1.1.1. Human iron metabolism 
When addressing iron metabolism in humans, two levels of regulation are to be identified. 
The lower level is cellular and refers to the mechanisms of iron uptake, transport and intra-
cellular use. The upper level or the systemic level comprises the correlation between iron 
uptake and iron sensing, iron demand signaling and signal transfer to the iron stores [10]. 
A multitude of regulators, transporters and enzymes are involved in the management of 
iron balance at both the cellular and systemic levels. The interplay of these actors in iron 
absorption, distribution, storage and recycling will be addressed further. 
1.1.1.1. Intestinal iron absorption 
Generally, humans procure iron exclusively from the diet. Typically, dietary iron is cate-
gorized as heme and non-heme iron. Heme iron is mostly found in meat as part of hemo-
globin or myoglobin, while non-heme iron consists of various forms of iron of both vegetal 
and animal origin (meat, fruits, vegetables, grains, nuts etc.) [12, 13]. The absorption of 
iron takes place in the duodenum, where new iron is imported in the body by epithelial cells 
called enterocytes [14]. In this regard, Figure 1.1 presents the biochemical pathway of iron 
uptake by enterocytes [15], wherein non-heme iron is transported inside the intestinal cell 
by a divalent metal transport protein (DMT1) [16]. Most of the dietary non-heme iron oc-
curs to be in the +3 oxidation state and, prior its uptake, requires reduction to the more 
soluble ferrous state by the duodenal cytochrome B (DCYTB), also known as ferrireductase 
[17]. 
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Further, the absorption of heme iron is not fully elucidated. However, it is suggested that heme 
is taken in by receptor-mediated endocytosis through the activity of heme carrier protein 1 
(HCP1). Heme is likely further degraded by heme oxygenase, and the released iron enters the 
same storage and transport pathways as non-heme inorganic iron [12, 18]. 
 
 
Figure 1.1: Iron absorption in the enterocyte [15]. 
Once iron penetrates the duodenal cell, the ferrous iron may follow two paths. The amount that 
is not needed for immediate use is stored in ferritin (up to 4500 atoms of iron/ferritin molecule 
[19]), an ubiquitous protein within the enterocyte [20, 21]. This is however lost after two-three 
days, owing to the sloughing of enterocytes into the gut lumen. [22]. Alternatively, depending 
on the body needs, iron can be released in the blood stream [14] via ferroportin (FPN) [23]. 
This export of cellular iron demands an associated ferroxidase activity. In this vein, ceruloplas-
min, a circulating multicopper oxidase, and hephaestin, a homolog of ceruloplasmin, seem to 
be responsible for oxidation of Fe2+ to Fe3+ in the duodenum [22]. 
It should be noted that FPN, also known as SLC40A1, is the sole known iron exporter [11] and 
serves as a target protein for iron regulation via hepcidin-25 (Hep-25). This will be addressed 
in detail in section 1.2. 
1.1.1.2. Iron distribution 
Once released in the blood, absorbed iron is almost exclusively bound to transferrin (Tf), an 
abundant, high affinity iron-binding protein [22]. Tf presents two binding sites for iron, there-
fore three different forms, namely apo-transferrin (not bound to iron), monoferric-transferrin 
and diferric-transferrin, can be identified in plasma [24]. In physiological conditions, up to 35% 
saturation of transferrin is achieved. In iron-overload though, iron levels can exceed the binding 
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capacities of plasma Tf and consequently, a supplementary iron compartment, non-transferrin-
bound iron (NTBI), occurs in plasma [25, 26]. Tf maintains iron in its soluble form and prevents 
the ferric iron from precipitating out of aqueous plasma [14]. Transferrin-bound iron, Fe-Tf, is 
further distributed to sites of use and storage in the human body. 
In this regard, two thirds of the body iron is transported to the erythrocytes in the bone marrow, 
where most of it is used for the production of erythroid precursors and red blood cells [14]. The 
uptake of Fe-Tf by erythroid precursors takes place by receptor-mediated endocytosis and is 
activated by cell surface transferrin receptors (TFRs). The disruption of Tf-TFR cycle can lead 
to shortfalls in the production of erythrocytes [27]. It should be mentioned that most of the other 
cells acquire iron by similar means, namely through TFR expressed on their membrane surface. 
Further tissues that need considerable amounts of iron are the muscles. Iron participates in the 
production of myoglobin, a protein seemingly responsible for oxygen delivery in active muscle 
[28]. Iron also proved to be a vital growth factor in the early development of kidneys. Lipocalin-
2, also known as neutrophil gelatinase-associated lipocalin (NGAL), is involved in innate im-
munity at renal level by sequestrating iron containing siderophores that sequentially limit bac-
terial growth [29]. Finally, iron is present within cells incorporated in various hemeproteins 
such as cytochromes, peroxidases or catalases, to facilitate their biological functions. 
1.1.1.3. Iron storage and recycling 
Two types of cells are relevant for iron storage: macrophages and hepatocytes. As mentioned 
before, the iron stored by ferritin within the enterocyte leaves the body when the intestinal cells 
die, thus enterocytes are not considered as member of the iron storage system [14]. 
Macrophages are white blood cells found essentially in all tissues, that ingest foreign substances 
and microbes in a process known as phagocytosis [30]. In the context of iron metabolism, the 
macrophages, mainly from the spleen, are responsible for recycling iron from senescent eryth-
rocytes. In this process, old and damaged erythrocytes are recognized by macrophages, and 
phagocytosed. Their lysis results in the liberation of iron from hemoglobin through catabolism 
by heme oxygenase [14, 31]. Iron can either be stored further in the macrophages, or released 
in plasma via ferroportin [32]. Similar to iron export from enterocytes, ferroportin is critical for 
the release of iron from macrophages, and can be regulated to modify the amount of iron 
stored/released by way of hepcidin-25 (see section 1.2.) [22]. 
Hepatocytes or liver cells serve as the major depot for the storage of surplus iron [14]. These 
can accommodate both Fe-Tf and NTBI. For this purpose, the uptake of iron by the hepatocytes 
is mediated mainly by TFR. Once inside the liver cells, most of the iron is stored in the form of 
ferritin, which, based on body requirements, can be mobilized to the blood stream through the 
activity of ferroportin [22]. 
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1.1.2. Systemic iron homeostasis 
1.1.2.1. Circulation of iron in the human body 
Total body iron in average human adults is known to be 2-4 g. In this context, the circulation 
of iron in humans is described in Figure 1.2. Only 1-2 mg of iron needs to be absorbed daily 
from the diet by the enterocytes to compensate for iron losses [33]. Iron absorption must be 
thoroughly regulated to keep the iron balance, since there is no mechanism for the excretion of 
surplus iron [34, 33]. For this reason, iron losses occur essentially only through desquamation 
of epithelial cells in the intestine and skin, minor hemorrhaging or menstruation (in women) 
[35].  
 
Figure 1.2: Iron distribution in the human body [36]. 
The absorbed iron is transported in plasma via transferrin to the bone marrow and developing 
tissues. The largest fraction of iron in the body is contained in the hemoglobin of the red blood 
cells. Erythrocytes encompass 2-3 g of iron, while plasma contains only 2-3 mg of iron bound 
to transferrin (Fe-Tf). The recycled iron from senescent erythrocytes amounts to be in the range 
of 20-30 mg/day. When the iron-binding capacity of transferrin is achieved, iron is deposited 
in parenchymal tissues. About 1 g of iron is stored in the cytoplasmic ferritin of the hepatocytes 
and the macrophages in the spleen [35, 36]. 
1.1.2.2. Iron regulation  
The lack of an iron-excretion system implies that the iron homeostasis is maintained by a good 
orchestration of iron absorption, distribution and storage. 
At cellular level, iron is regulated by two iron-regulatory proteins (IRP), which, when iron lev-
els are low, bind to RNA stem-loop iron-responsive elements (IRE) [22]. IRP1 and IRP2 are 
part of the family of iron-sulfur cluster isomerase [37] and are identified in the mRNA (mes-
senger ribonucleic acid) encoding proteins involved in iron transport and storage. IRP1 binds 
to IREs in the mRNA encoding ferritin and blocks the translation of the iron storage protein. 
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IRP2 follows a different mechanism by binding to the IREs found in the TFR mRNA, allowing 
the increase of TFR production in iron deficit [22, 38]. 
At systemic level, the organs majorly implicated in the handling of iron as presented in section 
1.1.1. include the duodenum involved in dietary iron absorption, the liver which is the main 
depot of iron storage, and the spleen containing macrophages that recycle iron from old eryth-
rocytes. Thus, three different cell types are engaged in iron metabolism, namely enterocytes, 
hepatocytes and macrophages. These present different pathways for iron uptake, but a single 
pathway for iron export into the blood stream represented by ferroportin [11, 33]. 
It has been postulated for a long time that a circulating factor operates between these organs to 
synchronize iron metabolism [25]. In recent past, this role was attributed to a newly discovered 
peptide hormone called hepcidin-25 [39], which binds to ferroportin, causing its internalization 
and degradation within lysosomes [40] (Figure 1.3). Ever since, hepcidin-25 became the main 
player in iron homeostasis (see section 1.2.4.). 
 
Figure 1.3: The regulation of iron by hepcidin-25. Hepcidin-25 binds ferroportin found 
in iron releasing cells (enterocytes, hepatocytes and macrophages) and causes its in-
ternalization and degradation within the lysosome. 
Prior the uncovering of hepcidin-25, the stimuli known for modulation of iron homeostasis were 
erythropoiesis, hypoxia, iron deficiency or overload and inflammation. The same stimuli were 
found to regulate the expression of hepcidin-25 [22], which will be discussed in detail in the 
section 1.2.3. 
1.1.3. Disorders of iron metabolism 
The iron regulator hepcidin-25 is involved in the pathogenesis of several iron-related disorders 
with a high public health impact worldwide. Details on these disorders, their cause and link to 
hepcidin-25 expression will be briefly discussed further. 
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1.1.3.1. Iron deficiency  
Iron deficiency anemia (IDA) 
Anemia is a common condition with heterogeneous etiologies , with a worldwide prevalence of 
around 33% of the population (2010) [41]. Anemia generally refers to the decrease in the red 
blood cell levels or hemoglobin (Hb) levels caused by an imbalanced relationship between 
erythropoietin, iron, erythropoiesis and hepcidin-25 [42, 43]. Erythropoietin represents a gly-
coprotein hormone secreted by the kidney that stimulates red blood cell production (erythro-
poiesis) [44, 45]. 
Iron deficiency (ID) is the most common cause for anemia, affecting especially children, 
women and the elderly. ID syndromes include two main forms: absolute and relative. Absolute 
ID occurs when total body iron stores are low or depleted, while relative or functional ID arises 
when total body iron stores are normal or even increased, but stimulated/increased erythropoi-
esis induces iron demand that exceeds the supply [41]. Taking this into account, absolute iron 
deficiency is known as iron deficiency anemia (IDA), while relative iron deficiency is usually 
associated to inflammatory diseases, hemoglobinopathies, chronic hemolytic anemias or to the 
treatment with erythropoiesis stimulating agents [42, 46]. 
According to WHO (World Health Organization), IDA is the most widespread nutritional dis-
order in humans [6], with more than one billion people affected worldwide. The main cause of 
IDA in children and pregnant women is the high iron demand, while gastrointestinal bleeding 
(due to high drug intake) and malabsorption are the most common causes of IDA in older indi-
viduals [46]. Moreover, secondary to blood losses or insufficient dietary intake, low hepcidin-
25 levels have also been associated with iron deficiency [47] (see section 1.2.4.). 
A distinct type of iron deficiency anemia is iron-refractory iron deficiency anemia (IRIDA), 
characterized by low levels of iron that cannot be corrected by oral iron therapy. IRIDA is a 
genetic disease caused by mutations in TMPRSS6, which encodes the membrane protease 
matriptase-2 (MT-2). This acts as inhibitor for the hepatic production of hepcidin-25. Hence, 
the lack of MT-2 generates elevated levels of hepcidin-25 which lead to hypoferremia by block-
ing iron outflow to the blood stream [48] (see section 1.2.4.). 
Anemia of chronic disease 
Anemia of chronic disease (ACD) or anemia of inflammation (AI) is a condition that can be 
associated with various chronic inflammatory disorders such as inflammatory bowel disease, 
cancer, chronic infections or rheumatological disorders. ACD can be defined as a moderate 
anemia, characterized by persistent and high production of pro-inflammatory cytokines [49, 
50]. 
In this regard, IL-6 (interleukin 6) and other pro-inflammatory cytokines induce hepcidin-25 
production (see section 1.2.4.2.), resulting in the blockage of iron efflux. Therefore, iron is 
sequestrated in the macrophages, resulting in low serum iron (Fe-Tf) levels which cause further 
inadequate erythropoiesis [47, 51]. Other mechanisms for decreased erythropoiesis or anemia 
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associated with ACD are shortened erythrocyte lifespan due to macrophage activation or eryth-
ropoietic suppression due to direct effect of cytokines on erythroid precursors [35]. 
ACD presents hypoferremia and mild anemia that can be treated by oral iron administration, 
blood transfusions or erythropoietic agents. However, disagreements exist with regard to the 
benefits of iron therapy, since duodenal iron absorption will be down-regulated by the increased 
levels of hepcidin-25 [51] (see section 1.2.4.2.). 
Anemia associated with chronic kidney disease 
Chronic kidney disease (CKD) is a general term used for heterogeneous disorders affecting the 
structure and function of the kidney [52]. With a global prevalence of 8% , CKD is a worldwide 
public health problem [53] which is generally associated with old age, diabetes, hypertension, 
obesity, cardiovascular disease and anemia [52]. This anemia shares the features of anemia of 
chronic disease, with additional typical characteristics that contribute to decreased erythropoi-
esis, such as renal insufficiency and accumulation of uremic toxins [51]. 
Table 1.1: Classification of CKD [54, 53]. 
CKD Stage Classification by severity 
GFR (mL/min/1.73 m2) 
Classification by treat-
ment 
1 (normal or ↑ GFR) ≥ 90 Kidney transplant 
2 (mild ↑ GFR) 60-89 Kidney transplant 
3 (moderate ↑ GFR) 30-59 Kidney transplant 
4 (severe ↑ GFR) 15-29 Kidney transplant 
5 (end stage renal disease ESRD) <15 Dialysis 
CKD represents a severe chronical condition classified based on the level of glomerular filtra-
tion rate (GFR), a calculated parameter which characterizes the renal excretion function [53] 
(Table 1.1). In this sense, CKD has no etiotropic treatment and eventually gets to a point where 
the kidneys stop working and the only treatments options are either the kidney transplant or 
dialysis. Hence, symptomatic treatment is applied to improve the quality of life of the patients. 
Generally, ESAs (erythropoietin stimulating agents) are used to correct the anemia due to inad-
equate erythropoietin production, historically attributed as the main cause for anemia. However, 
10-20% of the cases are not responsive to this therapy [53]. This is because CKD patients also 
suffer from an iron-restrictive disorder due to elevated levels of hepcidin-25 which contributes 
to decreased erythropoiesis [35]. Several studies found significantly high levels of circulating 
Hep-25 in patients suffering from CKD, especially ESRD patients on dialysis [55]. This can be 
explained by the up-regulation of the peptide in uremia and other inflammatory states (see sec-
tion 1.2.3.2.) and by a low renal clearance of hepcidin-25 due to impaired renal function [56]. 
In view of this, Hep-25 modulation could represent an alternative treatment to ESAs therapy 
by limiting the hypoferremia. 
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1.1.3.2. Iron overload  
Hereditary Hemochromatosis 
Hemochromatosis is a general term used since the 17th century for iron overload and accumu-
lation in the body [57]. 
Hereditary hemochromatosis (HH) is a group of genetic iron disorders caused mainly by muta-
tions of human hemochromatosis protein (HFE), discovered in 1997 as the HH responsible gene 
[58]. HH type 1, also known as classic HH or HH HFE-related, is the most common type of 
hemochromatosis [59], affecting mostly Caucasians [60]. HH type 2 or juvenile hemochroma-
tosis is a rare syndrome caused by HJV mutations (90% of the cases) and by HAMP mutations 
[61]. Hemochromatosis type 3 prevails rarely as well [62], and, together with HH type 2, is 
affecting all races worldwide [63]. HH type 4, also called ferroportin disease, is a rare autosomal 
dominant disorder, unlike the other three types, which are autosomal recessive diseases. It is 
characterized by a distinct mechanism of loss-of-function mutation of ferroportin [64]. Other 
hereditary iron overload disorders are aceruloplasminemia, atransferrinemia or neonatal hemo-
chromatosis [59]. 
Table 1.2:The genetic basis of hereditary hemochromatosis (HH) [65]. 
HH Type Mutated gene Encoded protein 
1 HFE HFE (Human hemochromatosis protein) 
2A HJV or HFE2 HJV (Haemojuvelin) 
2B HAMP or HFE2B Hepcidin-25 
3 TRF-2 or HFE3 TFR 2 (Transferrin receptor 2) 
4 SLC40A1 FPN (Ferroportin) 
Generally, HH types 1-3 are characterized by an excess of transferrin-bound iron (Fe-Tf). In 
this context, higher levels of circulating iron are caused on one hand by hyperabsorption of 
dietary iron with subsequently elevated iron export from the enterocytes, and by increased re-
lease of iron from the macrophages on the other hand [66, 63]. On this matter, the abnormal 
behavior of macrophages and enterocytes is linked to the unrestricted and ferroportin-mediated 
iron export induced by hepcidin-25 deficiency [67, 68, 63]. Levels of this peptide are low either 
because of mutations of HFE, HJV and TfR genes, which regulate hepcidin expression (see 
section 1.2.4.2.), or due to direct mutation of HAMP gene (HH type 2B) which encodes hep-
cidin-25 (Table 1.2). 
Iron accumulation, if not treated, particularly in parenchymal cells, results in damage of intra-
cellular structures by catalysis of the production of reactive oxygen species (ROS) [69, 63]. As 
a result, organs such as liver, pancreas, heart and gonads are impaired [63, 70]. In this respect, 
hemochromatosis is currently managed by bloodletting or phlebotomy to clear the iron excess. 
Although this treatment is effective, it is not suitable to all patients due to poor patient compli-
ance caused by precarious vascular access. In light of this, therapeutic modulation of hepcidin-
25 may be a future alternative treatment for HH [71, 35]. 
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Iron-loading anemias 
The term “iron-loading anemia” indicates anemias characterized by defective erythropoiesis 
and iron overload [72]. In this sense, the most common example is β-thalassemia, an autosomal 
recessive disease of hemoglobin (Hb). Patients suffering from this disorder present mutation of 
the gene encoding the β-globin chains of the Hb tetramer (which comprises of two alpha globin 
and two beta globin chains) which causes the apoptosis of erythroid precursors in the process 
of erythropoiesis [73, 35]. The resulting anemia triggers erythropoietin production. This gener-
ates further the production of erythroid precursors, which will not correct the anemia because 
these precursors will undergo apoptosis [35]. Further, iron overload is generated by a hyper-
absorption of iron, caused by low levels of hepcidin-25, as in the case of hereditary hemochro-
matosis [74]. 
Considering this, regular blood transfusions are acknowledged as the only way to sustain life 
in ß-thalassemia patients. Moreover, after each 12-14 transfusions, chelation therapy is re-
quired, which is administered 5–7 days a week by 12-hour continuous subcutaneous infusion 
via a portable pump [73]. In this regard, similarly as in the case of HH, hepcidin-25 modulation 
could be used as an alternative therapy in the future, which might help to resolve the precarious 
patient compliance [75]. 
1.2. Hepcidin  
The discovery of the peptide hormone hepcidin-25 and its crucial function in iron homeostasis 
led to a significant upgrade in the understanding of the systemic iron level [10]. Hepcidin-25 is 
considered nowadays the main iron regulator [35, 76]. Thus, over the past two decades, eluci-
dation of hepcidin activity, its structure and levels in biological fluids, have been the center of 
attention for several research groups worldwide. A comprehensive overview of the achieve-
ments in hepcidin research will be presented further. 
1.2.1. The discovery of hepcidin  
Hepcidin was discovered concurrently by two independent groups almost twenty years 
ago.Krause et al. isolated hepcidin in 2000 from human blood ultrafiltrate and characterized it 
as a cysteine-rich peptide with antimicrobial activity, termed LEAP-1 (liver-expressed antimi-
crobial peptide). LEAP-1 was identified by matrix-assisted laser desorption/ionization time-of-
flight mass spectrometry (MALDI-TOF MS) with a molecular mass of 2789.8 Da. The cysteine 
content determination using carboxamidomethylation revealed eight cysteine residues. Further 
sequence analysis performed by Edman degradation completed the primary structure of LEAP-
1 as follows: DTHFPICIFCCGCCHRSKCGMCCKT. Expression of the LEAP-1 gene exam-
ined by real-time quantitative RT-PCR (reverse transcription polymerase chain reaction) was 
mainly detected in the liver, and to a much lower extent, in the heart and brain. Additionally, 
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radial diffusion assays revealed several bacteria including Bacillus megaterium, Bacillus sub-
tilis, Micrococcus luteus, Staphylococcus carnosus and Neisseria cinereal exhibiting suscepti-
bility to LEAP-1 treatment [77]. 
Around the same time, Park et al. isolated the same cysteine-rich peptide hormone from human 
urine and, mainly because of its hepatic origin and antimicrobial activity, named it hepcidin. 
The authors determined that the human hepcidin gene (HAMP, OMIM 606464) was located on 
chromosome 19 and encoded an 84-residue precursor protein. This so-called pre-prohepcidin 
contained a 24-amino acid signal peptide at the N-terminus which was enzymatically cleaved 
to produce a 60-amino acid prohepcidin. Then, prohepcidin was further processed by proteoly-
sis to generate the mature hepcidin. The average mass of the peptide analyzed by MALDI-TOF 
MS was 2789.40 Da. The 25-amino acid sequence determined by Edman degradation was iden-
tical to the one reported by Krause et al.. Mass spectrometric (MS) data confirmed that all 8 
cysteines were engaged in intramolecular disulfide bonds, with no assignment of the pairings 
determined at this point. Additionally, two N-truncated variances of the 25-residue peptide, 
named hepcidin-20 and -22 respectively, were identified. Further MS measurements deter-
mined that most of the hepcidin found in urine is hepcidin-20 (Hep-20) and hepcidin-25 (Hep-
25). Hepcidin-22 (Hep-22), however, only occured in minute amount in urine. Hep-20 and Hep-
25 were also tested for antimicrobial activity using the colony-forming unit assay (CFU). Both 
peptides presented antibacterial activity against Escherichia coli, Staphylococcus aureus, 
Staphylococcus epidermidis, and group B Streptococcus, and antifungal activity against Can-
dida albicans, Aspergillus fumigatus and Aspergillus niger [39]. However, the half maximal 
inhibitory concentration (IC50) determined for the antimicrobial activity of hepcidin-25 was 14-
18 µM, whereas the mean physiological level of the peptide is around 3.5 nM (10 µg/L) (see 
section 1.3.3.). 
In 2001, Pigeon et al. determined overexpressed hepcidin mRNA in the liver of iron-overloaded 
mice by Northern blot analysis [78]. Additionally, Nicolas et al. performed PCR experiments 
that showed severe iron deficiency anemia in transgenic mice overexpressing liver hepcidin 
[79]. These findings suggested that hepcidin exhibits an additional role distinct from its antimi-
crobial activity, namely it is involved in iron regulation (see section 1.2.4.). 
Hepcidin was further identified in numerous species [80-82], with a total of more than 250 
entries of hepcidin sequences on protein sequence database UniProt by 2017 [83]. 
1.2.2. Structure of hepcidin 
1.2.2.1. NMR structure of hepcidin-25 
In 2002, Hunter et al. investigated the structure of synthetic human Hep-25 and Hep-20 using 
nuclear magnetic resonance (NMR) spectroscopy. Results of these examinations showed the 
existence of an amphipathic structure, which consists of a distorted β-sheet with a hairpin loop, 
stabilized by four intramolecular disulfide bonds. Using structure calculations and dynamic sig-
natures in the NMR spectra, the S-S connectivity was attributed between Cys7-Cys23 (1-8), 
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Cys10-Cys22 (2-7), Cys11-Cys19 (3-6) and Cys13-Cys14 (4-5), with the latter S-S bond cor-
responding to an unusual adjacent bond. Also, the authors reported that Hep-25 tends to aggre-
gate, in contrast to Hep-20. These aggregation properties were connected to the hydrophobic 
residues of the NH2-terminus, namely Phe4, Phe9 and Pro5 [84]. However, because the reso-
nances from the two vicinal cysteines Cys13 and Cys14 could not be detected due to exchange 
broadening, the NMR data presented was not complete. 
 
Figure 1.4: Amino acid sequence of hepcidin-25 with S-S connectivity. 
In 2009, Jordan et al. suggested a different S-S pairing for human hepcidin-25 between Cys7-
Cys23 (1-8), Cys10-Cys13 (2-4), Cys11-Cys19 (3-6) and Cys14-Cys22 (5-7) (Figure 1.4). Di-
sulfide mapping was achieved by chemical analysis employing partial reductive alkylation in 
addition to NMR spectroscopy. Moreover, previously encountered difficulties in the NMR anal-
ysis were overcome by performing experiments at different temperatures (325 K and 253 K). 
This permitted the evaluation of exocyclic conformations for the critical cysteines (Cys13 and 
Cys14), with the establishment of the solution NMR structure of hepcidin-25 with the currently 
accepted S-S pairing (PDB code 2KEF) (Figure 1.5). The S-S connectivity was confirmed for 
native human hepcidin-25 (extracted and purified from urine), synthetic hepcidin-25 (synthe-
tized and folded “in house”) and two types of recombinant hepcidin-25 (expressed in Chinese 
hamster ovary (CHO) cells and Escherichia coli). 
However, the authors reported that the N-terminus was highly flexible and the electron density 
of the first five residues was insufficient to accurately assign the position of the residues [85]. 
 
Figure 1.5: Solution NMR structure of human hepcidin-25 at 325K (PDB code: 2KEF), 
with residues 1-5 of the N-terminus not accurately assigned (different views) [86, 85]. 
It is of interest to be mentioned that the commercially available hepcidin-25 is obtained by 
synthesis of a linear 25-residue peptide, followed by oxidation of the eight cysteine-contained 
-SH groups, to form disulfide bridges of the folded peptide. Interestingly, the results of ion 
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mobility spectrometric (IMS) studies on two Hep-25 standards showed different conformers in 
terms of folding species, indicating the possibility of different hepcidin foldings achieved dur-
ing synthesis [87]. 
1.2.2.2. Isoforms of hepcidin 
In addition to Hep-25, two more N-truncated isoforms namely Hep-20 and Hep-22 were iden-
tified in urine by MALDI-TOF [39] (see section 1.2.1.). Later on, Kemna et al. confirmed using 
SELDI-TOF measurements that Hep-20 was present in both urine and serum, while Hep-22 
was identified only in urine. Hence, the authors suggested that this isoform represented a uri-
nary metabolite of Hep-25 [88]. Recently however, high resolution (HR) MS was able to detect 
Hep-20 and -22 in plasma, together with a novel hepcidin isoform, hepcidin-24 (Hep-24) [89, 
90] (Figure 1.6). 
In this context, several research groups investigated further the levels of the shorter hepcidin 
isoforms in serum relative to hepcidin-25 by liquid chromatography coupled to tandem mass 
spectrometry (LC-MS/MS) and high resolution mass spectrometry (HR-MS). The results indi-
cated relatively low level of the N-truncated isoforms compared to Hep-25 (Table 1.3). How-
ever, when cumulated, the isoforms could have an impact on the level of total hepcidin. 
 
 
Figure 1.6: The known isoforms of hepcidin. 
The bioactivity of these isoforms, evaluated as the ability to cause ferroportin internalization, 
was assessed by cellular studies. Experiments using synthetic N-truncated Hep-25 peptides [91] 
and mutated hepcidin-25 (alanine mutants in which each residue of the N-terminal region was 
individually replaced with alanine) [92] indicated that the lack of the N-terminal amino acids 
eliminates most of the bioactivity of the peptide (see section 1.2.4.1.). Laarakkers et al. per-
formed cellular studies which confirmed the loss of activity for the shorter isoforms of Hep-25. 
The authors reported that Hep-24 presents a 10-fold lower activity compared to Hep-25, and 
the activities of both Hep-20 and Hep-22 were at least 10-fold lower than that of Hep-24. The 
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same study also showed that for long-term storage (0-7 days) of serum samples at room tem-
perature, a decrease in Hep-25 was proportional to an increase in Hep-20, -22 and -24, indicat-
ing that the shorter isoforms represent serum breakdown products of hepcidin-25 [93]. 
Table 1.3: Serum level of hepcidin isoforms. 
 Hep-25 Hep-24 Hep-22 Hep-20 Reference 
Mean concent-
ration (µg/L) 
9 <LOQ (1 µg/L) <LOQ (1 µg/L) <LOQ (1 µg/L) [94] 
12  N/A 0.97 2.6 [95] 
 11* N/A N/A  3.9* [96] 
N/A = not available 
*geometric mean 
1.2.3. Hepcidin-25-copper(II) complex 
A particularity in the structure of hepcidin-25 is the presence of a small metal binding site called 
ATCUN (amino terminal Cu2+- and Ni2+-binding), identified in 2005 in the N-terminus of the 
peptide [97]. The affinity of hepcidin-25 for copper and the formation of a copper complex 
could be of notable importance for hepcidin analysis and its biological activity. 
1.2.3.1. ATCUN motif – structure and importance 
The ATCUN motif was first identified 50 years ago in human serum albumin (HSA) and has 
been studied intensively ever since. It depicts the presence of a metal binding site in the first 
three N-terminus residues of naturally occurring proteins. This small binding site is specific for 
the coordination of Cu2+ and Ni2+. Moreover, the ATCUN motif consists of four nitrogen atoms 
that act as metal ligands. These involve the free α-NH2 nitrogen, two intervening peptide nitro-
gen atoms and the imidazole nitrogen of a histidine residue in the third position. The crystal 
structure of the copper complex of Gly-Gly-His peptide shows the nitrogen atoms forming an 
approximately square planar geometry [98, 99]. Laussac et al. employed NMR spectroscopy to 
study the 24-residue N-terminus of BSA and suggested that the carboxylate group of the aspar-
tate residue in the Asp-Ala-His motif may interact with the metal ion, forming a penta-coordi-
nated structure [100]. This theory was however infirmed later by Hureau et al., when the X-ray 
structure of the [Cu(II)(DAHK)] complex was revealed. The authors reported an axial coordi-
nation provided by a labile water molecule (Figure 1.7) and showed that Asp does not act as a 
fifth ligand [101]. Nevertheless, the importance of the aspartic acid in position 1 was attributed 
to the fact that Asp increases the basicity of the nitrogen atoms involved in the metal complex 
and thus the copper binding is enhanced [102]. 
Unfortunately, there is no available real crystal structure of the native protein-copper complex, 
probably due to the flexibility of the N-terminus in the native form of proteins and the difficul-
ties encountered in the crystallization of large molecules. There are more than 25 structures of 
HSA reported on PDB, but none of these reveal the structure of the ATCUN motif. Neverthe-
less, it is generally accepted that this small metal binding site is included in the native form of 
the protein and, moreover, it is responsible for the action of albumin in transport of metals ions, 
including copper [98, 100]. 
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In this context, other proteins were found to contain ATCUN motifs, with a preserved histidine 
residue in the third position. Additionally, the metal binding site was found to have a significant 
impact on their biological function. It has been reported that ATCUN motifs have been involved 
in DNA cleavage, gene targeting and protein design. As an example, the ATCUN site in human 
sperm protamine P2a may be responsible for inducing carcinogenesis in individuals exposed to 
metals [99, 103]. 
Moreover, copper binding sites located more central in proteins rather than at the flexible N-
terminus and thus more accessible for structural and functional investigations, were shown to 
be responsible for catalysis, transport, detoxification and signaling [104]. Several enzymes and 
proteins such as cytochromes C oxidase, superoxide dismutase and metallothionein contain 
copper as a co-factor for their functional role in energy metabolism and antioxidant defense 
system. In this regards, ceruloplasmin, the main copper-containing protein, is a Cu2+-dependent 
ferroxidase essential for iron mobilization [105] (see section 1.1.1.1.). 
 
Figure 1.7: Crystal structure of [Cu(II)(DAHK)] [101] (CCDC — 809109 [106]) with 
a square-planar 4-N coordination geometry and an axial coordination of a labile H2O 
molecule. 
1.2.3.2. ATCUN motif in hepcidin-25 
Melino et al. first confirmed the presence of the ATCUN motif in the structure of Hep-25 by 
circular dichroism (CD) and UV-Vis spectroscopy. The binding of Cu(II) to the N-terminal 9-
amino acid fragment of hepcidin-25 yielded an absorption maximum at 525 nm in the pH range 
between 5.2 and 10.5. Moreover, the spectra of the whole hepcidin-25 in the presence of copper 
ions showed the presence of a maximum at 525 nm at a pH near neutrality [97]. 
Further, Tselepis et al. identified the ATCUN motif by HR-MS employing FTICR-MS (Fou-
rier-transform ion cyclotron resonance MS). The ability of several transition metals (Cu2+, Fe2+, 
Fe3+, Zn2+ and Ni2+) to form complexes with human hepcidin-25 was tested. The authors re-
ported no evidence of complex formation in the case of ferrous and ferric ions, while copper, 
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nickel and zinc ions all bound Hep-25 with a gradient of highest-to-lowest affinity as follows: 
Cu2+ > Ni2+ > Zn2+ [107]. 
Tandem mass spectrometry (MS/MS) was also employed to characterize the Hep-25-copper(II) 
complex. Konz et al. applied collision induced dissociation (CID) which resulted in the frag-
ment DTH-copper(II), representing the first three residues of the N-terminus of Hep-25 coupled 
to one copper ion. This indicated the stability of the copper-binding motif, which was preserved 
even during MS fragmentation [108]. 
Moreover, based on the affinity of Hep-25 for copper ions, immobilized metal ion affinity chro-
matography (IMAC) chips were applied for hepcidin purification (see section 1.3.2.2.) and ICP-
MS (inductively coupled plasma mass spectrometry) was employed for hepcidin quantification 
(see section 1.3.2.1.). 
Further, MALDI-TOF was used to characterize the interaction of Hep-25 to copper. A high 
affinity of the peptide hormone for copper was determined (KD=5·10-7 M). Nevertheless, the 
authors concluded that this affinity is not sufficient for hepcidin-25 to compete with albumin 
(KD=10-12 M) [24] for the extracellular “free” copper [109]. However, a recent study by Plonka 
et al. employing potentiometric titration and UV-Vis spectroscopy, which are widely recog-
nized as the standard procedure for binding constant calculations [110, 111], characterized the 
flexible N-terminal hexapeptide of hepcidin-25 (DTHFPI) as the strongest ATCUN motif ever 
reported with a dissociation constant of 10-14.66 M. Moreover, this high affinity for Cu(II) ions 
was confirmed by a quick transfer of Cu2+ from HSA to this peptide. Based on these results, the 
authors proposed that hepcidin-25 exists, at least sometimes, as Cu(II) complex in blood, and 
stated that hepcidin-25-copper(II) complex warrants a continued research [112]. 
1.2.3.3. Copper homeostasis 
The copper ions required for body needs arise generally from diet. The average dietary copper 
intake in adults is 0.6-1.6 mg/day. Copper is mainly contained in shellfish, organ meats and 
seeds. Relatively smaller amounts are also found in vegetables, muscle meats and water. 
Copper trafficking is a complex process influenced by both metal-protein binding constants and 
by the use of copper in biological processes [113, 105]. Once absorbed in the small intestine 
(mainly as Cu2+), copper is transferred to the blood stream where it can bind human albumin 
(HSA), which exhibits a high affinity for Cu2+ due to the presence of the ATCUN motif. How-
ever, only ≈ 180 µg of copper are incorporated by HSA, even though albumin has the capacity 
to accommodate approximately 40 mg of copper. The rest of Cu2+ (≈1 mg) is contained in 
ceruloplasmin (65%), transcuprein (12%) and other low molecular weight components such as 
peptides and amino acids (≈20-50 µg) [105]. Interestingly, ceruloplasmin does not bind copper 
directly in the presence of the metal ions, rather 6-7 molecules of Cu2+ are added during its 
synthesis in the liver. The lack of copper during the synthesis of ceruloplasmin leads to an 
unstable protein and the loss of its activity as ferroxidase (see section 1.1.1.1.). 
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A “free” extracellular copper concentration of 1-2 µM (unbound fraction) was reported by 
McMillin et al., that was obtained after separation from the bound fractions of copper through 
ultrafiltration, using a molecular weight cutoff of 30 kDa, which should eliminate albumin, 
ceruloplasmin, and other proteins expected to bind copper [114]. 
1.2.4. Hepcidin-25 activity 
The essential role of hepcidin in systemic iron homeostasis has been established by animal 
models, shortly after its discovery in 2001 (see section 1.2.1.). Therefore, considerable efforts 
have been made ever since for the elucidation of the mechanism of hepcidin-25 activity as the 
iron regulator and the factors implicated in hepcidin-25 regulation. 
1.2.4.1. The mechanism of action of hepcidin-25  
Hep-25 interrupts iron release into the blood stream from the three main sources of iron in the 
body: dietary iron absorption by the enterocytes, iron recycling by the macrophages and stored 
iron mobilization by the hepatocytes [35] (see section 1.1.2., Figure 1.8a). Studies on cultural 
cells expressing mouse FPN (cell line HEK293-Fpn) with a C-terminal green fluorescent pro-
tein (GFP) confirmed that hepcidin binds FPN, the 571-residue protein known as the sole iron 
exporter (see section 1.1.2.), causing its internalization and degradation. Concentrations of 100 
nM hepcidin-25 caused ferroportin internalization within 1 hour, while a 10 nM solution of 
hepcidin-25 led to ferroportin internalization within 3 hours [40]. In this context, the physio-
logical level of hepcidin-25 in human adults is around 3.5 nM (10 µg/L) (see section 1.3.3.3.). 
 
Figure 1.8: (a) Iron homeostasis regulated via hepcidin-25 by binding FPN in the three 
iron releasing cells: enterocytes, macrophages and hepatocytes; (b) Hep-25 – FPN 
interaction [115]. 
Further studies by Nemeth et al. using the same cell line, measuring the ability of hep-25 to 
induce ferroportin endocytosis, revealed that the lack of the five N-terminal amino acids re-
stricts the biological activity of the peptide [91]. Clark et al. also investigated the importance 
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of the N-terminus for the interaction with FPN by substituting the N-terminus individually with 
alanine (residues 1–6 and 8). The authors reported that His3, Phe4 and Ile6 were significant for 
Hep-25 activity [92]. Moreover, mini-hepcidins consisting of the first nine N-terminal residues 
were designed and tested for their iron regulation ability. They induced hypoferremia in mice, 
showing even superior bioactivity compared to native Hep-25 [116]. 
Recent studies employed by Fernandes et al. on the down-regulation of FPN by Hep-25, using 
similar HEK293 cell line with GFP showed the implication of the extracellular residue Cys326 
of FPN in Hep-25 binding [117] (Figure 1.8b). The authors hypothesized that the Hep-25 – FPN 
interaction is related to a disulfide bond formation or rearrangement involving the -SH group 
of the Cys326 residue of FPN and the disulfide bridge of Hep-25. Additionally, the interaction 
was not affected by modulation of an enzyme implicated in disulfide rearrangement (thiol iso-
merase), but was sensitive to reducing agents, indicating that the binding could be associated 
with a non-enzymatic disulfide rearrangement. 
1.2.4.2. Hepcidin-25 regulation  
Each of the stimuli known to alter iron homeostasis affect hepcidin expression as well. Hence, 
Hep-25 synthesis is stimulated in response to iron overload and inflammation and is down-
regulated by iron deficiency, increased erythropoietic activity and hypoxia [22]. However, the 
signaling pathways by which these stimuli affect hepcidin expression are not fully elucidated. 
It seems that the key signaling pathway for the regulation of Hep-25 expression is the 
BMP/SMAD pathway with haemojuvelin HJV as cofactor. The bone morphogenetic proteins 
(BMPs) represent growth factors also known as cytokines, involved in many processes such as 
bone development or tissue repair and formation. In the liver, the BMP pathway seems to be 
adapted specifically for iron regulation via a combination of cofactors including HJV [56, 35]. 
In this regard, the regulation of hepcidin expression via iron or BMP pathway leads to low 
levels of Hep-25 in HH type 1-3, owing to mutations of HFE, HJV, TfR and HAMP genes (see 
section 1.1.3.2.). 
Additionally, Hep-25, like other hormones, is regulated by the substance whose levels it con-
trols, namely iron. Hypoferremia and iron overload regulate hepcidin synthesis and excretion 
by the hepatocytes. The transferrin receptors (TfR1 and TfR2) and the membrane protein HFE 
(see section 1.1.3.2.) seem to be involved in this process [35]. 
Another signaling pathway for Hep-25 transcription, activated in inflammatory conditions, is 
represented by the signal transducer and activator of transcription 3 (STAT-3) which is regu-
lated by interleukin-6 (IL-6) and possibly other inflammatory cytokines. The increase of in-
flammation-induced Hep-25 is responsible for the hypoferremia that occurs in inflammatory 
diseases (see section 1.1.3.1.) [35, 118]. 
Recently, MT-2 was discovered as a novel regulator of hepcidin transcription which down-
regulates the HAMP expression following iron deprivation [119]. This explains the reason for 
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which a mutation of the gene encoding MT-2 (TMPRSS6) in IRIDA causes the stimulation of 
Hep-25 production (see section 1.1.3.1.). 
Finally, a new hormone called erythroferrone was identified in 2014. It is produced by erythro-
blasts in response to erythropoietin, and mediates hepcidin suppression during stress erythro-
poiesis [120]. 
1.2.5. The clinical value of hepcidin-25 
Several recent reviews (2013-2017) on hepcidin-25 highlight the potential of the peptide not 
only as a clinical parameter for the diagnosis and prognosis of iron-related disorders [121, 76, 
122, 123], but also as a therapeutic target [71, 124-126]. 
1.2.5.1. Hepcidin-25 – a promising biomarker in iron pathology 
The ability of body iron pools to change independently from each other makes the “iron status” 
a complex process that can vary significantly. In this respect, there is no single laboratory pa-
rameter that provides full information about iron metabolism [127]. Currently, several iron sta-
tus indicators are clinically available and a combination of these parameters is used for the 
diagnosis of iron disorders. The most common biomarkers tested in iron deficiency are ferritin 
(Ft), soluble transferrin receptors (sTfRs), transferrin saturation (TSAT) and reticulocyte he-
moglobin content (CHr). These are indicators for body iron stores (Ft), tissue iron deficiency 
(sTfRs), circulating iron (TSAT) and/or iron demand for erythropoiesis (CHr). However, the 
explosion of knowledge of iron metabolism regulated by Hep-25 make the clinicians uncertain, 
which approach to diagnose iron disorders is correct. Hepcidin-25, as the main regulator of 
systemic iron homeostasis, has direct influence on these parameters and can be a suitable can-
didate for a comprehensive iron indicator [128, 122]. An advantage of Hep-25 over the conven-
tional biomarkers is the “real-time” information of iron status provided. This is because the 
production of hepcidin is substantially increased within a few hours after iron administration 
[129, 130]. 
Most of the iron disorders were revised in the hepcidin era and were linked to hepcidin-25 (see 
section 1.1.3.). Level fluctuations of this peptide hormone are either the cause or the effect of 
iron overload or hypoferremia (Table 1.4). In this sense, Hep-25 can be particularly useful in 
differentiating distinct types of hypoferremia associated for example with IDA and ACD. The 
hypoferremia that occurs in IDA when iron stores (usually from the liver) are depleted, is com-
pensated by low levels of hepcidin-25 that would allow any absorbed iron in the enterocyte to 
be released in the circulation. On the other hand, the inflammation in ACD caused by IL-6 
stimulates the production of hepcidin-25 that leads to the blockage of iron export resulting in 
hypoferremia (see section 1.1.3.1. and section 1.2.4.2.). 
In 2002, Thomas et al. introduced a diagnostic plot correlating the ferritin index (sTfR/log fer-
ritin) and CHr, as an alternative to the conventional markers used in the diagnosis of iron defi-
ciency [131]. The authors showed that this so-called Thomas plot improved tracking the ID 
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progression. In 2011, the same authors tested the possibility to replace ferritin index with hep-
cidin-25 in the Thomas plot, emphasizing the potential of the peptide to discriminate between 
states of anemia [127]. 
Table 1.4: Hep-25 plasmatic levels in various iron disorders [69]. 
 Disorder Regulation of hepcidin expression Fluctuation of Hep-25 
and Fe plasmatic levels 
Iron  
overload 
HH 1-3 Mutation of HFE, HAMP, HJV, TfR Hep-25 ↓       Fe ↑ 
β-Thalassemia Defective erythropoiesis Hep-25 ↓       Fe ↑ 
Iron 
defi-
ciency 
ACD IL-6-mediated inflammation Hep-25 ↑       Fe ↓ 
IDA Depletion of iron stores Fe ↓       Hep-25 ↓ 
IRIDA Mutation of TMPRSS6 Hep-25 ↑       Fe ↓ 
Anemia of CKD IL-6-mediated inflammation Hep-25 ↑       Fe ↓ 
    
Numerous assays for the quantification of Hep-25 in biological samples have been developed 
(see section 1.3.), however, there is a lack of a reference method that could permit the use of 
Hep-25 as a clinically accepted parameter. In this vein, efforts towards worldwide hepcidin-25 
harmonization are ongoing [132] (see section 1.3.3.). 
Nevertheless, many relevant authors to the iron-related scientific community endorsed hep-
cidin-25 as a promising biomarker in the clinical field, with applications covering particularly 
the diagnosis of iron overload, diagnosis and management of IDA (especially IRIDA), differ-
entiation between ACD and IDA or ID monitoring and therapy in anemia of CKD [69, 76]. 
1.2.5.2. Hepcidin-25 therapy 
Since Hep-25 excess or deficiency influences the pathogenesis of iron disorders, Hep-25 ago-
nists and antagonists could improve the therapy applied for these diseases. Hepcidin deficiency 
is prevalent in most types of hemochromatosis (HH type 1-3) and in β-thalassemia. Hence, 
modulation of hepcidin in these patients to correct the iron overload could increase the patient 
compliance by replacing blood transfusions (see 1.1.3.2. section). Mini-hepcidins were de-
signed in this regard and were shown to reproduce Hep-25 activity in mice [116]. Such hepcidin 
mimetics were further developed by pharmaceutical companies to be used in therapy of iron 
overload and are in Phase I clinical trial (M012 by Merganser Biotech and LJPC-401 by La 
Jolla Pharmaceuticals Company). Additionally, hepcidin-25 agonists as stimulators of hep-
cidin-25 production by targeting the BMP pathway and TMPRSS6 gene were also suggested 
[71, 133]. 
Increased levels of hepcidin-25 are associated with ACD, IRIDA and anemia of CKD (see sec-
tion 1.2.4.1.). The current treatment available includes ESAs (see section 1.1.3.1.), however, 
erythropoietin resistance is frequently observed as a consequence of inflammation [134]. In this 
respect, Hep-25 antagonists could increase available iron to correct for anemia. Multiple strat-
egies can be applied on this account, such as decreasing hepcidin production with BMP antag-
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onists or IL-6 inhibitors or neutralizing the peptide with anticalins and spiegelmers. Pieris Phar-
maceuticals developed a bioengineered lipocalin that captures hepcidin to prevent FPN degra-
dation, which is in Phase I clinical trial. In this context, the most advanced Hep-25 antagonist 
is developed by Noxxon Pharma AG. NOX-H94, a L-RNA spiegelmer hepcidin inhibitor, is in 
Phase II clinical trial and is designed to antagonize the Hep-25-induced FPN degradation [71, 
133, 124]. Amgen and Eli Lilly and Company developed humanized monoclonal antibodies for 
capturing hepcidin. Eli Lilly’s anti-hepcidin antibody (LY2787106) finished the Phase I clinical 
trial, but was subsequently replaced by an anti-FPN antibody (LY2928057), that obstructs hep-
cidin binding but not FPN function. Concurrently, the anti-hepcidin antibody developed by 
Amgen (12B9m) is reported to be in preclinical development [71, 133]. 
1.3. Analytical strategies for the quantification of hepcidin-25 
The illustration of the clinical value of hepcidin-25 triggered significant efforts for the devel-
opment of a robust assay to be implemented in clinical laboratories for the quantification of this 
iron-regulator in biological fluids. Mainly, two types of strategies were applied for the clinical 
assessment of hepcidin-25: immunological and mass spectrometry-based methods. 
Initially, semi-quantification assays for hepcidin-25 in urine samples were developed, employ-
ing both antibody-based methods [118] and mass spectrometry [135]. Comparative studies of 
urine and serum samples showed that on one hand urinary hepcidin seems more affected by 
multiple freeze-thaw cycles, but on the other hand serum hepcidin is more influenced by diurnal 
variation. However, the urinary determination of Hep-25 requires further quantification of cre-
atinine, a parameter characterizing the renal clearance. Creatinine is used for the concentration 
normalization of most of the urinary parameters by adjusting alterations in urine concentrations. 
Thus, urinary assays could be hampered in the patients with renal diseases. In light of this, most 
of the quantification assays focused on analysis of the peptide hormone in serum samples. Ad-
ditionally, several studies showed no differences in the hepcidin-25 levels in human serum rel-
ative to plasma [136, 93]. Taking this into consideration, an overview of the analytical tech-
niques which focused on serum hepcidin-25 quantification will be highlighted in the next sec-
tions, underlining their general clinical usage and their potential for routine analysis. 
1.3.1. Immunoassays   
Principle of immunoassays 
In 1959, Yalow and Berson first reported the principles of immunoassays [137], a bioanalytical 
tool based on a response signal generated from an antibody-antigen interaction. Antibodies, 
also known as immunoglobulins (Ig), are proteins produced by the immune system to recognize 
and neutralize foreign substances (antigens) entering the body. The antibody presents a paratope 
or antigen-binding site that specifically binds the recognition site of the antigen called epitope. 
The response signal from the antibody-antigen reaction is produced by label (e.g. enzymatic, 
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radioactive, fluorescent or luminescent) attached to the antigen (analyte) or the antibody, and 
permits the quantitation of the analyte [138]. Mainly, two types of antibodies are used in im-
munoassays, namely mono- and polyclonal antibodies. A polyclonal antibody represents a col-
lection of antibodies from different antibody secreting B cells that recognize multiple epitopes, 
while a monoclonal antibody is secreted by a single B lymphocyte and binds with one unique 
epitope. There is a multitude of immunoassay formats available, for example with immobilized 
antigen or immobilized antibody on a solid surface, heterogeneous or homogeneous, competi-
tive or non-competitive. 
Immunoassays have wide applications in pharmaceutical analysis, medical research and routine 
analysis. The firstly established assays were radio-immunoassays (RIA), however, strict regu-
latory controls of the radioactive labels have favored the exclusion of RIA from the routine 
analysis, and their replacement with enzyme immunoassays (EIA), which use enzyme-labeled 
conjugates. One of the most popular EIA is enzyme-linked immunosorbent assay (ELISA). 
With a high throughput, low costs involved and high sensitivity for a wide range of analytes, 
EIA, especially ELISA, has become a reference method for medical laboratories, regulatory 
bodies or proficiency tests organizations [139]. However, a major limitation of immunoassays 
is the development of suitable antibodies against the desired analyte. In this respect, certain 
characteristics of antibodies, such as affinity (the ability to form antibody-antigen complex) or 
cross-reactivity (interactions of the antibodies with other compounds than the desired analyte) 
are often not sufficiently investigated, leading to misinterpretation of the results [140]. 
Immunoassays in hepcidin-25 analysis 
Immunoassays were the first analytical techniques developed for the quantification of hepcidin 
in biological samples due to their high potential for developing into a reference method for 
routine laboratories. Several formats were tested in this regard. 
The first immunoassay, developed by Ganz et al., was a competitive ELISA using biotinylated 
hepcidin-25 as tracer [141]. An alternative ELISA was also developed using recombinant 
tagged peptide (hepcidin-25-His) [142]. However, both techniques employed polyclonal anti-
bodies which were unable to differentiate sufficiently between different hepcidin isoforms. A 
monoclonal antibody was developed, however, its cross-reactivity relative to the other isoforms 
was not tested [143]. Nonetheless, a selective sandwich ELISA for Hep-25 was developed by 
Eli Lilly and Company employing a monoclonal antibody that showed no cross-reactivity to 
Hep-20 and Hep-22 [144]. Although the newly discovered Hep-24 was not tested at that time, 
the method assured a sensitive and robust hepcidin-25 quantification, with a reported LOQ of 
0.01 µg/L. Unfortunately, the developed antibody is not commercially available. 
Grebenchtchikov et al. developed a radioimmunoassay for hepcidin-25 quantification using a 
polyclonal antibody and 125I-labeled hepcidin [145]. Because of several disadvantages of RIA 
such as short shelf-life conjugates, complex equipment and highly trained personnel needed 
due to medical hazards, the aforementioned research group later developed a competitive 
ELISA using the same polyclonal antibody and biotinylated hepcidin-25 as a tracer [146]. This 
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method is currently used for total hepcidin measurements in the frame of the hepcidinanaly-
sis.com initiative on a fee-for-service basis. 
At this point, it can be concluded that the limited availability of suitable antibodies for the 
selective determination of bioactive hepcidin-25 hinders the applicability of immunoassays for 
the quantification of the iron regulator. Immunoassays are suitable for the measurement of total 
hepcidin, however, since the correlation between Hep-25 levels and the other isoforms is not 
fully elucidated, the results can be difficult to interpret. 
On this matter, there are several reasons that limit the development of a reliable immunoassay 
for hepcidin-25. Development of a selective antibody for the bioactive isoform is hampered by 
the small size of the molecule that reduces the number of antigenic epitopes, and by the struc-
tural similarities to the other isoforms, which could be relevant cross-reactants (see section 
1.2.2.2.). Additionally, Hep-25 is an evolutionarily conserved peptide. Therefore, the develop-
ment of a monoclonal antibody that implies the use of mice could be hindered by the similarity 
of amino acid sequences in humans and mice. Also, the shortage of suitable hepcidin-25 con-
jugates to be used as tracers could cause lack of reliable immunoassays. Reason for this is that 
the compact structure of Hep-25 and its tendency to aggregation, especially around its isoelec-
tric point of 8.2, make difficult the handling of the peptide at adequate pH values for bioconju-
gation (generally around 7.4-8.5 [147, 148]). 
In this context, mass spectrometry (MS) could provide an alternative to immunoassays for hep-
cidin-25 quantification. MS-based techniques represent an emerging tool for the clinical assess-
ment of proteins and small peptides in biological fluids due to high sensitivity and selectivity. 
Additionally, these methods can be developed in a relatively short period of time compared to 
immunoassays, where the development of affine monoclonal antibodies can last years. 
1.3.2. Mass spectrometry based methods 
Mass spectrometry (MS) is a technique that dates back more than a century, with a continuously 
developing technology applied initially solely in physics and chemistry, and, in the past two 
decades, extended to biology, biochemistry and biomedical research [149]. In the field of la-
boratory medicine, mass spectrometry is now generally considered as a fundamental tool for 
“next generation clinical chemistry” [150]. 
MS provides qualitative and quantitative information about chemical species after conversion 
to ions in the ionization source and subsequent separation of the obtained ions in the mass ana-
lyzer based on their mass-to-charge ratio (m/z). Ion signals are generated in the detector and 
recorded in a computer system as a function of the m/z ratio, generating the mass spectrum 
[151]. 
Mass spectrometry includes organic (molecular) MS used for analysis of (bio)molecules, and 
inorganic (elemental) MS, also known as inductively coupled plasma (ICP) MS, applied for the 
detection of metals and several non-metals. Molecular MS commonly refers to electrospray 
(ESI) MS and matrix assisted laser desorption/ionization (MALDI) MS. ICP-MS, MALDI-MS 
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and ESI-MS were employed for hepcidin-25 quantification. Suitability of these techniques for 
hepcidin-25 assessment in clinical samples will be evaluated in the following sections. 
1.3.2.1. ICP-MS 
Principle of operation 
Inductively coupled plasma mass spectrometry (ICP-MS), developed in the early 1980s, is a 
sensitive analytical tool for elemental analysis [152]. ICP-MS uses a plasma discharge at very 
high temperatures to generate positively charged ions. In this respect, the sample is first inserted 
into the sample introduction system, consisting of the spray chamber and the nebulizer. Then, 
an aerosol is generated, that reaches the base of the plasma through the sample injector. The 
sample is further dried, vaporized, atomized, and ionized through the different heating zones of 
the plasma torch. This means that the liquid aerosol is transformed first into solid particles, then 
into a gas. Subsequently, at approximately 6000–7000 K in the analytical zone of the plasma, 
the sample exists as excited atoms and ions, which provides the elemental composition of the 
sample [153]. 
An advantage of ICP-MS is the possibility to analyze gaseous, liquid and solid samples, due to 
the elevated temperatures of the plasma that provide an ideal atomizer and element ionizer for 
all types of samples and matrixes. Characterized by a high sensitivity (ppt), ICP-MS is consid-
ered the “gold standard” method for ultra-trace elemental analysis [152]. 
Hepcidin-25 quantification 
Konz et al. exploited this technique for the assessment of hepcidin-25 in serum samples by 
employing direct biomolecule labeling. The affinity of hepcidin-25 for Cu(II) due to the pres-
ence of the ATCUN motif (see section 1.2.3.) permitted the quantification of the peptide by 
determining the amount of copper binding to hepcidin-25 using LC-ICP-MS. Anion exchange 
chromatography was employed for separation of the peptide-copper(II) complex and the excess 
of metal [108]. However, the limited stability of these columns hinders a robust and reproduc-
ible quantification. Also, the mass ratio Hep-25:Cu2+ of approximately 43:1 determined an 
equivalent decrease in the limit of detection (LOD) for the peptide analysis. The very good 
sensitivity of the elemental MS achieved for copper (LOD 33 ng/L) corresponds to a LOD for 
hepcidin-25 of 1.4 µg/L and a reported LOQ of 1.8 µg/L. In contrast, ESI-MS provides quanti-
fication options that are more sensitive, as it will be presented in section 1.3.2.3. Additionally, 
ICP-MS provides no structural information on the biomolecule, hence there is no certainty that 
the quantified metal arises exclusively from the biomolecule complex. Because of this, the clin-
ical quantification of biomolecules using ICP-MS based on the analysis of their complexes with 
metals is debatable. Generally, ICP-MS is applied for trace analysis of metals (and some non-
metals) in environmental analysis, food analysis or forensics. However, for peptide quantifica-
tion in clinical chemistry, ESI-MS is the preferred MS-based technique due to high specificity 
and sensitivity [150]. 
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1.3.2.2. MALDI-MS 
MALDI-MS - Principle of operation 
Matrix-assisted laser desorption/ionization (MALDI), established by Karas and Hillenkamp in 
1988 [154], is a soft ionization technique consisting in the irradiation of an analyte-matrix mix-
ture with a laser, with minimal fragmentation. Here, the analyte of interest is co-crystallized on 
a metal plate (target) with a high molar excess of matrix. In this vein, the dried droplet approach 
is most commonly used, where droplets of matrix and sample are placed on the MALDI target 
and dried at room temperature. Typically, the matrix is a weak organic acid (e.g. α-cyano-4-
hydroxycinnamic acid, 2,5-dihydroxybenzoic acid, sinapinic acid), characterized by an absorp-
tion wavelength correspondent to the laser wavelength (usually in the ultraviolet range). Com-
monly, nitrogen lasers (337 nm) and frequency-tripled and quadrupled Nd:YAG lasers (355 nm 
and 266 nm respectively) are employed for this purpose [155]. Further, the matrix strongly 
absorbs the laser radiation energy, causing its vaporization and, indirectly, the vaporization of 
the analyte. Also, the matrix contains additives that can improve the co-crystallization, seques-
trate the excess of salts and function as H+ donors (e.g. trifluoroacetic acid TFA), which leads 
to the ionization of the sample analyte [156]. 
MALDI-MS provides molecular weight information on intact analytes with high accuracies in 
the low-ppm range. Therefore, MALDI-MS is an excellent analytical tool for peptide and pro-
tein identification and characterization. This technique is thus mainly used for qualitative pur-
poses, with limited applicability for quantitative analysis due to poor shot-to-shot repeatability 
caused by the inhomogeneity of the analyte-matrix mixture and laser fluctuations [155]. 
SELDI-MS 
A distinct type of laser desorption/ionization mass spectrometry is surface enhanced laser de-
sorption/ionization (SELDI) MS, established in 1993 by Hutchens and Yip [157]. SELDI can 
be considered a variation of MALDI that differs in the sample preparation. In this regard, the 
analyte of interest (usually proteins) is applied to a modified surface (chip) that plays an active 
role in the extraction, purification or modification of the analyte prior to desorption and ioniza-
tion for MS analysis. A variety of materials can be used for this purpose, such as metals, cat-
ion/anion exchangers, hydrophobic compounds similar to C8 reverse phase chromatography 
and others [158].The samples spotted on the MALDI target or the SELDI surface are subjected 
further to MS analysis, typically using time-of-flight (TOF) mass analyzers, where the ions are 
separated based on their velocity differences. The m/z ratio is further determined by measuring 
the time needed for the formed ions to reach the detector. 
SELDI/MALDI-MS quantification of hepcidin-25 
SELDI-TOF-MS was the first MS method employed for the semi-quantification of hepcidin-25 
in serum, using immobilized metal ion affinity chromatography (IMAC) chips [159], based on 
the affinity of hepcidin-25 for copper (see section 1.2.3.). Later, Swinkels et al. utilized similar 
IMAC chips in an improved SELDI-TOF quantification method using hepcidin-24 as internal 
standard [160]. However, different biochemical characteristics of the internal standard due to 
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the lack of aspartic acid caused different binding behavior to the IMAC chips and hampered a 
robust quantification assay. Weak cation exchange (WCX) beads were further investigated as 
an alternative modified surface by the same group. Also, with a better mass resolution, MALDI-
TOF “replaced” the SELDI-TOF analysis. This methodology was characterized by a coefficient 
of variation CV < 10% and LOD of 1.5 µg/L [146]. Furthermore, Anderson et al. used ready-
to-use MALDI chips with vacuum sublimated, ultra-fine homogeneous matrix composition that 
provided improved spot-spot reproducibility over the classic dried droplet approach [161]. A 
good precision was achieved (<15%), however, the method proved to be less sensitive with a 
reported LOQ of 2.8 µg/L. 
Additionally, commercially available hepcidin-25 measurements are available in the frame of 
the hepcidinanalysis.com initiative. WCX-MALDI-TOF with isotope enriched hepcidin-25+40 
as internal standard is applied for this purpose, with a reported LOQ of 1.4 µg/L [162, 93]. 
However, even though MALDI-TOF offers high throughput desired in routine laboratories, 
there are several disadvantages that restrict its use for absolute quantification in clinical field, 
such as the non-linear dependency of signal intensity and analyte concentration, with a dynamic 
range usually limited to less than two orders of magnitude. Also, the heterogeneity of analyte-
matrix deposits and laser fluctuations hinder reproducible data acquisition [163]. Moreover, 
many MALDI-MS systems do not offer tandem mass-spectrometry (MS/MS) capabilities, de-
termining limited selectivity compared to LC-ESI-MS/MS. On the other hand, isotope dilution 
(ID) LC-MS/MS (see section 1.3.2.3.) is accepted as the MS “gold standard” for quantification 
of biomolecules in clinical chemistry, providing high selectivity and excellent precision and 
accuracy [164]. 
In this context, the clinical assessment of hepcidin-25 is a case of quantification of a low abun-
dant analyte in complex matrixes (serum/plasma samples). Thus, the best choice for the quan-
tification of this analyte in biological fluids is LC-ESI-MS/MS with clearly superior specificity 
and reproducibility over MALDI-MS. 
1.3.2.3. ESI-MS, LC-(ESI)-MS/MS 
Advances in MS instrumentation, such as the development of electrospray ionization (ESI) 
source [165], the direct coupling of liquid chromatography to mass spectrometry (LC-MS) 
[166] or the coupling of two mass analyzers in tandem mass spectrometry (MS/MS) techniques 
[167], made mass spectrometry occupy a leading role in the field of clinical diagnostics, with 
applications in structural analysis and quantification measurements. LC-ESI-MS/MS is the 
most common mass spectrometry-based quantification method used in clinical laboratories 
nowadays [168], as an emerging alternative to immunoassays. An example in this regard is the 
quantification of steroid hormones in biological fluids, where LC-MS/MS is widely accepted 
as the preferred method, over immunoassays [169]. Also, reference quantification methods for 
the quantification of folates [170] and small endogenous metabolites [171] using LC-MS/MS 
were established. Further discussion on the principle of ESI, MS/MS and LC-ESI-MS/MS and 
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their applications in hepcidin-25 quantification is provided next, together with the pitfalls asso-
ciated and their troubleshooting. 
ESI - principle of operation 
Electrospray ionization, established by Yamashita and Fenn in 1984 [165], is a soft, atmos-
pheric pressure ionization technique, that occurs in liquid phase and is commonly applied to 
(polar) analytes in various polar solvents. Thus, ESI can be used for a wide range of molecules, 
including non-volatile, thermally labile biomolecules, that cannot be analyzed using more con-
ventional techniques such as atmospheric pressure chemical ionization (APCI) or electron im-
pact ionization (EI) [151]. 
Generally, ESI-MS can be divided into three steps: nebulization of a solution into electrically 
charged droplets with generation of a fine spray, evaporation of solvent with subsequent deliv-
ery of ions from droplets and transportation of the ions from the atmospheric pressure ionization 
source area into the vacuum of the mass analyzer [172, 173]. First, the sample solution is intro-
duced into a stainless steel or quartz vessel, called capillary, which ends in a very fine tip. Then, 
a high voltage (2-6 kV) is applied between the capillary tip and a counter-electrode which is 
located at the entrance of the mass analyzer, generating a mist of highly charged droplets with 
the same polarity as the capillary voltage (Figure 1.9). When the electrostatic repulsion of the 
charges overcomes the surface tension (Rayleigh limit), charged micro-droplets are released 
from the surface towards the counter-electrode [172]. In this vein, increased temperature and a 
nebulizing gas (e.g. nitrogen) assist the reduction in size of the charged droplets. Further, the 
droplet radius decreases progressively, while the surface charged density increases [151], fol-
lowed by the emission of the ions from the highly charged micro-droplet. Two models were 
proposed in this regard. Iribarne et al. suggested that when the strength of the electric field at 
the surface of the droplet is high enough, ions may be emitted directly from the highly charged 
droplet to the surrounding gas due to Coulomb repulsion forces (Ion Evaporation Model) [174]. 
A second theory by Dole et al. [175], supported later by Schmelzeisen-Redecker et al. [176], 
claims that repetitive Coulomb explosions lead to ion separation from the surface of the droplets 
as nano-droplets, released by de-solvation of the remaining solvent (Charged Residue Model). 
Either way, “naked” sample ions are finally generated, which are sampled by a sampling skim-
mer cone and further transported in the mass analyzer [172]. 
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Figure 1.9: Schematic of the ESI process (positive mode) [177]. 
Ionization process 
There are diverse ways to obtain sample ions in solution for ESI-MS analysis. Molecular ions 
are formed by the removal from (Mn+) or addition to (Mn-) a molecule of one or more electrons 
[178], where n represents the number of charges per ion. However, this is rarely the case in ESI. 
Usually, the molecule is protonated ([M+nH]n+) or deprotonated ([M-nH]n-), in which case the 
ions are named quasi-molecular ions. Consequently, the mass range of any mass analyzer is 
characterized by a n-fold enhancement. Therefore, compounds with high molecular masses 
such as proteins can be identified using ESI-MS at relatively small m/z ratios [179]. 
Some compounds already exist as ions in solution, for example quaternary ammonium salts or 
salts from strong acids (sulfates, phosphates). In other cases, the pH needs to be adjusted either 
to protonate a base or deprotonate an acid. Hence, the ionization of amines such as peptides or 
proteins requires acidic pH, whereas basic pH is employed for ionizing acidic samples such as 
carboxylic acids or phenols. However, protonation and deprotonation cannot be applied for 
other polar compounds that do not contain basic or acidic groups. Alternatively, these com-
pounds can be associated with other ions in solution [172]. Usually, sodium and potassium ions 
are used for the detection of a sample as positive ions [M−nH+mNa](m−n)+ or [M−nH+mK](m−n)+, 
due to their affinities for N-methylacetamide anion [180]. Negative ions such as acetate, for-
mate or trifluoroacetate are used for the detection of a sample as negative ions [M+nH-mX](m-
n)-. Examples of such compounds are amides, esters, ethers or carbohydrates [172]. 
For pH control, volatile bases, such as ammonium hydroxide, or volatile acids, such as formic 
acid (FA), trifluoroacetic acid (TFA) or acetic acid, are used. In high-performance liquid chro-
matography (HPLC), these reagents are commonly added in the mobile phases as ion-pairing 
agents to improve chromatographic resolution. Therefore, HPLC devices can be easily hyphen-
ated online to ESI sources, when compatible flow rates are applied. However, the ion-pairing 
reagents can be a source of ion suppression in MS. For example, the use of TFA is controversial. 
There are studies showing strong  suppression of the ionization efficiency of peptides using 
TFA in some ion sources [181]. In this vein, Kuhlmann et al. developed methods to reduce the 
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signal suppression of strong acids such as TFA by post-column addition of TFA-fix mixtures 
containing isopropanol and propionic acid [182]. On the other hand, some ion sources are not 
significantly affected by the use of TFA, even over long periods of time [183]. Generally, TFA-
based ion suppression influences strong basic compounds. The cause is intense ion pairing be-
tween the TFA anion and the protonated cation of basic compounds. The protonated cations are 
“camouflaged” and appear neutral to the electric fields of the ionization source. However, 
weakly basic molecules are not significantly affected by this process [182]. 
Nevertheless, signal suppression of the analytes of interest cannot be attributed to one cause 
only such as the ion-pairing reagents used as additives, but it is a complex process dependent 
on many factors. Signal suppression (or enhancement), defined as the variability in the ioniza-
tion response of the target compound, depends on the chemical properties of the target mole-
cule, the pH of the solution, the concentration of electrolytes and other matrix components, the 
clean-up protocol of the sample, the chromatographic conditions, including both stationary and 
mobile phases, and the MS instrumentation (source design, ionization mode) [184, 185]. In case 
of complex clinical samples such as plasma or serum samples, it was shown that ionization 
suppression is mainly caused by non-volatile materials from the biological sample extracts 
[185]. 
The sensitivity of ESI-MS is highly influenced by the ability to produce gas-phase ions from 
the molecules of the analyte in solution (ionization efficiency) and the capability to transfer the 
formed ions from atmospheric pressure to the vacuum area in the mass analyzer (transmission 
efficiency). The ionization efficiency, defined by IUPAC as “the ratio of the number of ions 
formed to the number of electrons or photons used in an ionization process” [178], can be af-
fected by several factors such as flow rate, interface design, solvent properties (polarity, pH) or 
analyte characteristics (basicity, polarity, volatility, molecular size). The transmission effi-
ciency, defined as “the ratio of the number of ions leaving a region of a mass spectrometer to 
the number entering that region” [178], has been mainly restricted by the loss of ions at the MS 
inlet and skimmer [186]. 
MS/MS 
Tandem mass spectrometry (MS/MS) is a general term used for MS methods, where the sample 
ion (“precursor ion”) of the m/z ratio of interest is selected and dissociated to generate fragment 
ions (“product ions”). Two main categories of instruments allow MS/MS analysis. One option 
is represented by two mass analyzers assembled in tandem, such as quadrupole time-of-flight 
q-TOF or triple quadrupole QqQ (tandem mass spectrometry in space). The second category 
includes mass analyzers able to store the ions, such as the ion cyclotron resonance (ICR) or the 
quadrupole ion trap (tandem mass spectrometry in time) [167, 187]. Different fragmentation 
techniques are available for ion fragmentation. In this regard, collision-induced dissociation 
(CID) is one of the most commonly applied method for ion fragmentation, wherein the molec-
ular ions are moved to a region of higher potential that determines their acceleration and the 
increase in kinetic energy. The subsequent collision with neutral molecules, usually helium, 
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nitrogen or argon, yields the enhancement of the ions’ internal energy. This results further in 
bond breakage and the fragmentation of the molecular ion into smaller fragments [188]. 
LC-MS/MS quantification (MRM) 
Particularly when analyzing multiple components mixtures, liquid chromatography (LC) is usu-
ally coupled to ESI-MS with the aim to achieve improved sensitivity and specificity yielded by 
the chromatographic separation of the sample constituents. In contrast to MALDI-MS, LC-ESI-
MS is commonly used for both qualitative and quantitative analysis of biological samples. In 
this respect, for structural analysis, LC is coupled to MS/MS instruments which offer high res-
olution (RFWHM=104-106), such as q-TOF, Orbitrap or FTICR (Fourier-transform ion cyclotron 
resonance). Here, the mass resolution (R) is defined as M/ΔM, where M designates the mass 
and ΔM the peak width necessary for separation at mass M. The resolution is given using the 
peak width definition by choosing the peak width measured at 50% of the maximum peak 
height, also known as Full Width of the peak at Half its Maximum height (FWHM) [178]. 
However, these instruments are generally less attractive for the quantification of biomolecules. 
Especially in the case of q-TOF devices, they provide high mass resolution but are restricted by 
a smaller linear dynamic range and lower sensitivity, compared to triple quadrupole instruments 
[189]. 
By contrast, for quantification purposes, LC coupled to triple quadrupole (QqQ) mass spec-
trometer represents the preferred instrumentation due to highly selective and sensitive quanti-
tation capabilities. Nevertheless, a rather low resolution (RFWHM=103) limits its qualitative ap-
plications. In tandem quadrupole MS, established in the late 1970s by Enke and Yost [190], the 
first and last mass analyzers (quadrupole 1 [Q1] and quadrupole 3 [Q3] respectively) are used 
as mass filters to select a precursor ion and its corresponding product ions. The second quadru-
pole (q2) is a non-mass-resolving, radio frequency (RF)-only quadrupole that acts as a cell for 
fragmentation (CID). The specific pair of m/z ratio values associated with the precursor and 
product ions is referred to as a “transition” and can be written as (precursor [m/z])  (product 
[m/z]) [168]. This MS/MS approach is named selected or multiple reaction monitoring (SRM 
or MRM respectively). 
In this context, the linear ion trap was also promoted as a suitable quantification tool. Here, the 
ability to apply a m/z ratio correlated resonant excitation frequency to the precursor ion, which 
is subsequently fragmented, typically affords a single-step fragmentation, since the product ions 
will have different mass-to charge ratios. This results is a product ion spectra with fewer ions 
at higher relative intensities. In contrast, the precursor ion accelerated through the pressurized 
collision cell (q2) in a triple quadrupole leads to a collision cascade or a multiple-step fragmen-
tation, which tends to generate a large number of product ions and hence relatively lower abun-
dance of the analyte ions. However, the MS/MS in ion trap offers a low duty cycle with a serial 
process occurring for collection, isolation of precursor ions, fragmentation and detection of 
product ions. This means that, especially when it comes to the analyte present in a low amount 
in the LC peak, there may not be sufficient time to fill the ion trap with enough ions to perform 
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an accurate quantitative measurement. On the contrary, the double-stage MRM analysis is car-
ried out with a continuous ion beam affording a nearly 100% duty cycle which provides superior 
LOQ and improved reproducibility [191]. 
Hence, the triple quadrupole is the instrument of choice for quantification of biomolecules due 
to a high duty cycle and a large dynamic range when operated in MRM mode, granting superior 
analytical figures of merit such as sensitivity, precision and accuracy. Moreover, LC-MS/MS 
employing MRM transitions ensures high specificity due to a three-step separation of the ana-
lyte based on (1) retention time, (2) precursor m/z, and (3) fragment m/z. This can be particu-
larly useful for the analysis of complex matrixes such as serum or urine [192]. 
Isotope dilution (IS) 
The principle of LC-MS/MS quantification lies in the comparison of the signal intensity (MRM 
signal in the case of triple quadrupole instruments) of the analyte in an unknown sample to the 
signal intensity obtained in calibration standards of known concentration of the same analyte. 
However, the signal intensity in MS or MS/MS is not only dependent on the concentration of 
the analyte, but also on various instrumental parameters, which will not remain constant 
throughout the measurement. It is required to compensate for the instrumental variables by rel-
ative measurements of a so-called “internal standard” (IS). The principle of measurement by 
MS permits the use of a stable isotope-labeled analogue of the analyte as IS, in which case the 
technique is called “isotope dilution-mass spectrometry” (ID-MS). Isotope-labeled ISs have 
almost identical physicochemical properties to those of the analyte, thus they are superior to 
homologous or other structurally analogous ISs [193]. Nonetheless, mathematical treatment of 
the calibration data should be cautiously performed, especially in the case of peptide quantifi-
cation, since the signal intensity of the monoisotopic mass of a stable isotope-labeled peptide 
differs from the unlabeled equivalent due to different isotope patterns. The magnitude of the 
variation (the so-called “response factor”) depends on the elemental composition of the mole-
cule, the number of labeled atoms, the type of labeled atom and the enrichment of the isotope-
labeled starting material [194]. 
LC-MS quantification of hepcidin-25 
Murphy et al. reported the first LC-MS/MS assay for quantification of hepcidin-25 in human 
and mouse serum employing Capcell Pak UG C18 column for sample fractionation and a triple 
quadrupole for MS/MS detection. Good intra- and inter-assay precision and accuracy were 
achieved (<20%). The LOD was reported at 1 µg/L. However, calcitonin gene-related peptide 
was used as IS, which is not ideal due to its different size and charge [195]. In-house synthetized 
isotope-labeled hepcidin-25+9 (13C815N) was employed by Bansal et al. to quantify serum hep-
cidin-25 using ultra-high-pressure liquid chromatography (UHPLC) coupled to a linear ion trap. 
The authors reported that the use of a triple quadrupole for Hep-25 analysis results in poorer 
fragmentation compared to a linear ion trap. The study used WCX magnetic nanoparticles for 
peptide extraction with a medium recovery (75%). Also, the calibration standards used were 
prepared with charcoal stripped serum [196], which is not a suitable analyte-free matrix due to 
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poor similarities to human serum. Intra-assay precision was reported <15% and a LOQ of 1.1 
µg/L was achieved. Later, Itkonen et al. used a linear ion trap for Hep-25 quantification with a 
reported LOQ of 0.8 µg/L. The authors compared their MS-based method with a commercially 
available immunoassay and found no significant correlation [136]. Bros et al. employed LC 
coupled to high resolution (HR) MS using ion trap-Orbitrap for identification of impurities in 
hepcidin-25 standards. The instrumentation used proved to be adequate for qualitative analysis 
and revealed valuable information about the purity of commercially available standards. Me-
thionine-oxidized and truncated N- and C-terminus forms were identified as impurities, under-
lining the need for a certified reference material [87]. However, the quantification of hepcidin-
25 in biological samples employing HR-MS was not found suitable. As a consequence, the 
same group reported a quantification assay based on LC-MS/MS analysis using a triple quad-
rupole [197]. This assay was adapted from a quantification method developed previously by 
Delaby et al. for serum hepcidin-25, with a reported LOQ of 6 µg/L [198]. The latter study 
however did not include matrix effect and recovery determinations. LC-MS/MS using triple 
quadrupole was also employed by Wolff et al., using isotope-labeled hepcidin-25 as IS. Oasis 
hydrophilic-lipophilic balanced reversed-phase (HLB) cartridges were used for sample prepa-
ration. The reported LOQ was 1.3 µg/L. However, no recovery data and matrix effects were 
reported [199]. 
To conclude, LC-MS/MS was used for the quantification of hepcidin-25, with triple quadrupole 
as the preferred mass analyzers. However, the use of inadequate analyte-free matrixes and the 
insufficient validation question the scientific value of these methods. It would be desirable for 
all the methods to be validated in compliance with the guidelines for clinical laboratory ap-
proved by CLSI (Clinical and Laboratory Standards Institute) [168]. These guidelines encom-
pass verification procedures of validation parameters, namely linearity, specificity, precision 
and accuracy, specified by the International Conference on Harmonization (ICH) of analytical 
procedures [200]. Additionally, CLSI directives refer to the parameters specific for clinical 
samples, such as recovery and matrix effects. 
Moreover, many difficulties in the analysis of hepcidin-25 were reported, such as the oxidation 
of the methionine residue, aggregation of hepcidin-25 in solution or adsorption of the peptide 
[87, 85, 160]. In this vein, the stability of hepcidin-25 standards in polypropylene and deac-
tivated glass vials was tested. No significant peptide losses were reported [87]. However, the 
concentrations tested seemed to be in the order of mg/L, which is not relevant for the quantifi-
cation range of 0.5-40 µg/L corresponding to the physiological levels of the peptide (see section 
1.3.3.3.). Also, the influence of the solvent on Hep-25 concentrations was not tested. 
One of the most common analytical challenges in LC-MS assays is the non-specific adsorption 
of peptides or proteins on solid surfaces, particles or matrix compounds. MS analysis can be 
hampered by the amphipathic character of the analyte, which makes it readily stick to plastic or 
glass surfaces, leading to adsorptive losses that can affect the accuracy of the measurement 
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results [201, 202]. In this regard, further improvement is necessary in the LC-MS/MS develop-
ment and validation of quantification methods for hepcidin-25 to assure the transfer of these 
methodologies from research to clinical application. 
1.3.3. Harmonization of hepcidin-25 measurements 
1.3.3.1. International Hepcidin Harmonization Studies 
Various MS-based methods and immunoassays have been developed for the measurement of 
hepcidin-25 concentration in biological samples. However, the reported serum hepcidin levels 
varied substantially between measurement procedures due to differences in methodology and 
analytical performance. Two international interlaboratory comparisons (the so-called Round 
Robin RR1 and RR2), organized by Radboud University Nijmegen, The Netherlands, addressed 
the method harmonization in hepcidin-25 analysis. In this respect, RR1 was organized in 2009 
and included eight laboratories that analyzed identical urine and serum samples. Major differ-
ences between absolute hepcidin levels were reported [203]. Considering this, a second RR 
took place three years later, involving 21 participants. Similarly, identical serum samples were 
tested. Additionally, two commercially available synthetic hepcidin-25 standards were ana-
lyzed to assess their suitability as a material for harmonization. The various methods used for 
the analysis of the human samples (10 MS-based methods and 11 immunoassays) showed up 
to 10-fold differences between results [204]. 
These discrepancies are caused partly by the usage of different calibrators and the lack of a 
reference material, and partly because of the reason that the used immunoassays quantify all 
hepcidin isoforms together (Hep-20, -22, -24, -25) (see section 1.3.1.), while MS-based meth-
ods measure selectively the bioactive Hep-25. Other reports about hepcidin quantification com-
pared “in house” developed LC-MS methods to commercially available immunoassays as ref-
erence method, with insufficient correlation [198, 136], most likely due to different analytes 
compared. Additionally, hepcidin was reported to bind to α-macroglobulin and albumin, but 
the found bound hepcidin fraction varied from 3% to 89% [205, 206]. It is unclear if the binding 
of Hep-25 to plasma proteins has any effect on the performance of the quantification assay or 
even its biological activity [76]. Also, it was reported that hepcidin-25 is a “sticky” peptide that 
can adhere to hydrophobic surfaces, a challenge that can be difficult to overcome in the MS 
analysis and can affect the accuracy of the results [84, 93, 55]. Methods recommended by the 
International Consortium for Harmonization of Clinical Laboratory Results were applied to 
further investigate interlaboratory variation of hepcidin-25 measurements. This resulted in the 
identification and production of a secondary reference material in the frame of the hepcidina-
nalysis.com initiative (conducted by the Department of Laboratory Medicine of the Radboud 
University Medical Center Nijmegen) [162, 132]. This is currently used as a calibrator set in an 
ongoing round robin study (Hepcidin Harmonization Study HHS2017) involving 10 laborato-
ries worldwide (see section 4.4.2.) [manuscript in preparation]. Nevertheless, the assignment of 
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absolute Hep-25 concentration is hindered by the lack of a primary reference material or a cer-
tified reference material (CRM). LNE Paris (Laboratoire national de métrologie et d'essais) 
seem to have produced a primary reference material that is not commercially available so far 
[162]. 
1.3.3.2. Quantification methods for clinical use 
The focus of harmonization in laboratory medicine is not only to harmonize and standardize 
the analytical methods, but also to include all other aspects of the total testing process (TTP), 
such as terminology and units, report formats, reference intervals and decision limits, as well 
as tests and test profiles request and criteria for interpretation [181]. In this vein, some quanti-
fication methods for Hep-25 are undergoing clinical approval (Table 1.5). The relevance of 
hepcidin-25 as a clinical parameter is supported by an increasing number of clinical studies 
showing positive diagnostic performance of serum hepcidin in different clinical settings [76]. 
Table 1.5: Hepcidin assays available for clinical use [76]. 
 Method Institution / Company Clinical credentials Ref. 
M
S 
m
et
ho
ds
 
WCX-TOF-MS Radboud University, 
hepcidinanalysis.com, 
Nijmegen (NL) 
Patient care: included in scope of ac-
creditation of clinical laboratory  
(Dutch CCKL/RvA Code of Practice, 
in transation to EN ISO 15189). 
[93] 
LC-MS/MS  
(reversed phase ex-
traction) 
University Hospital of 
Verona (IT) 
Embedded in laboratory accredited 
by Regional Health authority  
(Veneto Region law no. 838, April 8, 
2008). 
[207] 
LC-MS/MS  
(Hydrophilic-lipophi-
lic-balanced (HLB) 
extraction) 
HUSLAB at Helsinki 
University Central 
Hospital (FI) 
Embedded in accredited clinical la-
boratory (Finnish Accreditation Ser-
vice, T055, EN ISO/IEC 17025, 
EN ISO 15189) 
[136] 
Im
m
un
oa
ss
ay
s 
Sandwich ELISA Eli Lilly and Company 
(US) 
Clinical trials: CRO partner has vali-
dated test in GLP-like manner. 
[144] 
Competitive ELISA DRG Instruments (DE) CE-marked, approved as in vitro 
medical device (IVD directive 
98/87/EC) 
[208] 
Competitive ELISA  Intrinsic LifeSciences, 
La Jolla (US) 
Compliant with Clinical Laboratory 
Improvement Amendments (CLIA) 
and College of American Pathologist 
(CAP) standards 
[141] 
In this context, MS-based methods seem to have a more advanced status over immunoassays in 
terms of hepcidin-25 quantification in clinical environment, probably also due to the lack of 
suitable antibodies against the bioactive isoform (see section 1.3.1.). Furthermore, isotope di-
lution (IS) LC-MS/MS is widely recognized as the “gold standard” for quantification of bio-
molecules by accredited bodies such as Clinical and Laboratory Standards Institute (CLSI) 
[168] or National Institute of Standards and Technology (NIST) [5]. Nevertheless, further ef-
forts towards increasing the availability of validated assays followed by their clinical imple-
mentation are vital for universal recognition of this promising biomarker [76]. 
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1.3.3.3. Physiological levels of Hep-25 
The assignment of universal reference ranges for hepcidin-25 is hampered by the considerable 
variations in the physiological serum levels reported in humans. On one hand, the “intra-
method” Hep-25 levels vary widely in healthy subjects, which are reflected in large physiolog-
ical reference ranges. A study of 100 healthy patients reported a concentration range of <0.02 
– 25 µg/L, with 44% of the population showing levels < 0.9 µg/L [144]. Moreover, studies 
revealing diurnal fluctuations of Hep-25 concentrations suggest that the moment of the day 
when the serum is collected represents an influencing factor in hepcidin-25 quantification [209, 
210]. Additionally, a day-to-day variation of hepcidin-25 concentration was also reported. It 
was shown that within an individual, the peptide hormone level could vary as much as 2- to 5-
fold from day to day [209, 195]. On the other hand, the “inter-method” hepcidin-25 concentra-
tions vary substantially, as presented in section 1.3.3.1. The comparison between different val-
ues reported is even more difficult because some methods report the mean value of hepcidin-
25, either as arithmetic mean (average) or as geometric mean, whereas other methods list the 
median Hep-25 value. 
It must be mentioned that the hepcidinanalysis.com initiative reports reference ranges based on 
a population of almost 2000 healthy individuals. However, the values of the concentrations are 
ambiguous since these do not represent direct analytical measurements, rather calculated values 
based on a mathematical formula involving 2 methodologies, a WCX-MALDI-TOF method for 
Hep-25 quantification and an ELISA that measures total hepcidin [162]. Other noteworthy re-
ports suggested reference ranges for serum hepcidin-25 (Table 1.6). 
Taking into consideration the values reported by the research group of Eli Lilly and Company 
(Indianapolis, IN, USA), which applied both an immunoassay selective for Hep-25 and a LC-
MS/MS method for the quantification of the iron-regulator, the present work defines the median 
physiological level of Hep-25 in humans between 1-5 µg/L and the mean level (arithmetic mean 
or average) between 5-15 µg/L. In this respect, it has been reported that several samples are 
found to be <LOQ, which indicates that the median value could be more relevant than the av-
erage value. However, it is desirable that both values are reported, together with the level range 
determined, since hepcidin-25 serum concentrations seem to vary widely. 
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Table 1.6: Physiological levels of hepcidin-25 in humans reported by selected methodologies. 
Institution/ 
Company 
Quantification 
method 
Patient no. Mean  
(µg/L) 
Median (µg/L) Concentration 
range (µg/L) 
Ref. 
Elli Lilly and 
Company (US) Sandwich ELISA 100 N/A 1.2 <0.02 - 25 [144] 
Elli Lilly and 
Company (US) LC-MS/MS 10 9 3.6 <1.0 - 45.6 [195] 
HUSLAB/ Uni-
versity of Hel-
sinki (FI) 
LC-MS/MS 
 
Men: 109 
Women: 66 
Men: 14 
Women: 7 
Men: 12 
Women: 5.9 
Men: 3.1 – 43.5 
Women: 1.1 – 25.7 [136] 
hepcidinanaly-
sis.com (NL) WCX-TOF-MS
* Men: 1066 Women: 882 N/A 
Men: 12.6 
Women: 10 
Men: <1.4 – 41 
Women: <1.4 – 40.7 [162] 
* The reference levels for the WCX-TOF MS method are recalculated from those of an ELISA method based on the regression line: (ELISA - 1.00)/1.52 = WCX-TOF MS [162].  
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2. Materials and Methods 
2.1. Chemicals, reagents and biological samples 
The chemical substances used during this study were of highest grade of purity available. 
In this regard, Table 2.1 summarizes solids and liquids, as well as peptides and mass cali-
bration solutions used throughout this work, together with their corresponding grade of 
purity, supplier and product number. 
Table 2.1: List of chemicals used during this work. 
Chemical Purity Supplier Product number 
Solids and liquids 
1H,1H,2H,2H-Perfluoro-oc-
tyltriethoxysilane 98% Sigma-Aldrich, Taufkirchen, DE 667420 
3-(2-Aminoethylamino) propy-
lmethyl-dimethoxysilane 97% Alfa Aesar, Karlsruhe, DE B23159 
(3-Aminopropyl) trimethoxy-
silane 97% Sigma-Aldrich, Taufkirchen, DE 281778 
Acetic acid glacial  HPLC grade AppliChem, Darmstadt, DE 361008.161 
Acetonitrile  LC-MS grade ChemSolute, Renningen, DE 2697 
Ammonia solution 20% LC-MS grade Carl Roth, Karlsruhe, DE hN66.2 
Ammonium acetate  >99.9995% Sigma-Aldrich, Taufkirchen, DE 101707138 
Ammonium hydroxide solution 
28.0-30.0% ACS reagent Sigma-Aldrich, Taufkirchen, DE 221228-M 
Buffer solution pH 4.01 N/A Hanna Instruments, DE HI7004 
Buffer solution pH 7.01 N/A Hanna Instruments, DE HI7007 
Buffer solution pH 10.01 N/A Hanna Instruments, DE HI7010 
Citric acid  BioXtra (≥99.5%) Sigma-Aldrich, Taufkirchen, DE C0706 
Copper sulfate solution 0.1 M Titripur® Sigma-Aldrich, Taufkirchen, DE 35185 
Cysteine ≥98% Sigma-Aldrich, Taufkirchen, DE C7352 
L-Cystine ≥98% Sigma-Aldrich, Taufkirchen, DE C8755 
DY-654-NHS N/A Dyomics, Jena, DE 654-01 
EDTA BioUltra (≥99%) Sigma-Aldrich, Taufkirchen, DE EDS 
Formic acid LC-MS grade  Sigma-Aldrich, Taufkirchen, DE 5.33002 
Glutathione (oxidized) >98% Sigma-Aldrich, Taufkirchen, DE G4376 
Glutathione (reduced) >98% Thermo Fischer, Darmstadt, DE BP2521-10 
Guanidine hydrochloride ≥99 % Sigma-Aldrich, Taufkirchen, DE G3272 
HEPES ≥99,5 % Sigma-Aldrich, Taufkirchen, DE H4034 
Hydrochloric acid ≥32%  BioUltra Sigma-Aldrich, Taufkirchen, DE 84415 
Iso-propanol LC-MS grade ChemSolute, Renningen, DE 1164 
Methanol HPLC grade ChemSolute, Renningen, DE 1481 
Mucasol  N/A. Schülke&Mayr, Norderstedt, DE 230191 
Ortho-phosphoric acid 85% HPLC grade Honeywell, USA 79606 
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Potassium phosphate  
monobasic BioUltra (>99.5%) Sigma-Aldrich, Taufkirchen, DE 60218 
Sodium bicarbonate 99.5% AppliChem, Darmstadt, DE A1940.1000 
Sodium chloride BioUltra (>99.5%) Sigma-Aldrich, Taufkirchen, DE 71376 
Sodium citrate tribasic  
dihydrate BioUltra (>99.5%) Sigma-Aldrich, Taufkirchen, DE 71402 
Sodium hydroxide  ACS reagent (>98%) Sigma-Aldrich, Taufkirchen, DE 30620-M 
Sodium phosphate  
monobasic dihydrate BioUltra (≥99%) Sigma-Aldrich, Taufkirchen, DE 71643 
Sodium phosphate dibasic 
dihydrate BioXtra (≥99%) Sigma-Aldrich, Taufkirchen, DE S7907 
Sodium tetraborate  
decahydrate BioXtra (≥99.5%) Sigma-Aldrich, Taufkirchen, DE B3545 
Toluene  ≥99,5 % Carl Roth, Karlsruhe, DE 9558.3 
Trifluoroacetic acid  LC-MS grade Honeywell, US 14264 
α-Cyano-4-hydroxycinnamic 
acid N/A Bruker-Daltonik, Bremen, DE 8255344 
Peptides 
Human hepcidin-25 (linear) >95% peptides&elephants,  Hennigsdorf, DE 1006P06 
Human hepcidin-25 (folded) >95% (HPLC) Bachem, Bubendorf, CH H5926.0500 
[13C9,15N]Phe4,9, [15N]Gly12-
Hepcidin-25 >99% (HPLC) Peptide Institute, Osaka, JP 3405-v 
Peptide DTHFPI-NH2 99.9% peptides&elephants,  Hennigsdorf, DE lot 1211N01 
Mass calibration solutions 
MS Chemical Kit 1, Low-
High Conc. PPGs N/A AB Sciex, Darmstadt, DE 4406127 
Peptide Calibration  
Standard II N/A Bruker-Daltonik, Bremen, DE 8222570 
Pierce LTQ ESI Positive Ion 
Calibration solution N/A Thermo Fischer, Darmstadt, DE 88322 
N/A = not available 
Purified laboratory water was obtained from a Milli-Q water-purification system (Milli-
pore, Schwalbach, Germany). Serum samples used within the present work were obtained 
from various sources. Sterile-filtered sheep serum and bovine serum were purchased from 
Sigma-Aldrich, Taufkirchen, Germany (S2263 and B9433 respectively). Human serum 
samples were obtained from Dunn Labortechnik, Asbach, Germany. These human sera 
were collected from healthy volunteers at an FDA licensed commercial donor center/facil-
ity within the Unites States and were found negative for: HBsAg, HCV, HIV-1, HIV-2, 
HIV-1Ag or HIV-1-NAT, ALT and syphilis. Human serum samples for the experiments 
within the Hepcidin Harmonization Study (HHS2017) conducted by Radboud University 
Nijmegen and hepcidinanalysis.com were delivered from Radboud University Medical 
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Center, Nijmegen, The Netherlands, where the sample collection was conducted in accord-
ance with the local Ethics committee. Particular care was addressed to the laboratory ware 
used during this work. Low binding reaction tubes (LoBind Eppendorf tubes) and standard 
Eppendorf tubes were purchased from Eppendorf, Wesseling-Berzdorf, Germany. HPLC 
glass vials used for silanization (see section 2.3.2.) were obtained from Wicom, Heppen-
heim, Germany. Low adsorption (LA) glass vials were purchased from Supelco, Bellefonte, 
PA, USA, and polypropylene (PP) vials from Thermo Fischer, Darmstadt, Germany. 
2.2. Synthesis of conjugates and metal complexes 
2.2.1. Buffers 
Table 2.2 presents the buffers employed in this study for folding linear hepcidin-25, label-
ing folded Hep-25, preparation of peptide-metal complexes and solubility tests. 
The pH adjustments were performed using a pH meter Hanna 211 (Hanna Instruments, 
Vöhringen, Germany), calibrated daily using buffer solutions at pH 4.01, 7.01 and 10.01. 
Table 2.2: List of buffers used during this work. 
Buffer Recipe 
Folding buffer 0.4 mM reduced glutathione (GSH) 
0.4 mM oxidized glutathione (GSSG) [85] 
pH 7 (adjusted with ammonium hydroxide solution 30%) 
Borate buffer 50 mM sodium tetraborate decahydrate (Na2B4O7·10 H2O) 
pH 8 (adjusted with sodium hydroxide 20% and hydrochloric acid 20%) 
Ammonium acetate 
buffer 
10 mM ammonium acetate (CH3COONH4) 
(a) pH=8.3 (adjusted with ammonia solution 20%) 
(b) pH=7.4 (adjusted with ammonia solution 20%) 
Sodium bicarbonate 
buffer 
0.1 M sodium bicarbonate (NaHCO3) 
pH 7.8/8.5 (adjusted with sodium hydroxide 20% and hydrochloric acid 
20%) 
Phosphate-buffered 
saline (PBS) buffer 
10 mM sodium phosphate dibasic dihydrate (Na2HPO4·2 H2O) 
2.3 mM potassium phosphate monobasic (KH2PO4) 
137 mM sodium chloride (NaCl) 
pH 7.4 
Citrate buffer 46 mM sodium citrate tribasic dihydrate (Na3C6H5O7·2 H2O) 
54 mM citric acid (C6H8O7) 
pH 4.2 (adjusted with sodium hydroxide 20% and hydrochloric acid 20%) 
Phosphate buffer 100mM sodium phosphate monobasic dihydrate (NaH2PO4·10 H2O) 
137 mM sodium chloride (NaCl) 
pH 2.2 (adjusted with phosphoric acid H3PO4) 
HEPES buffer (a) 0.1 M HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) 
(b) 30 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) 
pH 7.4 (adjusted with sodium hydroxide 20% and hydrochloric acid 20%) 
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2.2.2. Peptide DTHFPI-copper(II) complex 
The peptide DTHFPI-CONH2 with a reported molecular weight of 729.6 was dissolved in 
30 mM HEPES buffer (pH 7.4) to a concentration of 10 mM.  The stock solution was 
immediately aliquoted into 100 µL fractions in LoBind Eppendorf tubes and stored at -
20°C until application in the experimental process. 
One aliquot (100 µL) of 10 mM peptide DTHFPI-CONH2 in 30 mM HEPES at pH 7.4 was 
thawed right before use. The peptide solution was titrated with subsequent additions of 1 
µL of 0.1 M CuSO4 standard solution. The formation of the DTHFPI-Cu2+ complex was 
observed in a molar ratio peptide:Cu2+ ranging from 1:0.1 to 1:2. Each addition of the Cu2+ 
solution was followed by thorough vortexing and UV-Vis measurements (see section 
2.4.1.). 
2.2.3. Production of folded hepcidin-25 
Lyophilized linear hepcidin-25 (DTHFPICIFCCGCCHRSKCGMCCKT-CONH2) with a 
reported molecular weight of 2797.8 was re-suspended in distilled water to a concentration 
of 10 g/L. The stock solution was immediately aliquoted into 100 µL fractions in LoBind 
Eppendorf tubes and stored at -20°C until use. For each folding experiment, a freshly 
thawed aliquot (100 µL) containing 1 mg of linear hepcidin-25 was added to 30 mL folding 
solution consisting of acetonitrile:folding buffer (see section 2.2.1.) 20:80 (v/v). Linear 
hepcidin-25 was oxidized overnight (16-24 h) under stirring at 100 rpm using a magnetic 
stirrer (Carl Roth, Karlsruhe, Germany). Then, the solution was acidified by addition of 
TFA (0.1%) [211] and further loaded onto a Zorbax C18 LC column (4.6x150mm, 5µm) 
for preparative purification, using a HPLC pump (Gynkotek, model 480) at a flow rate of 
0.5 mL/min. Chromatographic set 1 was employed for purification (see section 2.4.2.2.). 
Fractions between minute 14 and minute 16 containing folded hepcidin were collected 
manually and subsequent HPLC analysis of the fractions was performed (Chromatographic 
set 3). The fractions containing folded hepcidin were stored in the separation mobile phase 
(water/acetonitrile/TFA approximately 60/40/0.1 v/v/v) at 4°C until further use. MALDI-
MS was employed for exact mass confirmation. To assess the yield of the folding process, 
HPLC quantification of hepcidin was achieved using chromatographic set 3. Seven stand-
ards were prepared in the dynamic range 6.25 – 250 mg/L (6.25, 12.5, 25, 50, 100, 150, 
250 mg/L) using water/acetonitrile/TFA 60/40/0.1 v/v/v as dilution solvent. The quantifi-
cation of folded hepcidin-25 will be discussed in detail in section 2.5.3. 
2.2.4. Synthesis of hepcidin-25 labeled with a fluorescent tag 
One aliquot (100 µL) containing 0.1 mg of human hepcidin-25 (see section 2.3.1.1.), 
thawed immediately before use, was introduced in a vacuum oven (VDL 23, Binder, Tut-
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tlingen, Germany) set at room temperature until dryness. This dried residue was then dis-
solved in 200 µL reaction buffer consisting of a mixture of 0.1 M NaHCO3 (pH 8.5)/meth-
anol 50/50 (v/v). The fluorescent dye solution was prepared by dissolving DY-654-NHS in 
the reaction buffer at a concentration of 2 g/L immediately before use. 30 µL of dye solution 
was added to the peptide solution for a molar ratio peptide:dye of 1:1.5. The mixture was 
incubated overnight at room temperature, in the dark, and further purified by HPLC (Azura 
UHPLC). Chromatographic separation was achieved using chromatographic set 2 (see sec-
tion 3.4.2.2.). 
2.2.5. Solubility tests 
Hepcidin-25 folded “in house”, stored in water/acetonitrile/TFA approximately 60/40/0.1 
v/v/v (see section 3.2.2.), was used. Aliquots of 50 µL hepcidin solution 130 mg/L were 
introduced in a vacuum oven (VDL 23, Binder, Tuttlingen, Germany) set at room temper-
ature until dryness. Different solvent mixtures and buffers were used as reconstitution sol-
vents (50 µL) as follows: water/acetonitrile/TFA 60/40/0.1 (v/v/v), water, 20% methanol 
(v/v), 50% methanol (v/v), 100% methanol, 1% acetic acid (v/v), 20% acetic acid (v/v), 
100% acetic acid, acetic acid/methanol 1%/20% (v/v), 50mM borate buffer (pH 8), 50mM 
borate (pH 8)/methanol 80/20 (v/v), 10 mM ammonium acetate (pH 8.3), 10 mM ammo-
nium acetate (pH 8.3)/methanol 80/20 (v/v), 0.1 M sodium bicarbonate buffer (pH 7.8), 0.1 
M sodium bicarbonate buffer (pH 7.8)/methanol 80/20 (v/v), PBS buffer (pH 7.4) and PBS 
buffer (pH 7.4)/methanol 50/50 (v/v) (see section 2.1. and section 2.2.1.). Chromatographic 
set 1 (see section 2.4.2.2.) was used for HPLC analysis of the peptide solutions. 10 µL were 
injected in duplicates. 
2.2.6. Hepcidin-25-copper(II) complex 
2.2.6.1. LC-ESI-QqQ 
A freshly thawed aliquot of 50 µL of human hepcidin-25 (1 g/L) (see section 2.3.1.1.) was 
used. Fractions of 7.5 µL of hepcidin-25 (7.5 µg) were pipetted in an amino-silanized vial 
and incubated in the vacuum oven (VDL 23, Binder, Tuttlingen, Germany), set at room 
temperature, until dryness. A 0.1 mM Cu2+ solution was prepared by diluting an aqueous 
0.1 M CuSO4 solution using the solvent mixture at the start of the HPLC gradient: mobile 
phase A (pH 11)/mobile phase 95/5 (v/v) B (chromatographic set 4, see section 2.4.2.2.). 
The synthesis of the hepcidin-25-copper(II) complex was carried out at pH 11 by adding 
the CuSO4 solution (final concentration 1.8-180 µM) to the hepcidin-25 residue (final con-
centration 18 µM) in a 0.1 to 10-fold molar excess according to Table 2.3. This resulted in 
a hepcidin-copper(II) complex concentration of 50 mg/L (18 µM) for a total volume of 150 
µL. For a molar ratio hepcidin-25:Cu2+ of 1:10, 1 µL of 10 mM CuSO4 (pH 11) was added 
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to the prepared solution containing hepcidin-25-copper(II) 1:5 (molar ratio). The pH was 
controlled at every step using universal indicator paper (pH range 1-14). 
Table 2.3: Synthesis of hepcidin-25-Cu(II) complex in different molar ratios. 
Molar ratio 
Hepcidin-25:Cu2+ 
Volume (µL) 
0.1 mM CuSO4 
(pH 11) 
Volume (µL) 
H20/ACN/NH3  
(pH 11)* 
Conc. hepcidin-
25 in final solu-
tion (µM) 
Conc. Cu2+ in 
final solution 
(µM) 
Copper free 0 150 18  0 
1:0.1 2.7 147.3 18 1.8 
1:1 27 123 18 18 
1:5 135 15 18 90 
* mobile phase A (pH 11)/mobile phase B (chromatographic set 4) 95/5 (v/v)  
For the experiments at different pH values, hepcidin-25 folded in house was used (see sec-
tion 2.2.3.). 150 µL of CuSO4 in different buffer solutions at a final concentration of 18 µM 
was added in a molar ratio of approximately 1:1 to dried “in house” folded hepcidin-25 for 
a concentration of the peptide-metal complex of 50 mg/L (0.018 mM). For this purpose, 50 
µL solution of hepcidin-25 folded “in house” (150 mg/L) was dried out by using a vacuum 
oven set at room temperature. 100 mM phosphate buffer (pH 2.2), 100 mM citrate buffer 
(pH 4.2) and 50 mM borate buffer (pH 7.4) (see section 3.2.1.) were used for the preparation 
of peptide-copper(II) solutions. 
2.2.6.2. ESI-FTICR 
Hepcidin-copper(II) species were analyzed by applying direct infusion of the sample. For 
this purpose, volatile solvents/buffers were employed. A mixture of water/ACN/NH3 
95/5/0.1 v/v/v (pH 11), and 10 mM ammonium acetate (pH 7.4) were used in an identical 
protocol as described in section 2.2.6.1 for obtaining copper(II) complexes at molar ratio 
of 1:1 and 1:10. 
2.3. Sample preparation 
2.3.1. Preparation of serum samples for hepcidin-25 quantification 
The serum samples (human/sheep serum) were stored at -20°C (not more than 6 months) 
and equilibrated at room temperature before use. These were not kept more than 1 hour at 
room temperature after thawing. The sera were spiked with “heavy” hepcidin standards 
(human/sheep serum) and “light” hepcidin standards (sheep serum), followed by different 
sample cleaning methods to remove the high molecular weight compounds such as proteins. 
An exception from this protocol was made for the recovery tests (see section 3.5.2.). 
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2.3.1.1. Preparation of standards 
The stock solutions of “light” and “heavy” human hepcidin-25 were prepared based on the 
nominal value of peptide reported by the supplier. The lyophilized peptide was directly 
resuspended in the solvent indicated by the manufacturer (see below). Further dilutions 
were prepared using a mixture of water/ACN/TFA 60/38/2 v/v/v as dilution solvent. All 
the stock solutions were prepared gravimetrically using a XS105DU balance (Mettler To-
ledo, Gießen, Germany). In this regard, the densities were considered according to DDB 
(Dortmund Data Bank) as 0.998 for water and 1% acetic acid, 0.783 for acetonitrile and 
0.903 for the mixture water/ACN/TFA [212]. Serial dilutions to create a linearity set were 
avoided. Lyophilized human hepcidin-25, also referred to as “light” hepcidin-25 in LC-MS 
experiments, was characterized by a reported molecular weight of 2789.12 (chemical for-
mula C113H170N34O31S9) and a disulfide connectivity between Cys7-Cys23, Cys10-Cys13, 
Cys11-Cys19 and Cys14-Cys22 (as stated by the manufacturer). The lyophilized peptide 
(0.5 mg) was resuspended in 1% acetic acid to a concentration of 1 g/L, according to the 
manufacturer’s instructions. The stock solution was immediately aliquoted into 50 µL or 
100 µL fractions in amino-silanized autosampler vials and stored at -20°C until being used 
in experiments. Lyophilized 13C,15N isotope-labeled hepcidin-25 ([13C9,15N]Phe4,9, 
[15N]Gly12-hepcidin-25), also referred to as “heavy” hepcidin-25, was characterized by a 
reported molecular weight of 2810.20 (chemical formula C9513C18H170N3115N3O31S9) and a 
disulfide connectivity between Cys7-Cys23, Cys10-Cys13, Cys11-Cys19 and Cys14-
Cys22 (as stated by the manufacturer). The lyophilized peptide (24 µg) was resuspended in 
distilled water to a concentration of 56 mg/L, according to the manufacturer’s instructions. 
The stock solution was immediately aliquoted into 50 µL fractions in amino-silanized au-
tosampler vials and stored at -20°C until use. 
2.3.1.2. Protocol I 
Protocol I of serum sample preparation included a step of protein precipitation for the de-
pletion of serum proteins using an organic solvent (acetonitrile ACN) and an acid (trifluoro-
acetic acid TFA). 300 µL of serum sample (human and sheep serum) were transferred to a 
1.5 mL low binding plastic tube (Eppendorf, Wesseling-Berzdorf, Germany). Further, 20 
µL isotope enriched “heavy” hepcidin-25 standard 250 µg/L was added for a final concen-
tration of 10 µg/L and mixed thoroughly by using a vortex mixer. The sheep serum samples 
were subsequently spiked with appropriate dilutions of hepcidin-25 stock solution to pre-
pare calibration standards in a concentration range of 0.5-40 µg/L (0.5, 1, 2, 5, 10, 20, 40) 
and vortexed thoroughly. The total sample volume was adjusted to 500 µL by the addition 
of a mixture of ACN/TFA 95/5 v/v to the spiked serum, while the sample was continuously 
vortexed, to give a final concentration of approximately 38% ACN and 2% TFA. The sam-
ples were incubated for 10 minutes at room temperature. Subsequently, the precipitate was 
 46 
 
separated by centrifugation (21500 RCF, 10 min, 4°C) using a Mikro 220R centrifuge (Het-
tich, Bäch, Switzerland) with a fixed angle rotor. Further, the supernatant was transferred 
to a fluoro-silanized glass vial, followed by LC-MS/MS analysis using TFA-based mobile 
phases (chromatographic set 3). 
2.3.1.3. Protocol II 
Protocol II of serum sample preparation included a step of protein precipitation using an 
organic solvent (acetonitrile ACN) and an acid (trifluoroacetic acid TFA), similarly as in 
Protocol I, followed by an additional clean-up step of ultrafiltration using centrifugal filters 
and a pre-concentration step employing freeze-drying (lyophilization). 1.2 mL of serum 
sample (human and sheep serum) were added to a 2 mL low binding plastic tube (Eppen-
dorf, Wesseling-Berzdorf, Germany), further mixed with 20 µL isotope enriched “heavy” 
hepcidin-25 standard 1 mg/L to a final concentration of 10 µg/L and vortexed thoroughly. 
Similarly as in Protocol I, the sheep serum samples were subsequently spiked with appro-
priate dilutions of hepcidin-25 stock solution to prepare calibration standards in a concen-
tration range of 0.3-40 µg/L (0.3, 0.5, 1, 2, 5, 10, 20, 40) and mixed thoroughly using a 
vortex mixer. Then, a mixture of ACN/TFA 95/5 v/v was added to the spiked serum sample 
and the total volume was adjusted to 2000 µL, to give a concentration of approximately 
38% ACN and 2% TFA. The samples were incubated for 10 minutes at room temperature, 
followed by separation of the precipitate using centrifugation (21500 RCF, 20 min, 4°C) 
with a fixed angle rotor. A Mikro 220R centrifuge (Hettich, Bäch, Switzerland) was applied 
for this purpose. 1 mL of supernatant was transferred to a centrifugal filter Vivaspin 2, 5 
kDa, Hydrosart (Sartorius, Göttingen, Germany, VS02H11). The samples were centrifuged 
at 3300 RCF for 220 min at 4°C using an Eppendorf 6600 centrifuge (Eppendorf, Hamburg, 
Germany) with a swinging-bucket rotor. 450 µL of the obtained filtrate was transferred to 
a 1.5 mL low binding plastic tube and immersed in liquid nitrogen in preparation for freeze-
drying. The lyophilization was carried out overnight using a freeze dryer Lyovac GT2. The 
residue was resuspended in 120 µL water/ACN/TFA 60/38/2 v/v/v and transferred to a 
fluoro-silanized glass vial for LC-MS/MS analysis using NH3-based mobile phases (chro-
matographic set 4). 
2.3.1.4. International Hepcidin Harmonization Study (HHS2017) 
Human serum samples (low, medium and high level in duplicates) and lyophilized calibra-
tor set (low and medium level) were shipped on dry ice (-80°C) from Nijmegen, The Neth-
erlands, in the frame of the Hepcidin Harmonization Study (HHS2017).  
The human samples (300 µL each) were stored at -80°C until use. These were not left at 
room temperature any longer than 4 hours after thawing, according to received instructions, 
and were prepared according to Protocol I. Shortly, 20 µL isotope enriched “heavy” hep-
cidin-25 standard 250 µg/L was added to 300 µL of serum sample for a final concentration 
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of 10 µg/L and mixed thoroughly by using a vortex mixer. A mixture of ACN/TFA 95/5 
v/v was added further, while the sample was continuously vortexed, up to a total volume 
of 500 µL, to give a final concentration of approximately 38% ACN and 2% TFA. The 
sample preparation for hepcidin-25 extraction was performed within the company Prote-
ome Factory, Berlin. 
The lyophilized calibrator set (Calibrator low: 2016.1461, Calibrator middle: 2016.1462, 
lot 2016-146X) was kept at a temperature of 4°C after arrival, following the received in-
structions. Before its use for calibration, 0.3 mL of distilled water was added according to 
manufacturer’s instructions. The calibrator set was prepared gravimetrically by considering 
the density of water 0.998. The vial was kept upright at room temperature for 15 minutes, 
and then carefully mixed for 20 minutes, according to the manufacturer’s instructions. Fur-
ther, the product was processed as patient material employing Protocol I. 
2.3.2. Preparation of silanized glass vials 
Standard glass autosampler vials (Wicom, Heppenheim, Germany) were used for silaniza-
tion. Three types of silanes, 1H,1H,2H,2H-perfluorooctyltriethoxysilane, 3-(2-aminoethyl-
amino)-propylmethyl-dimethoxysilane and (3-aminopropyl)trimethoxysilane, were used 
for the preparation of fluoro- and amino-silanized vials respectively. The vials were rinsed 
with a solution of Mucasol 2%, followed by an activation step with a solution of HCl 10% 
(30 min). Further, several cycles of isopropanol and toluene rinsing were performed. 1% 
silane solution (v/v) was prepared in toluene containing 1% of distilled water (v/v). The 
vials were incubated overnight at room temperature in the silane solution. Then, the silane 
solution was discarded, followed by serial rinsing of the vials with toluene, isopropanol and 
acetonitrile. The vials were left to dry overnight under the hood and kept at room tempera-
ture until use. 
2.4. Instrumentation 
2.4.1. UV-Vis spectroscopy 
UV-Vis measurements were performed using an Evolution 220 UV-Visible spectropho-
tometer (Thermo Fischer Scientific, Dreieich, Germany) with a Double Beam (sample and 
reference cuvette positions), Czerny-Turner Monochromator, Xenon Flash Lamp, Dual Sil-
icon Photodiodes (detector) and a wavelength rage of 100 to 1100 nm. Spectra were rec-
orded in the range of 200 to 700 nm, using a wavelength width of 2 nm. Quartz cuvettes 
(Hellma, Müllheim, Germany) with a volume of 100 µL (minimum volume of 50 µL) were 
used. 
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2.4.2. Liquid chromatography (LC) 
2.4.2.1. HPLC systems 
For solubility tests and folding experiments, an Agilent 1260 Infinity Bio-inert LC system 
(Agilent Technologies, Waldbronn, Germany) with a quaternary pump, de-gasser, au-
tosampler, thermostat, column heater and UV-detector (diode-array detector DAD) was 
used. 
An Azura Analytical (U)HPLC (Knauer, Berlin, Germany) with a binary pump, de-gasser, 
autosampler, column heater, UV-detector, FL-detector (fluorescence detector) and fraction 
collector was employed for purification of labeled hepcidin-25. 
For chromatographic experiments with the AB Sciex 6500, an Agilent 1260 Infinity LC 
system (Agilent Technologies, Waldbronn, Germany) with a binary pump, degasser, au-
tosampler, column heater and UV-detector (diode-array detector, DAD) was coupled to the 
mass spectrometer. 
2.4.2.2. HPLC columns and related parameters 
Four chromatographic sets were used during this work, each characterized by a HPLC chro-
matographic column, mobile phases with specific gradient, a flow rate and an oven tem-
perature. 
Chromatographic set 1  
Chromatographic separation was achieved on a Zorbax C18 column, 4.6x150 mm, 5 µm 
(Agilent Technologies, Waldbronn, Germany). 
The mobile phases were (A) water with 0.1% TFA (v/v) and (B) ACN with 0.08% TFA 
(v/v). The flow rate used was 1 mL/min and the column oven temperature was set to 50°C. 
The elution gradient is presented in Table 2.4. The injection volume used was generally 5-
10 µL. 
Table 2.4: Gradient applied in chromatographic set 1. 
Time (min) Concentration B (%) 
0 20 
5 20 
35 60 
36 60 
50 20 
The instrumentation employed was Agilent 1260 Infinity Bio-inert. 
Chromatographic set 2 
Chromatographic separation was achieved on a Kinetex XB-C18 column, 2.6x150 mm, 3 
µm (Phenomenex, Aschaffenburg, Germany) with a UHPLC C18, 3 mm Phenomenex col-
umn guard. 
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The mobile phases were (A) water with 10 mM ammonium acetate and 0.1% acetic acid 
(v/v) and (B) methanol with 10mM ammonium acetate and 0.1% acetic acid (v/v). A flow 
rate of 350 µL/min was applied and the oven temperature was set to 50°C. The elution 
gradient is presented in Table 2.5. The injection volume was 27 µL (maximum injection 
volume allowed by the autosampler). 
Table 2.5: Gradient applied in chromatographic set 2. 
Time (min) Concentration B (%) 
0 20 
3 20 
8 95 
12 95 
14 20 
22 20 
Chromatographic set 2 was applied using Azura® UHPLC. 
Chromatographic set 3 
Chromatographic separation was achieved on an ACE UltraCore Super C18 column 2.1x50 
mm, 5 μm, with an ACE Excel pre-column filter (ACE, Aberdeen, Scotland). 
Table 2.6: Gradient applied in chromatographic set 3. 
Time (min) Concentration B (%) 
0 5 
2 5 
4 95 
7 95 
7.5 5 
14 5 
The mobile phases were (A) 90% water/10% ACN (v/v) with 0.1% TFA (v/v) and (B) 10% 
water/90% ACN (v/v) with 0.1% TFA (v/v). The flow rate employed was 0.6 mL/min and 
the column heater temperature was set to 40°C. The elution gradient is presented in Table 
2.6. Generally, the injection volume employed was 10 µL, unless specified otherwise (LC-
MS/MS quantification of serum samples, adsorption experiments and other experi-
ments).The instrumentation applied was Agilent 1260 Infinity coupled to AB Sciex 6500. 
Chromatographic set 4 
An ACE UltraCore SuperPhenylHexyl column 2.1x50 mm, 5 μm, with an ACE Excel pre-
column filter (ACE, Aberdeen, Scotland) was used for chromatographic separation. ACE 
UltraCore columns (SuperC18 and SuperPhenylhexyl) feature the Encapsulated Bonding 
Technology (EBTTM) that increases ligand coverage of the silica surface and eliminates the 
negative effects of un-bonded silanol groups. This offers excellent inertness and extended 
pH stability (recommended pH range 1.5-11.0). 
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Table 2.7: Gradient applied in chromatographic set 4. 
Time (min) Concentration B (%) 
0 5 
2 5 
7 95 
9 95 
9.5 5 
15 5 
The mobile phases were (A) water with 0.1% NH3 (v/v) and (B) 10% water/90% ACN 
(v/v) with 0.1% NH3 (v/v). A flow rate of 0.6 mL/min was applied and the column oven 
temperature was set to 40°C. The elution gradient is presented in Table 2.7. The injection 
volume employed for LC-MS/MS quantification of serum samples was 30 µL. An injection 
volume of 10 µL was used for LC-MS analysis of the hepcidin-25-copper(II) complex(es) 
and other experiments. 
The instrumentation used was Agilent 1260 Infinity coupled to AB Sciex 6500. 
2.4.3. Electrospray ionization mass spectrometry (ESI-MS) 
2.4.3.1. Triple Quadrupole (QqQ) 
A triple quadrupole mass spectrometer Triple Quad™ AB Sciex 6500 (AB Sciex, Darm-
stadt, Germany) with electrospray ionization (ESI) IonDrive™ Turbo V Source and 
IonDrive™ High Energy Detector was used. Electrospray ionization was performed in the 
positive mode (ESI+) with a source temperature of 400°C. Full scan Q1(+), product ion 
mode MS2(+) and multiple reaction monitoring MRM scan types were used. Typically, a 
scanning range of m/z ratio between 100-2000 was recorded. Further parameters used for 
ionization were 4500 V ion spray voltage, an entrance potential (EP) of 10 V, a curtain gas 
(CUR) with 35 psi, a nebulizer gas (GS1) with 62 psi, a turbo gas (GS2) with 62 psi and a 
collision gas (CAD) with 10 psi. The instrument was operated in high mass (HM) mode. 
Peptide solutions of 50 mg/L were analyzed in Q1+ and MS2+ mode. The mass calibration 
was performed regularly using polypropylene glycol polymer standards (PPGs) (Part no 
4406127, AB Sciex, Darmstadt, Germany). For quantification of hepcidin-25 using LC-
MS/MS analysis, the triple quadrupole coupled to Agilent 1260 Infinity HPLC system was 
used, employing chromatographic set 3 and 4 respectively (see section 3.4.2.2.). Isotope-
labeled hepcidin-25 (“heavy” hepcidin-25) was used as internal standard (IS). Further pa-
rameters used to produce fragment ions in multiple reaction monitoring mode (MRM), 
namely the declustering potential (DP), the collision energy (CE) and the collision cell exit 
potential (CXP), are presented in Table 2.8. The dwell time was 80 msec and the pause 
time was 5 msec. One MRM transition was used as quantifier and two transitions as quali-
fiers respectively, applied to both “light” and “heavy” hepcidin-25 (Table 2.8). The ratio of 
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the quantifier MRM peak area of “light” hepcidin-25 and “heavy” hepcidin-25 respectively 
was used for quantification purposes (see section 2.5.4.). 
Table 2.8: MS/MS transitions with fragmentation parameters for hepcidin-
25 and isotope-labeled hepcidin-25 (IS). 
Species Transition (MRM) DP 
(V) 
EP 
(V) 
CE 
(V) 
CXP 
(V) 
Hepcidin-25 
930.3  1144.7 (y21)2+ 40 10 45 6 Quantifier  
930.3  1218.2 (y22)2+ 40 10 45 6 Qualifier 1 
  930.3  354.0 (b3) 40 10 48 6 Qualifier 2 
[13C18, 15N3] 
Hepcidin-25 
937.3  1150.2 (y21)2+ 40 10 45 6 Quantifier  
937.3  1228.7 (y22)2+ 40 10 45 6 Qualifier 1 
  937.3  354.0 (b3) 40 10 48 6 Qualifier 2 
       
2.4.3.2. Fourier-transform ion cyclotron resonance (FTICR)-MS 
The ESI-FTICR Ultra MS (Thermo Scientific, Bremen, Germany) was operated in positive 
ionization mode (ESI+). A transfer capillary temperature of 200°C was applied. The spec-
tral resolution of the FTICR was set to 1,000,000. Mass calibration was achieved by using 
a Pierce LTQ ESI Positive Ion Calibration solution. The system was tuned using hepcidin-
25 solution 5 mg/L dissolved in water/ACN/TFA 60/38/2 (v/v/v). Typically, a scanning 
range of m/z ratio between 400-2000 was applied. Direct infusion was employed using the 
integrated syringe pump set at a flow rate of 30 µL/min. 
Hepcidin-25-copper(II) complex solutions (50 mg/L) at pH 11 and 7.4 respectively were 
analyzed. Volatile solvents/buffers were used as following: The chromatographic starting 
condition mixture of mobile phase A (pH 11)/mobile phase B 95/5 v/v (chromatographic 
set 4, see section 2.4.2.2.) and 10 mM ammonium acetate (pH 7.4) (see section 2.2.1.). 
2.4.4. Matrix-assisted laser desorption/ionization mass spectrometry 
(MALDI-MS) 
Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectra 
were acquired on a Bruker Autoflex III MALDI mass spectrometer (Bruker-Daltonik, Bre-
men, Germany) operated with a nitrogen laser (355nm, 200 Hz) at 24 kV acceleration volt-
age in reflectron positive mode (RP+). Mass calibration was performed using Peptide Cal-
ibration Standard II (Part no 8222570, Bruker-Daltonik, Bremen, Germany). 
A saturated solution of α-cyano-4-hydroxycinnamic acid (CHCA), which was used as a 
matrix, was freshly prepared before the MS analysis. CHCA powder was dissolved in wa-
ter/ACN/TFA 33/66/0.1 (v/v/v) at a concentration of 10 g/L. The sample preparation was 
performed using the dried droplet technique (see section 1.3.2.2.) on a MALDI target 
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SteelTM 600/384 (Bruker Corporation, Billerica, USA). One droplet of 0.75 μL of sample 
(peptide) at a concentration of 10-50 µM was placed on the MALDI target. 0.75 μL of 
matrix was added to the matrix droplet. The resulting mixture was dried at room tempera-
ture. When the liquid has completely evaporated, the sample was loaded into the mass 
spectrometer. For hepcidin-25 analysis, an m/z ratio between 1000-4000 was applied. The 
spectra were recorded using 500-1500 laser shots and a laser intensity of 70%. 
2.5. Data analysis and treatment  
2.5.1. Software 
The devices used in the present work were managed by computers running software that 
allowed for specialized data analysis. As part of this data analysis, the software employs 
algorithms that convert the detector output signal into qualitative or quantitative data [168]. 
In this respect, data acquisition and data analysis for HPLC analysis employing Agilent 
1260 Infinity Bio-inert was performed using ChemStation® (Agilent Technologies, Wald-
bronn, Germany). OpenLab® EZChrom (Knauer, Berlin, Germany) was used for chroma-
tographic data treatment using Azura® UHPLC. For experiments using AB Sciex 6500 
coupled to Agilent 1260 Infinity, LC-MS data acquisition and analysis were carried out 
using the software Analyst® 1.6.2 (AB Sciex, Darmstadt, Germany). FTICR-MS spectra 
have been generated and exported by using Xcalibur® 2.2 (Thermo Fischer Scientific, 
Dreieich, Germany). MALDI-MS spectra were obtained and analyzed using FlexAnaly-
sis® 1.0 and FlexControl® 1.3 (Bruker-Daltonik, Bremen, Germany). The UV-Vis spec-
trophotometer was controlled using the software INSIGHTTM 1.4.40 (Thermo Fischer Sci-
entific, Dreieich, Germany). 
All calculations of dilution series and concentration determination for sample preparation 
and LC-MS analysis were conducted by using Excel 2016 and Origin 2017. The graphs and 
figures were generated and edited by using Origin 2017 and Illustrator CS6. 
2.5.2. Exact mass/accurate mass 
According to IUPAC definition, exact mass refers to the calculated mass of an ion whose 
elemental formula, isotopic composition and charge state are known using one isotope of 
each atom involved, usually the lightest isotope. Nominal mass refers to the mass of an ion 
or molecule calculated using the mass of the most abundant isotope of each element 
rounded to the nearest integer value and equivalent to the sum of the mass numbers of all 
constituent atoms. Accurate mass refers to the experimentally determined mass of an ion 
measured to an appropriate degree of accuracy and precision [213]. For mass calculations 
in this work, exact mass will be referred to as theoretical exact mass, and accurate mass 
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will be referred to as experimental accurate mass or experimentally determined accurate 
mass. The software Xcalibur® 2.2 was used for theoretical exact mass determinations. 
2.5.3. HPLC quantification  
The quantification of “in house”-folded hepcidin-25 was performed using HPLC, chroma-
tographic set 3. Seven calibration solutions were measured in the same analytical run in 
triplicates. The mean HPLC peak area was plotted against the standard concentration. Lin-
ear regression was employed for the construction of the calibration curve in the dynamic 
range 6.25 – 250 mg/L using 7 standards (6.25, 12.5, 25, 50, 100, 150, 250 mg/L). The 
unknown concentrations of the solutions of hepcidin-25 folded “in house” were calculated 
from the equation: peak area = a ∗ concentration + b, 
where a and b were determined from the equation of the calibration curve y=ax+b. 
2.5.4. ID-LC-MS/MS quantification 
2.5.4.1. LC-MS/MS calibration curve 
The LC-MS/MS quantification of Hep-25 using TFA-containing mobile phases was per-
formed by employing chromatographic set 3 and was based on a 7-point calibration curve. 
Similarly, the LC-MS/MS analysis where NH3-containing solvents were applied used chro-
matographic set 4 and an 8-point calibration curve. Isotope-labeled hepcidin-25 was used 
as internal standard (IS). Thus, both external and internal calibrations were applied. 
To lower the risk of bias, nine human serum samples and seven sheep calibrators (see sec-
tion 2.3.1.) were measured in the same analytical run three times alternatively as follows: 
• calibrators 1-7 1x 
• human samples 1-9 1x 
• calibrators 1-7 1x 
• human samples 1-9 1x 
• calibrators 1-7 1x 
• human samples 1-9 1x 
The mean quantifier MRM peak area of the triplicates was considered further (see section 
2.4.3.1.). Linear regression was performed on the ratio of the concentrations of “light” and 
“heavy” hepcidin on the x-axis and the ratio of the corresponding mean MRM peak area of 
“light” and “heavy” hepcidin on the y-axis. The calibration curve was constructed in the 
dynamic range 0.5 – 40 µg/L using 7 standards (0.5, 1, 2, 5, 10, 20, 40 µg/L) and 8 standards 
respectively (0.3, 0.5, 1, 2, 5, 10, 20, 40 µg/L). 
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2.5.4.2. International Hepcidin Harmonization Study (HHS2017) 
The international Hepcidin Harmonization Study (HHS2017) for the harmonization of hep-
cidin-25 measurement results was organized by Radboud University Nijmegen, the Neth-
erlands, and hepcidinanalysis.com as a follow-up to previous steps taken towards harmo-
nization (see section 1.3.3.). The aim was to perform a proof of principle study on hepcidin 
harmonization among various worldwide leading hepcidin assays by using a secondary 
commutable lyophilized reference material. A calibration set and three human serum sam-
ples were delivered from Radboud University Nijmegen. The organizers requested the 
quantification of the unknown human samples with the assay calibrated with and without 
the calibration set. The quantification was performed using LC-MS/MS (chromatographic 
set 3, TFA-based mobile phases) by employing two calibration methods in separate analyt-
ical runs: 
a. 7-point calibration (without HHS2017 calibration set) 
For method calibration, seven sheep calibrators were prepared and linear regression was 
performed for a 7-point calibration curve as presented in section 2.5.4.1.  Isotope-labeled 
hepcidin-25 was used as internal standard. 
Three human serum samples and seven calibrators were measured in the same analytical 
run three times alternatively as presented in section 2.5.4.1. 
b. 2-point calibration (with HHS2017 calibration set) 
For method calibration, a secondary reference material developed by hepcidinanalysis.com 
(Nijmegen, the Netherlands) was used and linear regression was performed for a 2-point 
calibration curve. Isotope-labeled hepcidin-25 was used as internal standard. The calibrator 
set contained pooled lyophilized native human serum with the addition of stabilizer CLP 
(Chymotrypsin Like Proteinase) and consisted of one “HHS2016 calibrator low level” and 
one “HHS2016 calibrator middle level”, with values assigned from the calculated mean 
value of 9 validated methods worldwide [214] (Table 2.9). 
Three human serum samples and two calibrators were measured in the same analytical run 
in triplicates, according to the received instructions. The calibrators were measured at the 
start, middle and end of the sample run as follows: 
• calibrators 1-2 3x 
• human samples 1 3x 
• calibrators 1-2 3x 
• human samples 2 3x 
• calibrators 1-2 3x 
• human samples 3 3x 
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Similarly as in the 7-point calibration, linear regression was performed on the ratio of the 
concentrations of “light” and “heavy” hepcidin on the x-axis and the ratio of the corre-
sponding mean MRM peak area of “light” and “heavy” hepcidin on the y-axis. A 2-point 
calibration curve was constructed for each human sample based on the calibrator set ana-
lyzed beforehand. A total of three calibration curves were obtained and the unknown con-
centrations of the human samples were calculated from their correspondent regression line. 
Table 2.9: Assigned values for calibrator set (hepcidinanalysis.com). 
Level Mean value (SD) nmol/L 
Low 2.38 (1.22) 
Middle  7.03 (3.15) 
 
2.5.4.3. Concentration calculations 
The isotope-labeled hepcidin-25 is used for internal calibration and the sheep serum cali-
brators/calibrators set as external calibration. The quantification is based on using the ratio 
of the internal calibration to extrapolate the unknown concentrations from the calibration 
curve (external calibration). In this sense, the calibration curve (7-point or 2-point) resulted 
in the formula y=ax+b. The parameters a and b were calculated. The unknown concentra-
tion of the human serum samples (concentration lH) was calculated from the formula: peak area MRM lHpeak area MRM hH = a ∗ concentration lHconcentration hH + 𝑏𝑏 
where lH = “light” hepcidin-2 and hH = “heavy” hepcidin-25. 
2.6. LC-MS/MS validation 
The validation of the LC-MS/MS methods was carried out in accordance to the LC-MS 
guidelines of the Clinical and Laboratory Standards Institute (CLSI) [168] regarding spec-
ificity, linearity, precision, accuracy, recovery and matrix effects, and the European direc-
tives 2002/657/EC concerning the performance of analytical methods and the interpretation 
of results [83] in terms of relative ion intensities in MRM mode. The acceptance criteria 
were defined accordingly based on the mentioned guidelines. 
Specificity 
Specificity was defined as the ability of a method to measure solely the analyte of interest 
[168]. This was assessed by verifying the absence of interference peaks in the surrogate-
matrix at the same retention times as light and heavy hepcidin-25. For this purpose, bovine 
and sheep serum were tested as a surrogate matrix (free of human hepcidin-25). Two MRM 
transitions were used as qualifiers for both “light” and “heavy” hepcidin-25 (see section 
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3.4.3.1.). The maximum permitted tolerance for relative ion intensities (% MRM quali-
fier/MRM quantifier) of >20% to 50%, as in the case of both “light” and “heavy” hepcidin-
25, was ± 25% [83]. 
Linearity 
Linearity was defined as the ability of the method to provide measured quantity values that 
are directly proportional to the value of the analyte in the sample within a given measuring 
interval [168]. In this regard, the assessment of the calibration curve was performed on 
seven sheep serum standards (0.5, 1, 2, 5, 10, 20, 40 µg/L) for the LC acidic conditions 
with an additional standard at 0.3 µg/L for the LC basic conditions. A linear regression 
analysis was performed to set up the calibration line within the dynamic range of 0.5-40 
µg/L and 0.3-40 µg/L respectively. Serial dilutions to create a linearity set was avoided, 
due to additive pipetting errors that can introduce systematic errors [168]. 
Precision and accuracy 
Precision was defined as closeness of agreement between measurement results obtained 
under stipulated conditions [168]. Intra- and inter-assay precision were determined. Intra-
assay precision or repeatability expressed the precision under the same operating conditions 
over a short interval of time (same analytical run). Inter-assay precision or intermediate 
precision expressed within-laboratory variations in consecutive days (different analytical 
runs). Precision was expressed as coefficient of variation (CV) and calculated as percentage 
relative standard deviation (% RSD = standard deviation/ mean ∙ 100). 
Accuracy was defined as closeness of agreement between a measured quantity value and a 
true quantity value of the analyte [168]. In the absence of reference materials, the conven-
tional true value was considered the nominal value of analyte reported by the supplier for 
“light” and “heavy” hepcidin-25 (see section 2.3.1.1.). Accuracy was calculated as percent-
age relative error (% RE = [(value found/ conventional value) – 1] ∙ 100). 
[[13C9,15N]Phe4,9,[15N]Gly12]-Hepcidin-25 was used as IS to compensate for instrumenta-
tion variables. 
Five sheep serum standards were considered over the quantification range (0.5-40 µg/L) 
for the assessment of intra-assay precision and accuracy. The samples were measured in 
triplicates within the same day. Three quality control (QC) samples at high (25 µg/L), me-
dium (10 µg/L) and low (2 µg/L) level were chosen for the determination of inter-assay 
precision and accuracy. The samples were measured in five replicates in two consecutive 
days. According to CLSI guidelines [168], the imprecision of the concentration should not 
exceed 15% CV except for the LOQ, where ≤ 20% CV is acceptable. Also, an accuracy 
<±15% is considered satisfactory. 
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LOD, LOQ 
The limit of detection (LOD) was defined as the lowest concentration at which the signal-
to-noise ratio S/N was higher than 3:1. The limit of quantification (LOQ) was determined 
in an analogous way for S/N greater than 10:1 [168]. 
Matrix effect and recovery 
The matrix effect was defined as the MRM signal suppression caused by the matrix (sheep 
serum). The occurrence of matrix effects was tested by comparing the peak areas of two 
QC samples (5, 10 µg/L) in neat solution and sheep serum respectively [168]. The samples 
in neat solutions were prepared by diluting hepcidin-25 standards to the desired concentra-
tion using a mixture of water/ACN/TFA 60/38/2 v/v/v (see section 2.3.1.1.). The samples 
in sheep serum were prepared as described in Protocol I and Protocol II respectively (see 
section 2.3.1.2. and 2.3.1.3. respectively). The recovery was defined as the yield of the 
extraction and/or pre-concentration step for the analyte divided by the amount of analyte in 
the original sample. Two QC samples (5, 10 µg/L) were used for the assessment of recovery 
by comparing peak areas of the quantifier MRM for measuring sheep serum samples spiked 
before and after sample preparation respectively [215, 168]. The sheep serum samples 
spiked before sample preparation were handled as described in Protocol I and Protocol II 
respectively (see section 2.3.1.2. and 2.3.1.3. respectively). In the case of the samples 
spiked after sample preparation, “light” hepcidin-25 (50 µg/L) was added to the supernatant 
obtained after sample preparation to achieve the desired concentration. Generally, the IS 
([[13C9,15N]Phe4,9,[15N]Gly12]-Hepcidin-25) was spiked in the early stage of the sample 
preparation, to compensate for losses during sample handling and for matrix effects [168]. 
For a good sensitivity of the method, the allowed magnitude of matrix effects was defined 
as < 35% signal suppression and a recovery > 95% was considered acceptable. 
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3. Results and Discussions 
3.1. Characterization of the physico-chemical properties of hepcidin-25 
Hepcidin-25 is a 25-residue peptide with the following amino acid sequence DTH-
FPICIFCCGCCHRSKCGMCCKT (Figure 3.1), which forms a distorted β-sheet with a flexible 
N-terminus. The eight cysteine residues are involved in four disulfide bridges, namely between 
Cys7-Cys23 (1-8), Cys10-Cys13 (2-4), Cys11-Cys19 (3-6) and Cys14-Cys22 (5-7) [85] (see 
section 1.2.2.), with the resulting chemical formula C113H170N34O31S9. 
 
Figure 3.1: Amino acid sequence of hepcidin-25 containing acidic amino acids (red) 
and basic amino acids (blue). 
Hep-25 contains aspartic acid D as acidic residue and histidine H, arginine R and lysine K as 
basic residues (Figure 3.1), with an additional acidic -COOH moiety at the C-terminus and a 
basic N-terminal amino group. Having an approximate net charge of +4 at neutral pH, hepcidin-
25 is a basic peptide, with an isoelectric point of 8.2 [146]. Also, Hep-25 shows an amphipathic 
character due to the presence of hydrophilic residues (e.g. lysine K, arginine R, histidine H, 
aspartic acid D) and hydrophobic uncharged residues (e.g. leucine L, isoleucine I, methionine 
M, proline P, phenylalanine P). 
The amino acid content of Hep-25 together with the complexity of the disulfide network influ-
ences the physico-chemical behavior of the peptide and will be discussed further. In this regard, 
the folding process of hepcidin-25 will be presented, followed by solubility tests and conjuga-
tion of the peptide. Furthermore, the copper binding capacity of hepcidin-25 due to the presence 
of the ATCUN motif will be addressed. 
3.1.1. Production of folded hepcidin-25  
The folding of hepcidin-25 can be challenging and miss-folding artifacts can occur because of 
the complex network of disulfide bonds [85]. Two different assignments of the intramolecular 
disulfide bridges by Hunter et al. in 2002 and by Jordan et al. in 2009 (see section 1.2.2.) indi-
cate that the folding of linear hepcidin-25 is a critical issue in the analysis of the peptide. The 
unanimously accepted correct disulfide connectivity of hepcidin-25 is nowadays considered the 
version published in 2009 between Cys7 and Cys23 (1-8), Cys10 and Cys13 (2-4), Cys11 and 
Cys19 (3-6), and Cys14 and Cys22 (5-7) [85]. Although the vendors who commercialized syn-
thetic human hepcidin-25 before 2009 reported the “wrong” connectivity (2002), it is unclear 
if the peptide ever presented two different folding patterns. Recent ion mobility spectrometry 
DTHFPICIFCCGCCHRSKCGMCCKT
7       10 11     13 14                   19             22 23
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(IMS) experiments performed by Bros et al. on two hepcidin-25 standards obtained from dif-
ferent synthesis pathways determined several compounds with different mobility profiles (size-
to-charge ratios) in the composition of the standards. The authors suggested that these com-
pounds could represent different folding products resulted from different synthesis protocols, 
which could indicate that the folding protocol can lead to conformational variety [87]. However, 
the products obtained in the IMS experiments could not be further identified and no disulfide 
connectivity was attributed. Also, no details about the synthesis protocols were provided. The 
need remains for effective folding methods to be developed that can be correlated to the cur-
rently accepted disulfide connectivity. Thus, the present work investigated the folding possibil-
ities of the linear hepcidin-25. Furthermore, a reliable route for the “in house” preparation of 
folded hepcidin from the linear peptide was developed. In order to characterize the different 
possible folding products obtained, HPLC was chosen as an analytical technique able to differ-
entiate between different conformers. 
Three different folding conditions available in the literature were compared. By such, linear 
hepcidin-25 was incubated (once at a time) in reduced-oxidized glutathione solution at pH 7.4 
(Jordan et al. [85]), cysteine-cystine-guanidine-EDTA-PBS buffer at pH 7.8 (Clark et al. [92]) 
and HEPES/urea mixture at pH 7 (Tselepis et al. [107]) respectively. The complete formation 
of the intramolecular disulfide bonds was carried out overnight (approximately 20 hours). 
HPLC analysis of the resulting solution showed one sole folding product in all three cases, 
characterized by a retention time corresponding to the commercial synthetic human hepcidin-
25 (data not shown). It could be concluded that human hepcidin-25 presents one disulfide con-
nectivity that is thermodynamically stable and can result from the oxidation of the linear 25-
residue peptide. This came in agreement with previously reported findings where different fold-
ing protocols applied led to a single folded product [211]. The reduced-oxidized glutathione-
based folding buffer was chosen out of the three folding conditions to further investigate and 
characterize the folding process. 
3.1.1.1. HPLC characterization 
The commercial linear (reduced) human hepcidin-25 was folded applying an adapted protocol 
from Jordan et al. as presented in section 2.2.3. The authors indicated an oxidized-reduced glu-
tathione mixture at a pH of 7.4. However, lowering the pH value proved to increase the amount 
of folded peptide obtained (data not shown), probably due to the increase in the solubility 
caused by moving the pH value away from the isoelectric point of 8.2, and thus increasing the 
charge of the peptide. Therefore, the folding of linear hepcidin-25 was performed at a pH of 7. 
The use of organic solvent (ACN) and acid (TFA) was also found necessary to enhance the 
solubility of the peptide (see section 3.1.2.). 
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Figure 3.2: Hepcidin-25 species (HPLC) at 220 nm: 25 µM hepcidin-25 commercial 
standard (black trace), 50 µM linear hepcidin-25 (blue trace), 50 µM hepcidin-25 
folded “in house” (red trace). 
The commercial hepcidin-25 standard (folded), the commercial linear hepcidin-25 and the fold-
ing product underwent HPLC analysis (Figure 3.2). The commercial peptides were analyzed in 
an aqueous solution of 50 µM (linear hepcidin-25) and 25 µM (folded hepcidin-25). The “in 
house” folded species was injected at a concentration of approximately 50 µM (140 mg/L) in 
the folding buffer. The hepcidin-25 standard (oxidized) showed an eluting peak characterized 
by a retention time of 14.3 minutes, while the reduced species is more hydrophobic due to 
presence of the free -SH groups and eluted later at a retention time of 15.9 minutes. It could be 
observed that the “in house” folded hepcidin-25 co-eluted with the commercial standard, dis-
playing an identical retention time of 14.3 minutes. At this point it could be concluded that a 
folding procedure of hepcidin-25 was developed which yielded a sole product. This presented 
identical chromatographic behavior as the commercial hepcidin-25 standard, which reports the 
currently accepted disulfide connectivity between Cys7 and Cys23 (1-8), Cys10 and Cys13 (2-
4), Cys11 and Cys19 (3-6), and Cys14 and Cys22 (5-7) [85]. MS characterization by MALDI-
TOF confirmed the mass and isotope pattern of the folded product to be identical to the com-
mercially available standard (see section 3.1.1.2.). 
Further, with the aim to obtain multi-milligram quantities of oxidized hepcidin-25, the folding 
protocol was examined using various amounts of linear hepcidin, by scaling up the process 
from low (33 mg/L) to high (2 g/L) peptide concentration. Unfortunately, highly concentrated 
solutions of linear hepcidin showed very poor folding yields. This could be explained by the 
aggregation tendency of the peptide [84] that might form three-dimensionally cross-linked pol-
 62 
 
ymers at high concentrations. The use of reducing agents such as Tris-(2-carboxyethyl)-phos-
phine (TCEP) and of folding enzymes such as protein disulfide isomerase (PDI) did not have 
any effect on the polymers formed (data not shown). 
The concentration of 33 mg/L was selected to achieve good yields of the folding process.  For 
practical reasons, not more than 1 mg linear hepcidin was used, for which 30 mL of folding 
solution were required. Semi-preparative HPLC was employed for the purification of the fold-
ing product (chromatographic set 1, see section 2.4.2.2.). The peptide solutions were stored in 
a mixture of water/ACN/TFA 60/40/0.1 (v/v/v) at 4°C and used within a month from prepara-
tion. The quantification of the obtained oxidized peptide and the yield of the folding process 
will be discussed in sections 3.1.1.3. and 3.1.1.4., respectively. 
3.1.1.2. MS characterization 
The three hepcidin-25 species (commercial standard, commercial linear peptide and “in house” 
folded peptide) were analyzed using MALDI-TOF-MS for mass determinations. The sample 
preparation was described in detail in section 2.4.4. 
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Figure 3.3: MALDI-TOF-MS spectra of commercial linear hepcidin-25. 
The theoretical exact mass of hepcidin-25 was 2787.02576 Da for the folded species and 
2795.0884 Da for the linear species respectively (see section 2.5.2.). The difference of 8 Da is 
represented by the loss of 8 hydrogen atoms due to the formation of the four disulfide bridges. 
In case of linear hepcidin-25, the manufacturer stated a purity of >95% assessed by amino acid 
analysis. MALDI-TOF characterization of a solution of 50 µM linear hepcidin-25 revealed a 
[M+H]+ of 2795.96 (Figure 3.3), which is in agreement with the theoretical exact mass of 
2795.0867150, considering a resolution of the device of approximately 0.1 Da. It was concluded 
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that the peptide is suitable to be used further in the production of folded hepcidin-25. Further, 
the commercial standard (purity >95% assessed by HPLC analysis) was compared with the “in 
house” folded peptide. Similarly, as in the HPLC analysis, an aqueous solution (1% acetic acid) 
of 25 µM commercial folded hepcidin-25 and a 50 µM solution of “in house” folded species in 
folding buffer were analyzed. 
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Figure 3.4: MALDI-TOF-MS spectra of commercial hepcidin-25 (folded). 
The MS spectra of the commercially purchased standard and the “in house” folded hepcidin-25 
showed a very similar isotope pattern, with a [M+H]+ of 2788.08 and 2788.10 respectively 
(Figures 3.4 and 3.5 respectively). This came in agreement with the theoretical exact mass of 
2787.0252 Da of human hepcidin-25. 
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Figure 3.5: MALDI-TOF-MS spectra of hepcidin-25 folded “in house”. 
Figure 3.5 shows the MS spectra of the “in house” folded peptide, analyzed before purification. 
One single folding product could be identified as corresponding to the mass of hepcidin-25 
([M+H]+ 2788.10). The spectra also indicated a MS peak corresponding to a mass of 2806.10 
Da. The mass difference of 18 Da indicated that this peak correlated to the ammonium adduct 
of hepcidin-25 (folded) [M+NH4]+. This could be explained by the addition of ammonium hy-
droxide to the folding buffer for pH adjustment (see section 2.2.1.). 
3.1.1.3. Quantification of folded hepcidin-25 
The high amounts of purified “in house” folded hepcidin-25, obtained in the concentration 
range of 20-250 mg/L, permitted a simple and quick quantification of the peptide by reversed-
phase (RP)-HPLC, chromatographic set 3 (see section 2.4.2.2.). A calibration curve was con-
structed using 7 standards in the dynamic range of 6.25 - 250 mg/L, by plotting the HPLC peak 
area of the standards versus standard concentration (Figure 3.6). Applying a quantification ap-
proach including external calibration and without the use of an internal standard was considered 
suitable for the assessment of the folding yield in the selected dynamic range. 
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Figure 3.6: 7-point calibration curve (y = 17.928x - 170.170, r2 = 0.999) by HPLC. 
The average correlation coefficient (r2) was 0.999. A very good intra-assay precision (<3%) 
was achieved (Table 3.1). A LOQ of 6.25 mg/L was obtained for the quantification of hepcidin-
25 using HPLC. 
Table 3.1: Intra-assay precision (n=3) defined as coefficient of variation (CV). 
Hep-25 concentration (mg/L) CV (%) 
250 1.1 
100 0.1 
25 1.0 
6.25 2.9 
3.1.1.4.  Yield of the folding process 
The yield of the folding process was determined by considering the amount of linear hepcidin-
25 subjected to folding and the amount of oxidized peptide obtained. In this sense, the formula 
below was applied: 
Yield (%) = 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑎𝑎𝑜𝑜 𝑜𝑜𝑎𝑎𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓  ℎ𝑓𝑓𝑒𝑒𝑒𝑒𝑒𝑒𝑓𝑓𝑒𝑒𝑎𝑎−25 (𝑎𝑎𝑚𝑚)
𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑎𝑎𝑜𝑜 𝑓𝑓𝑒𝑒𝑎𝑎𝑓𝑓𝑎𝑎𝑙𝑙  ℎ𝑓𝑓𝑒𝑒𝑒𝑒𝑒𝑒𝑓𝑓𝑒𝑒𝑎𝑎−25 (𝑎𝑎𝑚𝑚) ∗ 100 
The amount of linear hepcidin-25 used was 1 mg each time. The amount of folded Hep-25 was 
determined after purification using RP-HPLC. The total yield characterized the folding and the 
purification processes. A peptide purity of >95% was achieved. 
Good yields were achieved using a concentration of linear hepcidin of 33 mg/L (10-50%) (Ta-
ble 3.2). The values were similar or even higher as compared to previously reported yields 
(12%) [211]. A mean yield of approximately 25% was obtained. This indicated an amount of 
2.5 mg “in house” folded peptide obtained from 10 mg linear hepcidin-25. No correlation could 
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be assigned between the folding time and the yield of the process. Any folding duration between 
16 and 24 hours seems to be suitable for the complete folding. In this context, it needs to be 
mentioned that an investigation of partial folding was not the aim of the study. The standard 
deviation of approximately 13% for the calculated yields indicated an average reproducibility 
of the folding process. The main source of variability was probably the purification process 
when fluctuating losses of folded hepcidin-25 could have arisen while loading the folding so-
lution onto the semi-preparative C18 column (see section 2.2.3.). 
Table 3.2: Calculated total yields for the folding process (concentration of linear 
hepcidin-25 of 33 mg/L). 
Folding time 
(h) 
Total yield* 
(%) 
22 19 
19 32 
19 22 
17 9 
17 48 
17 44 
17 11 
16 20 
16 39 
16 20 
*hepcidin-25 purity >95% (HPLC analysis) 
The purchase of linear hepcidin-25 was found to be 20-fold more cost effective compared to 
that of the hepcidin-25 standard (folded). The development of an “in house” folding method 
offered not only insights into the folding process, but also delivered a considerably higher 
amount of peptide that could be used for various experiments within the context of this work. 
3.1.2. Solubility of hepcidin-25 
Generally, the amino acid content determines the solubility of the peptides in water, solvents 
and buffers at different pH values. Hepcidin-25 comprises of a high number of basic residues 
and shows an amphipathic character, with both hydrophilic and hydrophobic amino acids con-
tained in its structure. To test the solubility of hepcidin-25, initially, the peptide was dissolved 
in water. Further, acidic solutions and polar solvents were used to solubilize hepcidin-25. Usu-
ally, acetic acid or stronger acids such as TFA are used for basic peptide solubilization. Then, 
various polar solvents were applied. Methanol and acetonitrile were selected because they rep-
resent solvents compatible with LC-MS analysis. Ultimately, various buffers were tested to 
assess the solubility of the peptide close to the physiological pH (pH range of 7.4 to 8.3). For 
this purpose, 50 µL of 130 mg/L hepcidin-25 folded “in house” (65 µg) were dried in the vac-
uum oven (see section 3.2.5.). Then, various reconstitution solvents were tested as described 
above. HPLC analysis was applied to determine the peptide solubility by comparison of the 
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HPLC peak areas. As expected, the solubilization of the basic peptide was facilitated by acidic 
solvents such as acetic acid or TFA. The solubility in water was lower in comparison to other 
polar solvents or acidic solutions. ACN, methanol, acetic acid and TFA seemed to be good 
solvents for the peptide. The increase in concentration of the polar solvent (methanol, acetic 
acid) led to an increase in the solubility of the peptide. However, a mixture containing ACN 
and TFA seemed to be the best solvent for hepcidin-25. Water/ACN/TFA 60/40/0.1 (v/v/v) 
showed a higher solubilization capacity compared to 100% methanol or 100% acetic acid (Fig-
ure 3.7). The choice for the optimum ratio of water/ACN/TFA will be considered in more detail 
in section 3.3.3.1. 
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Figure 3.7: Area of the peak (HPLC analysis) for hepcidin-25 solutions in different 
solvents. 
Further, the peptide showed poorer solubility in all the aqueous buffers in the pH range of 7.4 
to 8.3 compared to water (and other organic solvents). As expected, the solubilization capacities 
of the buffers decreased in the proximity of the isoelectric point (8.2). Ammonium acetate 
buffer at a pH of 8.3 or borate buffer at a pH of 8 were the least effective solvents compared to 
sodium bicarbonate buffer at a pH of 7.8 or PBS buffer at a pH of 7.4. However, an addition of 
50% of methanol visibly increased the solubility of hepcidin-25 (Figure 3.8). 
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Figure 3.8: Area of the peak (HPLC analysis) for hepcidin-25 solutions in different 
buffers and solvent-buffer mixtures. 
As a conclusion, a guideline in preparing hepcidin-25 solutions was established. The peptide 
was most soluble in acidic solutions (1% acetic acid or 0.1% TFA) using polar solvents (40% 
ACN). Various buffers (in the pH range of 7.4 to 8.3) did not show very good solubilization 
capacity, however their effectiveness was greatly enhanced by the addition of higher concen-
trations of polar solvents (e.g. 50% methanol). 
3.1.3. Synthesis of labeled hepcidin-25 with a fluorescent dye 
Labeled hepcidin-25 species could be extremely valuable for different quantification purposes 
or in bioactivity assays. The lack of suitable immunoassays for hepcidin-25 quantification (see 
section 1.3.1. and 1.3.3.) can partly be because of challenging production of hepcidin-25 con-
jugates, particularly of the mono-labeled peptide. Due to the compact structure of hepcidin-25 
and its tendency to aggregate, especially around the isoelectric point of 8.2 which is usually the 
required pH value for bioconjugation, the synthesis of such conjugates can be difficult.  
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Figure 3.9: Structure of the fluorescent dye DY-654 [216].  
Moreover, hepcidin-25 presents three amino groups that could participate in conjugation reac-
tions, namely one -NH2 group at the N-terminus and two amino groups within the lysine resi-
dues. Therefore, the synthesis of a mono-labeled peptide requires careful choice of the pH and 
possibly a separation step from multi-labeled peptide species.  
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Figure 3.10: HPLC chromatogram of the conjugation products of hepcidin-25 
(654nm). 
The synthesis of fluorescent mono-labeled hepcidin-25 was performed using the N-hydroxy 
succinimid (NHS) ester of DY-654 (Figure 3.9), a dye soluble in water and methanol, with a 
maximum absorption/emission at the wavelengths 654 nm/677 nm respectively. NHS ester-
activated labeling compounds react with primary amines in the pH range of 7.2 to 9 to yield 
stable amide bonds [147, 148]. 
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As a consequence, two types of labeled hepcidin-25 species were obtained. These represent a 
mono-labeled and a bis-labeled peptide. The purification of the two species was performed by 
HPLC using chromatographic set 2 (see section 2.4.2.2.). Figure 3.10 shows the chromatogram 
at 654 nm indicating four compounds. The MS analysis of the obtained products identified the 
hydrolyzed unreacted dye (free acid) at the minute 5.4 with a mass of 942 Da, and the mono- 
and bis-labeled hepcidin-25 species at minute 12.6 and 13.2 respectively. The compound at 
minute 6.6 could not be attributed. The MS spectra of the two fluorescent-labeled hepcidin-25 
species showed the triply and quadruply charged quasi-molecular ions. A mass of 4635 Da was 
recorded for the species containing two labels ([M+4H]4+ of 928.7 and [M+3H]3+ of 1237.6 as 
shown in Figure 3.11), which correlates to one molecule of Hep-25 and two molecules of fluo-
rescent dye with the loss of two water molecules (2787+2∙942-2∙18). Moreover, a mass of 3711 
Da was obtained for the mono-labeled peptide ([M+4H]4+ of 1159.2 and [M+3H]3+ of 1545.1 
as presented in Figure 3.12) which corresponds to one molecule of hepcidin-25 and one mole-
cule of dye DY-654 with the loss of one molecule of water (2787+942-18). 
600 800 1000 1200 1400 1600 1800
0,0E+00
2,0E+06
4,0E+06
6,0E+06
8,0E+06
1,0E+07
In
te
ns
ity
 (c
ps
)
m/z
1159,2
1545,1
 
Figure 3.11: ESI-MS spectra of bis-labeled hepcidin-25.  
Other fluorescent-labeled hepcidin-25 species have also been reported in literature using Texas 
Red-X dye, however no structural information such as the product mass or number of labels 
has been provided [117].The synthetized hepcidin-25 with a fluorescent tag can be applied in 
anti-hepcidin-25 antibody screening protocols  with fluorescence detection. 
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Figure 3.12: ESI-MS spectra of mono-labeled hepcidin-25.  
3.2. Structural considerations of hepcidin-25-copper(II) complexes  
The presence of the ATCUN motif, a small metal binding site in the structure of hepcidin-25 is 
responsible for the high affinity of the peptide for Cu(II) ions (see section 1.2.3.). Enzymes and 
proteins that contain copper binding sites include copper both in their structure and biological 
function. As an example, human serum albumin HSA exhibits its function in copper transport 
due to the ATCUN motif present at the N-terminus (see section 1.2.3.1.). This indicates that the 
presence of a copper binding site in the structure of a peptide or protein should not be ignored. 
Generally, the affinity of the ATCUN motif for copper can be explained by the presence of 
nitrogen donors that attract copper ions with the simultaneous formation of three connected 
chelate rings. Cu(II) is one of very few metal ions able to deprotonate and coordinate the peptide 
bond nitrogen. Moreover, binding with the Nδ of the histidine side chain creates a stable 6-
membered chelate ring with the preceding amide nitrogen. Also, the amino group at the N-
terminus anchors the metal in a 5-membered chelate which contributes to the stability of the 
complex [110]. The 4N metal complexes (see section 1.2.3.1.) formed in this way seem to be 
the most stable ones formed by peptides [217]. Furthermore, reports showed that the presence 
of aspartic acid (D) as residue 1 in the ATCUN motif increases the basicity of the nitrogen 
atoms involved in the metal complex and thus enhancing the copper binding [102]. 
Investigations by Plonka et al. of the N-terminus of hepcidin-25 (DTHFPI) resulted in the high-
est affinity of an ATCUN motif for copper ever reported. Additionally, the 6-residue peptide 
could exchange the copper ions from HSA [112] (see section 1.2.3.2.). 
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Figure 3.13: Iron homeostasis. Suggested iron and copper traffic in the blood stream. 
(Ferroportin (blue) is expressed on the membrane surface of iron releasing cells (en-
terocytes, hepatocytes and macrophages), allowing the iron ions (yellow) to exit the 
cell (yellow arrow) and bind transferrin (pink) for transport through the blood stream. 
Circulating hepcidin-25 (red) blocks the iron export by binding to ferroportin. Copper 
ions (green) released from intestinal cells are bound by various molecules in blood. 
Iron and copper ions are exchanged between various complexing agents based on 
chemical affinities and biological needs). 
Most of the copper present in humans is bound to ceruloplasmin, albumin and transcuprein, 
however, the copper trafficking in the human body is not fully elucidated. Small amounts of 
copper can be exchanged to low molecular weight molecules (see section 1.2.3.3.). Considering 
the high affinity of the 6-residue N-terminus of hepcidin-25 for copper (KD=10-14.66 M) [112], 
the concentration of “free” extracellular Cu2+ available to small molecules and peptides of 1-2 
µM [114] (see section 1.2.3.3.) and the mean physiological level of hepcidin-25 in humans of 
5-15 µg/L (1.8-5.4 nM) (see section 1.3.3.3.), it is reasonable to assume that a considerable 
fraction of hepcidin-25 is present in the copper-bound form under physiological conditions 
(Figure 3.13). 
Additionally, a screening of hepcidin sequences in the UniProt (Universal Protein resource) 
databank showed that the 6-amino acid N-terminus of hepcidin-25 containing the ATCUN mo-
tif is conserved among most of the species (Table 3.3), which suggests a specific receptor in-
teraction. 
ENTEROCYTE
MACROPHAGE
HEPATOCYTE
Ferroportin
Transferrin
Hepcidin-25
Exchangeable iron
Exchangeable copper
Ceruloplasmin
Transcuprein
Albumin 
Other small molecules
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Table 3.3: Conservation of hepcidin-25 amino acid (AA) sequences among some 
species (blue-conserved AA in the 6-residue N-terminus, red-different AA in the 
6-residue N-terminus). 
Species  Uniprot* code Hepcidin-25 AA sequence  
Human  P81172 DTHFPICIFCCGCCHRSKCGMCCKT 
Bovine  Q2NKT0 DTHFPICIFCCGCCRKGTCGMCCRT   
Rabbit  G1U3P2 DTHFPICIFCCSCCRNSKCGICCKT 
Dog  Q5U9D2 DTHFPICIFCCGCCKTPKCGLCCKT 
Sheep  E0X9N1 DTHFPICIFCCGCCRKGTCGICCKT  
Pig Q8MJ80 DTHFPICIFCCGCCRKAICGMCCKT    
Chimpanzee  A7XEH6 DTHFPICIFCCGCCHRSKCGMCCKT   
Sumatran orangutan Q5NVR8 DTHFPIYIFCCGCCHRSKCGMCCKT 
Mouse  Q9EQ21 DTNFPICIFCCKCCNNSQCGICCKT 
Rat Q99MH3 DTNFPICLFCCKCCKNSSCGLCCIT 
Crocodile E8ZAD0 NSHFPICSYCCNCCRNKGCGLCCRT 
* Universal Protein resource [218]  
Hence, analytical techniques may be needed for the analysis of the copper-bound form of hep-
cidin-25. Investigations of the ATCUN-copper(II) complex within hepcidin-25 were performed 
using UV-Vis spectroscopy, LC-MS/MS (Triple Quadrupole) and FTICR-MS, and will be pre-
sented in the following sections. 
3.2.1. Peptide DTHFPI-copper(II) complex 
To study the formed metal complex between hepcidin-25 and copper, first, the 6-amino acid N-
terminus containing the ATCUN motif was considered (Figure 3.14). The N-terminus of Hep-
25 was reported to be unstructured, in contrast to the rest of the molecule, which is highly 
compact due to presence of four intramolecular disulfide bridges [85] (see section 1.2.2.). This 
indicated that the flexible NH2-terminus is a good model for hepcidin-25 structural analysis. 
Additionally, the use of the N-terminus was previously reported in bioactivity studies of hep-
cidin-25 [116] (see section 1.2.4.1.) and in ATCUN-copper(II) interaction studies [97, 112] (see 
section 1.2.3.3.). 
 
DTHFPICIFCCGCCHRSKCGMCCKT
7         10 11       13 14                      19                22 23
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DTHATCUN motif
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Figure 3.14: Amino acid sequence of hepcidin-25, its 6-residue N-terminus and AT-
CUN motif. 
The behavior of the 6-amino acid N-terminus (DTHFPI) was investigated spectrophotometri-
cally in the presence of copper ions at physiological pH (7.4). Initially, a 1 mM peptide solution 
was tested in the presence of an equimolar Cu(II) solution. However, such low concentrations 
did not lead to significant changes detected in the optical spectrum of the peptide at 525 nm. 
Further, a 10 mM peptide solution was titrated with 10 mM copper (Cu2+) solution. The binding 
of copper ions to the peptide DTHFPI yielded an absorption maximum at 525 nm, which is an 
indicative of the ATCUN motif [100]. In the case of peptides and proteins that do not coordinate 
copper, a broad maximum near 600 nm is observed, which eventually shifts to 525 nm only at 
pH > 10 [97].  
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Figure 3.15: Optical spectra of 10 mM Cu2+ binding to 10 mM peptide DTHFPI 
(HEPES, pH 7.4) at different molar ratios. 
As it can be seen in Figure 3.15, the copper complex was formed even at a molar ratio pep-
tide:Cu2+ of 1:0.1. The signal intensity increased as the molar ratio peptide:Cu2+ increased. A 
saturation was reached at the molar ratio of 1:1. The complex was also found stable in the 
presence of copper ions in excess (molar ratio 1:2). Such large concentrations (10 mM) would 
imply high UV-Vis experimental costs in the case of full hepcidin-25. Additionally, the “sticky” 
character of the peptide (see section 3.3.2.1.) could hinder its robust handling in plastic and 
quartz cuvette. Therefore, MS-based techniques were employed for hepcidin-25-copper(II) 
complex analysis. 
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3.2.2. Chromatographic separation of hepcidin-25-copper(II) complexes 
The MS-based analysis of the hepcidin-25-copper(II) complex using FTICR or MALDI-MS 
has so far been performed without the separation of the copper-bound and copper-free peptide 
(see section 1.2.3.2.). This hampers an accurate and sensitive analysis of a mixture of the pep-
tide species, especially in more complex matrixes such as biological samples. The addition of 
an LC separation step in the MS analysis improves analyte detection and reduces ion suppres-
sion effect. Anion exchange chromatography has been previously employed for the separation 
of the copper-labeled peptide from the excess of copper in an LC-ICP-MS method, which was 
developed for the quantification of Hep-25 by measuring the amount of copper bound to the 
peptide [108] (see section 1.3.2.1.). Unfortunately, this method provides no molecular infor-
mation of the peptide species present in the solution. Also, the limited stability of the anion 
exchange columns complicates a robust and reproducible analysis. 
In the present work, a RP-HPLC (reversed phase high performance liquid chromatography) 
separation step, which was complementary to MS detection, was tested for an accurate and 
robust analysis of the species resulting from the complexation of Hep-25 with copper. Previous 
reports showed that the complex hepcidin-25-copper(II) is not stable at pH <5.2 (see section 
1.2.3.3.). This can be explained by the fact that, in order to bind to the biomolecule, the metal 
ion must replace hydrogen ions of the peptide, which is facilitated by increasing the pH of the 
peptide solution. Thus, for LC analysis of the copper-bound form of hepcidin-25, a neutral to 
basic pH of the mobile phases was required for metal complex stability. Initially, a chromato-
graphic separation at physiological pH (7.4) was tested (data not shown). This proved to be 
unsuccessful, probably because a good chromatographic resolution is usually achieved when 
fully ionized or fully non-ionized species are examined. Hepcidin-25 is a basic peptide with the 
isoelectric point of 8.2. More than 99% of hepcidin will be ionized at a pH value approximately 
2 pH units above its isoelectric point of 8.2. However, such high pH values are usually not 
suitable for commonly used conventional reversed phase chromatography columns, stable up 
to a pH of 8. Nevertheless, in the present work new generation HPLC columns were employed 
for performance at high pH. An ACE Super Phenyl-Hexyl HPLC column with extended pH 
stability allowed the HPLC analysis at pH 11, using mobile phases containing 0.1% ammonia 
(chromatographic set 4, see section 2.4.2.2.). The formation of the hepcidin-25-copper(II) com-
plex at different molar ratios and at various pH values was tested and will be discussed in the 
following sections. 
3.2.2.1. Influence of molar ratio on hepcidin-25-copper(II) complex behavior 
The simultaneous monitoring of the metal complex and the remaining free hepcidin-25 was 
performed via LC-MS analysis by addition of a 1.8-180 µM Cu2+ solution to an 18 µM (50 
mg/L) hepcidin-25 solution in a 0.1-10 molar excess (see section 2.2.6.). The complexation of 
the peptide with the copper(II) ions was performed at a pH value of 11 (as the pH of the em-
ployed mobile phases). Three peaks were identified (Figure 3.16) and subsequently attributed 
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(via MS/MS) to hepcidin-25 (copper-free) and the complex of hepcidin-25 with one and two 
copper ions respectively. 
4 5 6 7
0
10
20
30
40
In
te
ns
ity
 a
t 2
14
 n
m
 (m
A
U
)
Time (min)
 hepcidin:Cu2+ 1:0.1
 hepcidin:Cu2+ 1:1
 hepcidin:Cu2+ 1:5
 hepcidin:Cu2+ 1:10
 blank
he
pc
id
in
-2
5
he
pc
id
in
-2
5 
/ 2
C
u2
+
he
pc
id
in
-2
5 
/ C
u2
+
 
 Figure 3.16: The influence of molar ratio on hepcidin-25-copper(II) complex behavior 
at pH 11 (HPLC separation) (mobile phase A: H2O/NH3 100/0.1 v/v pH 11, B: 
ACN/H2O/NH3 90/10/0.1, hepcidin-25 concentration 50 mg/L (18 µM)). 
The HPLC peaks were recorded in the wavelength range of 210-220 nm, where absorbance 
arises primarily due to peptide bonds. No signal was detected at 525 nm (absorption maximum 
of ATCUN-Cu(II) complex), probably due to lower concentrations of the analyte (18 µM). 
Copper has a smaller value of the extinction coefficient in comparison to peptides, thus higher 
concentrations are needed for DAD detection. This came in accordance with previous UV-Vis 
experiments (see section 3.2.1.), where a concentration of 10 mM peptide-copper(II) led to UV-
Vis signal at 525 nm. 
As expected, the DAD signal at 214 nm showed a decrease in the hepcidin amount with the 
addition of Cu2+ which could be explained by the metal complex formation (Figure 3.16). In-
terestingly, a significant amount of copper complex was formed even at a molar ratio hepcidin-
25:Cu2+ of 1:0.1, in agreement with previously described results involving the 6-residue N-
terminus DTHFPI (see section 3.2.1.). Additionally, the decrease in hepcidin-25 signal at molar 
ratio 1:5 and 1:10 coincides with significantly increased amounts of a second compound iden-
tified by MS/MS as the complex of hepcidin with two copper ions. This species was briefly 
mentioned previously in the literature [109], but no comprehensive MS characterization of the 
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complex was performed. Figure 3.16 also shows that at pH 11 there was unreacted peptide 
present at an equimolar ratio, while the excess of copper (1:5) led to quantitative complex for-
mation. Contrarily, in the case of the 6-amino acid N-terminus, the saturation was achieved at 
a molar ratio of 1:1. However, the experiments with the short peptide were performed at phys-
iological pH (7.4). At this point it was concluded that the behavior of hepcidin-25-copper(II) 
complex is pH-dependent. This is also supported by previous reports, which show different 
results for quantitative hepcidin-25-copper(II) complex formation at different pH values. Some 
authors applied FTICR-MS measurements at pH 6.8 and found total complex formation at a 
molar ratio hepcidin-25:copper of 1:1 [107], while others recorded the presence of unreacted 
peptide at equimolar concentrations, in a q-TOF-MS (quadrupole-time-of-flight mass spec-
trometry) experiment performed at pH 8.2 [108]. In the case of the applied pH of 11, an expla-
nation for the presence of free peptide could be that the high pH determined by 0.1% NH3 drives 
the copper ions to form highly stable complexes with the hydroxyl and ammonia groups. In the 
light of these reports, the influence of the pH value of the peptide-copper(II) solution was in-
vestigated further. 
3.2.2.2. Influence of pH on hepcidin-25-copper(II) complex behavior 
The behavior of the metal complex prepared in different buffers (pH 2.2, 4.2, 7.4 and 11 re-
spectively) was tested using stoichiometric Cu2+ solution (molar ratio 1:1). The chromato-
graphic separation was achieved in all cases using mobile phases containing 0.1% ammonia. 
The results confirmed complete complex formation of hepcidin-25 with one copper ion at phys-
iological pH. However, at basic pH (11), traces of free peptide could be observed (Figure 3.17), 
as described in the previous section. Surprisingly, the species containing one copper ion was 
present even at pH values below the reported complex stability limit of 5.2, namely 4.2 and 2.2. 
This could be explained by rapid metal complex formation during sample injection, promoted 
by the basic pH of the LC mobile phases (11). Additionally, the formation of the peptide com-
plex with two copper ions occurred preferably at high pH (11). At physiological pH (7.4), the 
metal complex present was mainly the mono-copper(II) complex. These findings were in line 
with the previously described results at a pH value of 6.8. 
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Figure 3.17:  The influence of pH on hepcidin-25-copper(II) complex behavior at molar 
ratio 1:1 (HPLC separation) (mobile phase A: H2O/NH3 100/0.1 v/v pH 11, B: 
ACN/H2O/NH3 90/10/0.1, hepcidin-25 concentration 50 mg/L (18 µM)). 
3.2.3. LC-MS/MS analysis of hepcidin-25-copper(II) complex(es) at pH 11 
Mass spectrometric detection of hepcidin-25 and hepcidin-25-copper(II) was performed using 
a triple quadrupole (QqQ-MS), coupled to the HPLC. Previously presented chromatographic 
separation (chromatographic set 4, see section 2.4.2.2.) by employing mobile phases at pH value 
of 11 was used. The samples containing a peptide solution of 50 mg/L (18 µM), prepared in 
0.1% ammonia at pH 11 (the solvent mixture at the start of the HPLC gradient), were analyzed 
at different molar ratios of hepcidin-25:Cu2+ (1:1, 1:10). ESI-MS parameters such as curtain 
gas flow, nebulizer gas or ion spray voltage were optimized. Full scan mode (Q1+) and product 
ion mode (MS2+) were applied. Collision induced dissociation (CID) was employed for frag-
mentation purposes. Initially, ESI was operated in negative mode (ESI-), which resulted in poor 
specific quasi-molecular ions and no specific fragmentation of the most abundant quasi-molec-
ular ion ([M+3H]3+) could be achieved. Therefore, positive mode (ESI+) was employed further. 
Hepcidin-25 
First, a solution of hepcidin-25 (50 mg/L) was tested. Full scan mode (+Q1) was employed in 
the range of m/z ratio between 100 and 2000. The doubly, triply and quadruply charged quasi-
molecular ions were identified with m/z of 1394.6 ([M+2H]2+), 930.3 ([M+3H]3+) and 697.8 
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([M+4H]4+) respectively. [M+3H]3+ was the most abundant quasi-molecular ion and was se-
lected as precursor ion for fragmentation. Product ion spectra (+MS2) resulted in the loss of b3 
(354 Da) and b4 (500.4 Da) to yield y222+ (1218.2 Da) and y212+ (1144.7 Da) respectively (Figure 
3.18). 
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Figure 3.18: Full scan (MS) and product ion (MS/MS) spectra of hepcidin-25 (basic 
mobile phase, pH 11). 
The fragmentation of hepcidin-25 (Figure 3.19) seems to be highly influenced by the intra-
molecular disulfide bonds and the ATCUN motif. N-truncation occurred before the first cyste-
ine in position 7. This yielded 3- or 4-amino acid fragments, the shortest of which corresponded 
to the metal binding motif ATCUN (DTH), illustrating its stability during fragmentation. C-
fragmentation resulted in longer fragments encompassing all four disulfide bridges. This proved 
the stability of disulfide network. 
The calculated mass of hepcidin-25 resulting from the triply charged quasi-molecular ion was 
found to be 2787.9 Da. The difference of roughly 0.9 Da as compared to the theoretical exact 
mass of 2787.0258 Da could be explained by taking into consideration the uncertainty of the 
unit mass resolution (considered Full Width at Half Maximum FWHM) of the triple quadrupole 
MS device. Accurate masses were confirmed by employing HR-MS (see section 3.2.4.). 
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Figure 3.19: Fragmentation pattern of hepcidin-25 in ESI MS. 
Hepcidin-25-Cu2+ 
Further, the analysis of the hepcidin-Cu2+ solution (molar ratio 1:1) showed similar series of 
ions in full scan mode (+Q1) as compared to hepcidin-25. The quasi-molecular ions with m/z 
of 1425.0 ([M+Cu]2+), 950.3 ([M+H+Cu]3+) and 713.1 ([M+2H+Cu]4+) were identified (Figure 
3.20).  
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Figure 3.20: Full scan (MS) and product ion spectra (MS/MS) of hepcidin-25-Cu2+ 
(basic mobile phases, pH 11). 
The fragmentation of the triply charged quasi-molecular ion as the most intense precursor ion 
resulted in the same fragment y222+ (1218.2 Da) as in case of hepcidin-25. Another fragment 
(415 Da) was attributed to the copper-adduct of b3, which represents the N-terminal fragment 
containing the three amino acids at the ATCUN motif (DTH). The difference of 61 Da corre-
sponds indeed to the addition of one copper (62.9 Da), with the loss of 2 Da and 2 positive 
charges (2 H+), in accordance to previous findings [108, 107]. The species could be identified 
as hepcidin-25 complexed with one copper ion binding the ATCUN motif. The fragmentation 
DTHFPICIFCCGCCHRSKCGMCCKT
7       10 11     13 14                   19             22 23
y22  y21
b3  b4
 81 
 
pattern of the peptide complexed with one copper ion showed similar behavior as compared to 
hepcidin-25. The compact structure determined by the four intra-molecular disulfide bridges 
was preserved in the product ion mode. Also, the ATCUN motif complexed with Cu2+ remained 
intact during fragmentation, demonstrating the stability of the metal complex. This is in accord-
ance to previously reported findings [108, 107]. The calculated mass of hepcidin-25-Cu2+ com-
plex was determined to be 2847.9 Da, which is comparable to the theoretical exact mass of 
2847.9397 Da. The accurate mass and the isotope pattern corresponding to a copper-containing 
peptide were confirmed by HR-MS as in the case of hepcidin-25 (see section 3.2.4.). 
2Cu2+/Hepcidin-25 
The analysis of the solution of hepcidin-Cu2+ (molar ratio 1:10) revealed a two Cu2+/hepcidin-
25 species. The peptide complexed with two copper ions was previously reported in literature 
using MALDI-TOF analysis [109], but never characterized using LC-MS/MS.  
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Figure 3.21: Full scan (MS) and product ion spectra (MS/MS) of hepcidin-25 com-
plexed with two Cu ions (basic mobile phases, pH 11). 
 
The doubly, triply and quadruply charged quasi-molecular ions were observed with m/z ratio 
of 1456.1, 971.0 and 728.5 respectively (calculated mass 2910 Da), but the signal intensity was 
lower compared to the other two species (Figure 3.21), probably due to a lower concentration, 
which was also observable in the LC chromatogram. 
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The product ion spectra of the triply charged quasi-molecular ion allowed the identification of 
the 415 Da fragment corresponding to the copper-adduct of the DTH motif. Another fragment 
of 1248.7 Da was identified that could be attributed to a copper-adduct of the fragment (y22)2+, 
taking into consideration the mass difference of 30.5 Da for the doubly charged fragment. This 
indicated a two Cu2+/hepcidin-25 species with one copper ion complexed at the metal binding 
motif and a second Cu2+ binding the rest of the biomolecule. This fact has never been reported 
before and it could be speculated that the second copper ion binds the histidine in position 15, 
due to the high affinity of the imidazole group for copper. Further investigations of the interac-
tion of hepcidin-25 to the second copper ion were performed using HR-MS (see section 3.2.4.). 
Hepcidin-25 was analyzed on a triple quadrupole in positive mode. Remarkably, even at pH 11, 
the ESI ionization process worked efficiently in positive mode leading to a sensitive detection 
of protonated hepcidin species. This shows that the ionization process is not always correlated 
to the pH of the sample, which is understandable, when considering the complexity of the ion 
formation process in gas phase. 
3.2.4. HR-MS of hepcidin-25-copper(II) complex 
The triple quadrupole coupled to HPLC offers excellent sensitivity for quantification of bio-
molecules. However, the limited mass resolution does not permit reliable structural characteri-
zation of peptides or metal-peptide complexes (accurate mass, isotope composition determina-
tions). Thus, in order to validate the results obtained at unit-mass resolution and to accurately 
characterize the isotope pattern of hepcidin-25 and its complexes with copper, high resolution 
MS (HR-MS) was employed. For this purpose, FTICR-MS experiments were performed by 
operating the mass spectrometer in positive mode (ESI+) and at highest resolution (FWHM 
106). Direct infusion of the hepcidin-25-copper(II) solution prepared at a pH of 11 (see section 
2.2.6.2.) resulted in the identification of the two peptide-copper(II) species. The triply charged 
quasi-molecular ions presented isotope patterns corresponding to the chemical formula 
C113H168N34O31S9Cu (Figure 3.22) and C113H168N34O31S9Cu2 respectively (Figure 3.23). A mass 
accuracy in the range of 1-4 ppm was obtained using the formula “mass accuracy (ppm) = 
(accurate mass – exact mass)/exact mass ∙ 106” [213].  
The mass difference between hepcidin-25 and its complexes with one and two copper ions was 
60.9 Da (63.9-2) and 124.8 (2∙63.9-2) Da respectively. This indicated that the interaction with 
the first copper ion occurred with the loss of two H+ as confirmed previously by LC-MS/MS. 
This correlated with the formation of the ATCUN-copper(II) complex which generally takes 
place with deprotonation of the two nitrogen atoms involved in peptide bonds. However, the 
second copper ion binds without proton expulsion. This could represent a much weaker inter-
action of copper(II) with the second histidine residue in position 15. The extra nitrogen donor 
atom of arginine residue, found in the immediate vicinity of histidine, or the alcoholic-OH of 
serine in position 17 could contribute to the coordination chemistry which might characterize 
this interaction [219]. 
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Figure 3.22: FTICR-MS spectra of hepcidin-25/Cu2+ at pH 11 (C113H168N34O31S9Cu1 + 
3H, charge +3): (a) experimental accurate mass; (b) theoretical exact mass. 
 
Figure 3.23: FTICR-MS spectra of hepcidin-25/2Cu2+ at pH 11 (C113H168N34O31S9Cu2 
+ 3H, charge +3): (a) experimental accurate mass; (b) theoretical exact mass. 
The FTICR-MS experiments were performed in the absence of LC mobile phases (pH 11), 
using direct infusion. This permitted, additionally as in the case of LC-MS/MS experiments, 
the comparison between the behavior of hepcidin-25/Cu2+ at basic and at physiological pH. 
Very similar isotope patterns of hepcidin/Cu2+ were obtained at both pH values of 7.4 (Figure 
3.24) and 11. 
  
Figure 3.24: FTICR-MS spectra of hepcidin-25-Cu(II) at pH 7.4 (C113H168N34O31S9Cu1 
+ 3H, charge +3): (a) experimental accurate mass; (b) theoretical exact mass. 
FTICR offered superior resolution compared to the triple quadrupole, which has been used pre-
viously in the LC-MS/MS experiments. However, HR-MS would be less attractive for quanti-
fication purposes. In this regard, the developed chromatographic separation at basic pH com-
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plemented by MS/MS detection using the triple quadrupole could represent in future a quanti-
fication tool of the copper-bound hepcidin-25 form. This would require however the develop-
ment of a sample preparation protocol at physiological or basic pH which would assure metal 
complex stability. 
3.2.5. 3D-model structure of hepcidin-25-copper(II)1 
In the light of the mass spectrometric characterization of hepcidin-25/Cu2+, further structural 
analysis of the metal complex employing NMR was performed, with the development of a first 
structural model of the Cu2+-bound hepcidin-25.  
Initially, the solution structure of the N-terminal hexapeptide complexing Ni2+ at physiological 
pH (7.4) was determined based on NMR experimental data. The strong paramagnetism of the 
Cu2+ ATCUN complex gives rise to large chemical shift changes and line broadening effects of 
the NMR resonances preventing high structural resolution close the metal ion [101]. Thus, 
Ni(II) ions were employed that also bound Hep-25 with high affinity and serve an appropriate 
substitute for Cu2+ forming a diamagnetic ATCUN complex amenable to high-resolution struc-
ture determination by NMR [220, 103]. Internuclear distance restraints were calculated from 
ROESY cross peak volumes, and dihedral angle restraints of the peptide backbone were gener-
ated from backbone chemical shifts using the program TALOS. In addition, the square-planar 
coordination known to be present in metal-bound ATCUN motifs (see section 1.2.3.1.) was 
imposed by additional distance and dihedral angle restraints. 
Subsequently, models of full-length hepcidin complexing Cu2+ were generated by combining 
the 3D structure of the N-terminal hexapeptide, described above, with the 3D structure of the 
19 C-terminal amino acids as determined by Jordan et al. (PDB code: 2KEF) [85]. The resulting 
model with lowest restraint violation energy of copper-bound hepcidin-25 is shown in Figure 
3.25 [221]. 
                                               
1 The work presented in this section was conducted by Marija Vranic and Heiko Möller at the University of Pots-
dam. 
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Figure 3.25: The lowest energy structure of the hepcidin 25/Cu2+ model structure (Fig-
ure provided by Marija Vranic and Heiko Möller, University of Potsdam, Germany). 
The results of the LC-MS/MS, HR-MS and NMR investigations of hepcidin-25/Cu2+ support 
the theory that copper is as an inherently incorporated entity in the native form of the iron 
regulator. This copper-peptide could offer more relevant information regarding iron homeosta-
sis as compared to hepcidin-25. However, further research should be conducted in this direction 
to identify hepcidin-25/Cu2+ in biological samples and investigate its biological function. 
3.3. LC-MS/MS methods for the quantification of hepcidin-25 in human se-
rum 
Sections 3.1. and 3.2. mainly comprised qualitative studies of the peptide hepcidin-25. High 
concentration ranges (50-250 mg/L), which occurred in the course of the folding process, solu-
bility investigations or during the studies regarding the formation of the peptide-copper com-
plex, allowed the use of HPLC for peptide amount determination. Mass spectrometry or tandem 
mass spectrometry were complementarily used for mass characterization and identity confir-
mation of hepcidin-25 species. However, for the development of quantification methods suita-
ble for the assessment of Hep-25 in biological samples (human serum), improved sensitivity is 
required. In healthy individuals, the concentration of hepcidin-25 varies from below reported 
LOQ of around 1 µg/L to 25-40 µg/L (see section 1.3.3.3.). Therefore, HPLC and MS/MS were 
coupled to develop a selective and sensitive analytical method for peptide quantification. Iso-
tope-labeled hepcidin-25 was employed as internal standard (IS). Based on the median and 
mean physiological level defined previously at 1-5 µg/L and 5-15 µg/L respectively (see section 
1.3.3.3.), the targeted dynamic range for Hep-25 quantification in healthy subjects was consid-
ered to be between 0.5 µg/L and 40 µg/L. 
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As discussed in section 1.3.2.3, isotope dilution liquid chromatography tandem mass spectrom-
etry ID-LC-MS/MS (particularly using triple quadrupole) is increasingly used as an alternative 
to immunoassays in the field of clinical chemistry and laboratory medicine for quantification 
purposes. Moreover, several internationally well reputed institutions such as CLSI or NIST 
acknowledge (ID-)LC-MS/MS as the “gold standard” for small biomolecule quantification 
[168, 5]. 
3.3.1. LC-MS/MS work flow 
The development of a LC-MS/MS method for quantification of Hep-25 in human serum implied 
3 major steps which are typical for clinical determination of endogenous biomolecules in bio-
logical samples (Figure 3.26): 
• Sample preparation 
• Chromatographic separation (HPLC) 
• Detection by tandem mass spectrometry (MS/MS) 
 
Figure 3.26: Work flow for Hepcidin-25 quantification emplyoing LC-MS/MS [222]. 
In the present study, two sample preparation protocols were developed for hepcidin-25 extrac-
tion (see section 3.3.2.3.) and two chromatographic separation strategies were tested by em-
ploying acidic, TFA-based, (see section 3.3.3.1.) and basic, ammonia-containing, mobile 
phases (see section 3.3.3.2.). A triple quadrupole instrument operated in MRM mode was used 
for peptide quantification (see section 1.3.2.3.). The final goal was the development and vali-
dation of a LC-MS/MS quantification method for hepcidin-25 that can be recommended for 
routine laboratory implementation (see section 3.4.). By such, in addition to good precision, 
accuracy and sensitivity, the method required characteristics such as fast, robust and cost-effec-
tive, implying simple procedures, economic reagents involved and low sample volume used. 
Therefore, each step of the LC-MS/MS method was selected in accordance with these aspects. 
Additionally, the properties of the desired analyte, Hep-25, were taken into consideration. In 
this regard, its amino acid content (one acidic amino acid and five basic residues as presented 
in section 3.1.) could strongly influence the LC-MS/MS analysis. The choice of the sample 
preparation technique, the chromatographic protocol (HPLC column and other parameters) and 
1. Serum sample     
preparation 2. HPLC separation 3. MS/MS detection
• Mass spectrometer
• Fragmentation
• Internal standardSerum 
sample
HPLC 
autosampler
vial
HPLC column
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the ionization parameters depend on the charge of the molecule and the hydrophilicity/hydro-
phobicity ratio. Moreover, the reported “stickiness” of hepcidin-25 [84, 93] was investigated to 
determine its influence on the LC-MS/MS analysis. 
3.3.2. Sample preparation 
3.3.2.1. Hepcidin-25 adsorption 
Due to their generally amphipathic character, peptides and proteins readily adsorb to most sur-
faces such as glass or plastic laboratory ware. When LC-MS quantification of a peptide is the 
main end-point, the adsorption effects need to be evaluated [201]. In the case of hepcidin-25, 
the “stickiness” of the peptide is well known from literature [84, 93, 55]. Since the LC-MS/MS 
quantification can be severely affected by a non-specific interaction of the peptide to the labor-
atory ware in terms of reproducibility, sensitivity and accuracy, the adsorption effects were 
tested prior to further LC-MS optimization. Chromatographic set 3 (see section 2.4.2.2.) em-
ploying acidic mobile phases (containing TFA) was used for LC-MS/MS experiments. The in-
fluence of the chromatographic mobile phases on the adsorption of the peptide to laboratory 
tube surfaces was examined by testing also the ammonia-containing solvents (chromatographic 
set 4) that led to similar peptide losses (data not shown). The signal intensity (relative MRM 
peak area – see section 2.4.3.1.) of hepcidin-25 was monitored during 3 to 5 consecutive injec-
tions. Each sample was freshly prepared directly before LC-MS/MS analysis, with the duration 
of one LC-MS/MS run of 14 min (see section 2.4.2.2.).  
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Figure 3.27: The influence of hepcidin-25 concentration on the MRM signal of hep-
cidin-25 of sequential injections. 
A loss of signal was soon identified in the LC-MS analysis of hepcidin-25. To determine the 
possible causes, three parameters were tested that could influence the MRM signal alteration as 
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follows: The concentration of the analyte, the sample injection composition (solvent) and the 
vial material. Firstly, different concentrations of hepcidin-25 solutions were tested in standard 
HPLC glass vials. This could indicate if the signal was altered by the ionization process, inde-
pendent of the concentration of the analyte. The material used was hepcidin-25 folded “in 
house”, stored in a mixture of water/ACN/TFA 60/40/0.1 v/v/v (see section 2.2.3.) The results 
showed that the peptide losses were not significant for concentrations of 35 mg/L. However, in 
the case of concentrations lower than 1 mg/L, which are usually needed for preparation of hep-
cidin-25 standards in the desired quantification range (0.5-40 µg/L), up to 90% peptide loss has 
been observed (Figure 3.27). This showed that the loss of signal was not generated by ion sup-
pression due to the additives used in the mobile phases (TFA), but was rather caused by adsorp-
tion of the peptide, for example to the walls of the glass vial. An explanation for this could be 
that the basic character of the 25-amino acid peptide led to electrostatic interactions with the 
acidic silanol groups of the glass surface. 
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Figure 3.28: The influence of different solvents on the MRM signal of hepcidin-25 (50 
µg/L). All solutions were prepared in standard autosampler glass vials. 
Secondly, the preparation of hepcidin-25 solutions in different sample injection solvents using 
standard HPLC glass vial was investigated. Figure 3.28 shows that none of the solvents assured 
stable MRM signal when using autosampler glass vials. However, it could be observed that a 
high pH (0.1% NH3) significantly reduced the adsorption of hepcidin to the glass surface. This 
phenomenon reflected the influence of pH on the electrostatic behavior of hepcidin-25. Thus, 
acidic solutions containing TFA cause the protonation of the peptide, and the positively charged 
hepcidin-25 becomes attracted by the negatively charged hydroxyl groups in the glass compo-
sition. In contrast, the basic pH of ammonia-containing solutions leads to less positive charges 
to interact with the silanol groups of the glass surface. Nevertheless, a mixture of wa-
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ter/ACN/TFA of 60/38/2 (v/v/v) was selected as standard sample injection solution for hep-
cidin-25 samples not only because it facilitates a favorable MS ionization in positive mode (see 
section 3.3.3.1.), but also because it offers good compliance with the sample preparation con-
ditions (see section 3.3.2.3.). 
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Figure 3.29: The influence of different vial materials on the MRM signal of hepcidin-
25 (350 µg/L). 
Lastly, the influence of vial material on hepcidin-25 concentration was investigated using the 
chosen sample injection solvent water/ACN/TFA 60/38/2 (v/v/v). Plastic laboratory tubes and 
autosampler vials of three different materials were tested for this purpose. Using standard and 
low adsorption commercial HPLC glass vials resulted in a respective reduction of 20% and 
30% in MRM relative peak area. Plastic tubes (polypropylene vials and Eppendorf tubes) 
showed better suitability for storage, although the MRM signal indicated some instability (Fig-
ure 3.29). These instabilities were attributed to the non-specific interaction of the hydrophobic 
residues of Hep-25 with the highly hydrophobic polypropylene (PP) surface. 
At this stage, it could be concluded that inert surfaces were required to reduce the interactions 
of hepcidin-25 with handling laboratory vessels. 
3.3.2.2. The development of silanized vials 
In order to reduce adsorption effects of hepcidin-25 to the autosampler vials at low concentra-
tions (<1 mg/L), silanized vials were developed during the present work by treating standard 
glass HPLC vials with a 1% silane solution in toluene containing 1% of water (see section 
2.3.2.). In this regard, it is known that glass can undergo silanization in reaction with 
trialcoxysilanes by hydrolysis of the silane reagent to the silanol groups of the glass followed 
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by surface reaction and crosslinking, leading to chemically modified glass surface. For the pur-
pose of vial silanization, two types of silanes, namely an amino-silane (3-(2-aminoethyl-
amino)propylmethyl-dimethoxysilane) and a fluoro-silane (1H,1H,2H,2H-perfluorooctyl-tri-
ethoxysilane) were employed (Figure 3.30).  
 
Figure 3.30: Glass silanization chemical reaction. 
Adsorption effects were investigated using NH2- and F-silanized vials, in the case of hepcidin-
25 neat solution (water/ACN/TFA, 60/38/2, v/v/v) and of serum samples spiked with the pep-
tide (Protocol I, see section 2.3.1.2.). All experiments were performed at peptide concentrations 
below 500 µg/L. Compared to commercial glass and plastic vials, the chemically modified au-
tosampler vials showed practically no alteration in the hepcidin MRM signal, when Hep-25 
solutions (350 µg/L) in water/ACN/TFA mixture 60/38/2 (v/v/v) were tested (Figure 3.31). 
Moreover, the inert vials were tested using several reconstitution solvents for Hep-25, with 
similar results (data not shown). 
Additionally, when hepcidin-25 serum samples (10 µg/L) were handled in standard autosampler 
glass vials for LC-MS/MS analysis, the results showed MRM signal instability of hepcidin-25, 
probably caused by the interaction of plasma components to the walls of the vial. In this case 
as well, inert surfaces provided by the silanized vials permitted a stable MRM signal of the 
peptide for an accurate quantification (Figure 3.32). 
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These results enabled the conclusion that silanized glass vials represented an excellent choice 
of laboratory ware for hepcidin-25 handling, allowing a sensitive, precise and accurate quanti-
fication of the peptide. 
1 2 3 4 5
0
20
40
60
80
100
Re
la
tiv
e 
M
RM
 p
ea
k 
ar
ea
 (%
)
Standard
autosampler vial
1 2 3 4 5
0
20
40
60
80
100
LA
vial
1 2 3 4 5
0
20
40
60
80
100
PP 
vial
1 2 3 4 5
0
20
40
60
80
100
LA Eppendorf
tube
1 2 3 4 5
0
20
40
60
80
100
-F silanized 
vial
1 2 3 4 5
0
20
40
60
80
100
Injection #
-NH2 silanized
vial 
 
Figure 3.31: Comparison of MRM signal of hepcidin-25 solutions (350 µg/L) prepared 
in standard laboratory ware and in silanized glass vials (LA – low adsorption, PP – 
polypropylene). 
It needs to be mentioned that two amino-silanes, namely 3-(2-aminoethylamino)-propylmethyl-
dimethoxysilane and (3-aminopropyl)trimethoxysilane, were tested for the preparation of NH2-
silanized vials. The obtained vials showed identical behavior when used for handling Hep-25 
standards (data not shown) and 3-(2-aminoethylamino)propylmethyl-dimethoxysilane was se-
lected for further use in amino-silanization. However, differences in the performance of the 
amino-silanized vials compared to the fluorinated vials were found in the low concentration 
range (≤25 µg/L). NH2-silanized vials proved to be the best choice when handling hepcidin 
standard solutions, especially at very low concentrations (10 µg/L), because the amino groups 
on the glass surface repel the positively charged hepcidin molecules, avoiding adsorption on 
the vial wall. On the other hand, F-silanized vials showed the best MRM stability in serum 
samples, particularly for low Hep-25 concentrations (25 µg/L) (Figure 3.33). This could be 
explained by taking into consideration the complex mixture of components in the matrix, which 
do not interact detrimentally with the surface of the non-charged inert vial. Hence, the type of 
silane used for surface modification should be optimized depending on the application. 
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Figure 3.32: Comparison of MRM signal of serum samples spiked with hepcidin-25 (10 
µg/L) prepared in standard laboratory ware and in silanized glass vials. 
To conclude, the optimization of sample preparation is a key challenge in achieving a sensitive 
and accurate LC-MS/MS quantification of hepcidin-25. In this regard, the use of correct sol-
vents and appropriate laboratory ware are crucial for avoiding peptide losses. Therefore, all 
experiments for LC-MS/MS quantification were conducted using silanized glass vials. These 
were also employed for the preparation of hepcidin-25 standard solutions, which was essential 
for the correct assignment of Hep-25 concentrations. 
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Figure 3.33: Different behavior of the F- and NH2-silanized glass vials for neat samples 
and serum samples. 
3.3.2.3. Serum sample preparation 
For the purpose of removing or minimizing highly abundant serum proteins (such as albumin 
or immunoglobulins) and other serum components, which can suppress the MS ionization, dif-
ferent serum treatment protocols were used. Also, sample pre-concentration techniques were 
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employed for MS signal enhancement. The mechanisms underlying the sample preparation 
methods are explained below (i.-iii.). 
i. Protein precipitation 
The principle of precipitation relies on altering the solvation capacity of a solvent, namely by 
lowering the solubility of the soluble species through addition of a reagent. The amino acid 
content of a protein or peptide, specifically the charged residues and the hydrophilic and hydro-
phobic amino acids, influences its solubility. Molecules with a high content of hydrophilic 
amino acids possess a higher solubility in aqueous medium compared to those consisting of 
mainly hydrophobic residues. In addition, charged amino acids can increase the solubility of a 
species. When an organic solvent is added to a protein solution, solvent molecules progressively 
displace water molecules from the protein surface causing the decrease of its solvation layer 
and ultimately its aggregation due to attractive electrostatic interactions. Another technique for 
achieving protein aggregation is by applying isoelectric precipitation at the isoelectric point (pI) 
of the molecule. At a solution pH above or below its pI, the surface of a protein is predominantly 
negatively or positively charged respectively, and repulsion between similarly charged mole-
cules occurs. However, at the pI value, the negative and positive charges cancel each other, and 
the attraction forces predominate, which consequently leads to aggregation and precipitation. 
Since the pI of most proteins is in the pH range of 4 to 6, organic acids such as trifluoroacetic 
acid or trichloroacetic acid are used in various concentrations for protein precipitation. 
ii. Centrifugal filters 
Membrane filters with a cut-off of 5 kDa and 30 kDa allow the removal of (most of) high-
molecular weight serum compounds, while small molecules usually pass through the filter 
membrane and are collected for analysis. 
iii. Freeze-drying (lyophilization) 
Freeze-drying represents the removal of ice or other frozen solvents from a material via subli-
mation and the removal of bound water molecules via desorption. Usually, the serum samples 
are frozen by immersion in liquid nitrogen and then freeze-dried overnight. 
The serum sample preparation protocols have been described in section 2.3.1. Protocol I was 
employed for LC-MS/MS analysis using TFA-based mobile phases, while protocol II was ap-
plied in the case of LC-MS/MS analysis using NH3-based mobile phases. 
Protocol I 
Although both C18 [195] and weak cation exchange [197, 210] solid phase extraction (SPE) 
were widely suggested as sample preparation techniques for hepcidin-25 quantification, a faster 
and more cost-effective extraction of hepcidin from serum samples, which is compatible for 
routine laboratory usage, was evaluated using acetonitrile-trifluoroacetic acid-precipitated se-
rum. Initially, protein precipitation using 40%-70% ACN was tested. However, the LC-MS/MS 
analysis was unsatisfactory, with no analyte detected in the obtained supernatant (data not 
shown). Further, isoelectric precipitation employing 2% TFA was applied additionally for se-
rum treatment. The combination of ACN and TFA resulted in good sensitivity (LOQ of 0.1 
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µg/L in neat solution and 0.5 µg/L in serum), excellent recovery (99%) (see section 3.3.4.) and 
was further considered as a cheap and fast extraction procedure for the quantification of hep-
cidin-25 in serum samples. Hep-25 solutions containing >40% acetonitrile resulted in elution 
of the peptide at the injection peak (see section 3.3.3.1.). Therefore, 38% ACN (v/v) and 2% 
TFA (v/v) were applied for serum sample preparation. The supernatant obtained after protein 
precipitation was subsequently used for LC-MS/MS analysis, applying an injection volume (10 
µL) (Figure 3.34). 
 
Figure 3.34: Serum sample preparation - Protocol I. 
Protocol II 
The use of basic mobile phases (NH3-based) was characterized by high background noise and 
a S/N ratio that led to a LOQ of 10 µg/L. This did not meet the requirements for hepcidin-25 
quantification (dynamic range 0.5-40 µg/L) (see section 3.3.3.2.). For improved sensitivity, the 
clean-up procedure was optimized and a pre-concentration step was added. The supernatant 
resulted after protein precipitation employing 38% ACN and 2% TFA was further processed 
using 5 and 30 kDa cut-off filters (hepcidin-25, MW=2.8 kDa). Low adsorption filter mem-
branes (Hydrosart) were used at this stage to avoid peptide losses due to the stickiness of hep-
cidin-25. Both filters showed improved S/N in the LC-MS/MS analysis, with the 5 kDa cut-off 
filters offering slightly decreased background noise as compared to the 30 kDa filters (data not 
shown). Therefore, these were considered for further sample preparation. The use of mem-
branes served as an additional clean-up step to protein precipitation in the serum sample treat-
ment. Moreover, a pre-concentration step consisting of overnight freeze-drying of the filtrate 
was considered (Figure 3.35). The reconstitution of the dried material led to higher concentra-
tions of hepcidin-25 and allowed increased sensitivity for the detection of the peptide. In addi-
tion, different sample injection volumes were investigated in order to achieve an improved LOQ 
using Protocol II. Applying larger injection volumes represents a way to increase sensitivity. 
Nevertheless, too high sample injection volume affects the peak shape and resolution, and can 
overload the column [168]. 10, 20, 30 and 40 µL of the sample were individually injected in 
the LC device using the same hepcidin-25 solution (10 µg/L). An increase in the injected vol-
ume generated a relatively proportional increase in the amount of peptide. However, broadening 
of the MRM peak was observed when volumes > 30 µL were injected (data not shown), which 
adversely affects the quantification [223]. Therefore, the injection volume of 30 µL was se-
lected in Protocol II. 
0.3 mL serum 150 µL sample
38% ACN,
2%TFA
21500 RCF
10 min
10 µL
LC-MS/MS
 95 
 
 
Figure 3.35: Serum sample preparation - Protocol II. 
The addition of ACN (38%) and TFA (2%) applied for serum treatment was also employed for 
the preparation of the hepcidin-25 standards (see section 3.3.3.1.). This allowed the use of an 
“universal” solvent in the LC-MS/MS quantification of hepcidin-25. The selection of an ana-
lyte-free matrix (sheep serum) will be discussed in section 3.3.4.1. 
3.3.2.4. Effect of storage in silanized vials on hepcidin-25 
The stability of hepcidin-25 in standard solutions prepared in silanized vials was assessed over 
a period of 7 months to determine the suitability of the chemically-modified vials. Hep-25 
standard solutions were prepared in a mixture of water/ACN/TFA 60/38/2 (v/v/v), as described 
in section 2.3.1.1., and stored in amino-silanized vials at 4°C and -20°C respectively. LC-
MS/MS analysis of the samples was performed using the TFA-based mobile phases (chroma-
tographic set 3, see section 2.4.2.2.). The amount of hepcidin-25 was determined based on a 7-
point calibration curve as described in section 2.5.4.1. 
Storage at 4°C 
A 400 µg/L solution of hepcidin-25 (which was generally used for the preparation of sheep 
standards in the low concentration range <10 µg/L) was monitored, after being store in silanized 
vials at 4°C for one week, one month, 4 months and 7 months (Table 3.4). Hepcidin-25 level 
after storage was defined as the relative ratio of the amount of peptide quantified by LC-MS/MS 
and the expected amount of peptide. The experiments indicated a good storage stability of the 
vials for at least one month. After a 7-month period however, a loss of up to 20% of hepcidin-
25 was found. 
Table 3.4: Relative change of hepcidin-25 stored in water/ACN/TFA 60/38/2 in 
silanized vials at 4°C.   
Storage period  Hepcidin-25 level (%) CV (%) 
Fresh 103 12 
1 week  99 5 
1 month 101 9 
4 months 88 5 
7 months 79 6 
The decrease in hepcidin-25 level after several months could be explained by taking into ac-
count its possibility of degrading into the shorter isoforms (Hep-24, -22 and -20). Studies by 
Laarakkers et al. showed that hepcidin-25 degraded into its N-truncated isoforms in human 
serum, when stored for more than 7 days at 4°C [93]. A faster degradation in serum could be 
attributed to the multitude of components present, particularly enzymes. 
Storage at -20°C 
1.2 mL serum 1 mL supernatant
38% ACN,
2%TFA
21500 RCF
20 min
450 µL filtrate
5 kDa cut-off 
membranes
Freeze-drying
overnight
Resuspension
H20/ACN/TFA 
60/38/2
120 µL sample
3300 RCF
220 min
30 µL
LC-MS/MS
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Hepcidin-25 level in a 400 µg/L solution prepared in water/ACN/TFA 60/38/2 (v/v/v) was 
tested after 7 months of storage in NH2-silanized vials at -20°C. No significant change was 
recorded in the peptide concentration. Additionally, hepcidin-25 standard solution of 1mg/L 
prepared in 1% acetic acid (according to the manufacturer’s instructions) was tested after a 7-
month period. No considerable change of the Hep-25 level was found. These results indicate 
that the developed amino-silanized vials represent a good choice not only for the preparation of 
hepcidin-25 standards (as shown in section 3.3.2.2.), but also for storage of the peptide calibra-
tor solutions for a minimum of one-month duration at 4°C and a 7-month period at -20°C. This 
can be very useful in routine analysis in terms of saving time and costs required for the 
preparation of new standards per each calibration. 
3.3.3. LC-MS/MS analysis 
The LC-MS/MS analysis was tested by employing both acidic (TFA-based) and basic mobile 
phases (NH3-based). A solution of 50 mg/L hepcidin-25 folded “in house” (water/ACN/TFA 
60/40/0.1 v/v/v) was used to determine optimal MS system settings and to gain information 
about the ionization behavior of the peptide. Generally, the MS ionization of peptides is influ-
enced by the amino acid content and the MS polarity applied is selected depending on the charge 
of the peptide in solution. In this sense, for the use of positive ion mode, the analyte is intro-
duced in the MS device at low pH to encourage positive ion formation. Conversely, in negative 
ion mode, the analysis is usually carried out well above the isoelectric point of the analyte, in 
order to deprotonate the molecule. However, the ion behavior in the gas phase is a complex 
process that cannot be correlated to the pH of the sample [224]. Hence, both positive and neg-
ative modes were tested when employing acidic and basic mobile phases, respectively. The 
triple quadrupole was operated in full scan mode (Q1), followed by product ion mode (MS2) 
using CID to induce fragmentation. Multiple reaction monitoring (MRM) mode for selected 
transitions was applied for quantification purposes.   
3.3.3.1. Acidic mobile phases - TFA-containing  
As discussed in section 1.3.2.3., volatile acids such as formic acid (FA), trifluoroacetic acid 
(TFA) or acetic acid can be used as additives in the LC-MS analysis of basic peptides. FA is 
usually preferred over TFA due to high suppression of the ionization efficiency of the latter 
one. However, TFA proved to be a preferable additive for chromatographic separation of hep-
cidin-25 (see section 3.1.1.) and a suitable precipitation reagent (see section 3.3.2.3.). Hence, a 
comparison of FA and TFA determined which additive was more suitable to be used for the 
quantification of hepcidin-25. 
Chromatographic set 3 (see section 2.4.2.2.) using a C18 column was employed for the LC-
MS/MS analysis. The mobile phases A (water/acetonitrile 95/5 v/v) and B (acetonitrile/water 
95/5 v/v) were prepared with 0.1% TFA and FA respectively. Aiming for a fast method, suitable 
for routine analysis, chromatographic parameters were optimized to yield efficient separation 
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in the minimum time. A binary gradient with a linear increase from 5% to 95% B in 1, 2, 4, 5 
and 7 minutes respectively was tested. The chromatographic conditions applying a gradient in 
2 minutes showed good separation capacity and were selected further. The increase of the gra-
dient up to 95% B was necessary due to the complex matrix used (human serum). Then, a 3-
minute washing step (95% B) and a 6.5-minute re-equilibration (5% B) step were added. 
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Figure 3.36: Full scan and product ion MS spectra of “light” hepcidin-25 (FA-based 
mobile phases). 
The LC-MS/MS behavior of hepcidin-25 was highly influenced by the acidic reagent used. The 
chromatographic separation in the case of TFA-based mobile phases yielded a sharper peak as 
compared to FA-containing solvents. Moreover, the use of FA as additive in the mobile phases 
resulted in the quadruply charged quasi-molecular ion ([M+4H]4+) as the most abundant pre-
cursor ion in full scan mode (Q1+), which underwent subsequent fragmentation (MS2+) (Figure 
3.36). In the case of TFA-based mobile phases, [M+3H]3+ was obtained as the most intense 
quasi-molecular ion that was selected further for fragmentation. The most abundant MRM tran-
sitions in the case of the two additives were further compared as follows: 698.0  354.0 (FA-
based mobile phase) and 930.3  1144.7 (TFA-based mobile phases). As it can be observed in 
Figure 3.37, the MRM signal intensities were very similar for both TFA and FA. This means 
that there was no signal suppression recorded for TFA, in contrast to its general behavior re-
ported by the mass spectrometry community (see section 1.3.2.3.). These findings show that 
the preferential use of FA as additive in LC-MS analysis is not always justified. Moreover, in 
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the case of hepcidin-25 quantification, the use of TFA led to a 40-fold increase in S/N as com-
pared to FA, mostly due to low spectral background. Thus, TFA was selected as acidic additive 
for improved sensitivity of the LC-MS/MS analysis. 
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Figure 3.37: Superposed MRM chromatograms of hepcidin-25 (500 µg/L) using mobile 
phases containing 0.1% TFA (green trace) and 0.1% FA respectively (blue trace). 
Full scan and product ion spectra of hepcidin-25 employing TFA-containing mobile phases are 
presented in Figure 3.38. MS analysis was carried out by operating the device in positive mode 
(ESI+). Negative mode ionization (ESI-) led to [M-2H]2- as the most abundant quasi-molecular 
ion, but the sensitivity was poor and no specific fragmentation could be achieved (data not 
shown). Mass spectrometric parameters, such as the spray ionization voltage, curtain gas and 
nebulizer gas, were optimized. The fragmentation pattern was highly influenced by the disulfide 
network, similarly as in the MS/MS analysis of hepcidin-25-copper(II) species (see section 
3.2.3.). In this sense, the sulfur-sulfur bonds provided high stability to the biomolecule, pre-
served even when CID was applied. Thus, fragmentation of the triply charged quasi-molecular 
ion resulted in the identification, in the product ion spectra (MS2+), of b3 (354.0), b4 (500.4), 
y212+ (1144.7) and y222+ (1218.2). No full fragmentation of the precursor ion ([M+3H]3+) was 
achieved, although different values for collision energy (CE) were tested for fragmentation pur-
poses (20-60 V). However, the most abundant MRM transition (930.3  1144.7) that was em-
ployed as quantifier offered a very good sensitivity using a CE of 45 V. In addition to the quan-
tifier transition, two more qualifiers were used, namely 930.3  1218.2 and 930.3  354.0. 
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Generally, in peptide quantification, it is recommended to use the most intense ion for quanti-
fication of the peptide, and to monitor the next two most abundant fragment ions for specificity 
evaluation of the assay.[201]. 
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Figure 3.38: Full scan and product ion MS spectra with fragmentation pattern of 
“light” hepcidin-25 (TFA-containing mobile phase). 
It is worth mentioning that the triple quadrupole MS was previously criticized for its poor frag-
mentation capacities and lack of sensitivity for hepcidin quantification [196]. However, opti-
mized MS parameters described in this work (see section 2.4.3.1.) yielded a LOQ of 0.5 µg/L 
(see section 3.3.4.). It could be concluded that the triple quadrupole is a suitable mass analyzer 
to be employed for sensitive hepcidin quantification. 
In the next step, different ratios of ACN and TFA in the solvent mixture used for the preparation 
of hepcidin-25 standards were tested. The results indicated that the sensitivity of the LC-
MS/MS analysis was enhanced by the increase of the organic solvent ratio. This came in agree-
ment with the results of the exploratory tests that showed a superior solubility of the peptide in 
the case water/ACN/TFA 60/40/0.1 (v/v/v) mixture, as presented in section 3.1.2. However, 
ACN concentrations higher than 40% resulted in the elution of the peptide in the injection peak 
(data not shown). Therefore, the optimum concentrations for both Hep-25 standard preparation 
and serum sample preparation were considered as 38% ACN and 2% TFA. Moreover, the pep-
tide standards proved to be stable at 4°C and -20°C, when stored under these conditions (see 
section 3.3.2.4.). 
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Figure 3.39: Full scan and product ion MS spectra of “heavy” hepcidin-25 (TFA-con-
taining mobile phase). 
Thereafter, the internal standard (IS), which was represented by isotope-labeled hepcidin-25 
(13C18, 15N3), was investigated using LC-MS/MS. The main advantage of using an internal 
standard is that, upon its addition, any possible losses due to sample handling or ionization 
variables are compensated, as discussed in section 1.3.2.3. 13C and 15N labeled ISs generally 
represent a superior choice as compared to 2H labeled standards. The reason behind this is that 
in some instances, the position of deuterium atoms can lead to hydrogen-deuterium exchange 
(in a mass spectrometer interface or in the gas phase), which results in alteration of the IS re-
sponse and, in extreme cases, even in complete loss of deuterium atoms [168]. In addition, 
deuterium-based internal standards may be chromatographically separated from their “light” 
counterparts. 
A solution of 56 mg/L isotope-labeled hepcidin-25 (also called “heavy” hepcidin-25) was con-
sidered for the LC-MS/MS analysis. The MS behavior of “heavy” Hep-25 resembled that of the 
“light” species. The doubly, triply and quadruply charged quasi-molecular ions were obtained 
in full scan mode (Q1+). The fragmentation of the most abundant ion [M+3H]3+ resulted in the 
fragments b3 (354.0), b4 (510.4), y212+ (1150.2) and y222+ (1228.7), corresponding to the respec-
tive isotope-labeled fragments of hepcidin-25 (Figure 3.39). As in the case of “light” Hep-25, 
one quantifier (937.3  1150.2) and two qualifiers (937.3  1228.7 and 937.3  354.2) were 
further monitored. This LC-MS/MS method was validated using sheep serum as surrogate ma-
trix (see section 3.3.4.2.), and further used for hepcidin-25 quantification in human serum (see 
section 3.3.5. and 3.4.). Protocol I was applied for sample preparation (see section 3.3.2.3.). 
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3.3.3.2. Basic mobile phases - NH3-containing  
So far, LC-MS/MS has been applied by different research groups for the quantification of hep-
cidin-25, by employing reversed phase chromatography, using exclusively acidic additive-
based mobile phases (see section 1.3.2.3.). In the present work, however, a new quantification 
method using ammonia-containing mobile phases (pH 11) for RP-HPLC was considered. This 
was based on the LC-MS/MS method developed for the chromatographic separation and MS 
identification of hepcidin-25-copper(II) species (see section 3.2.2.). The chromatographic pa-
rameters, together with the MS and MS/MS analysis of the peptide, have been presented in 
detail in sections 2.2.2. and 2.2.3. Two HPLC columns, namely ACE Super C18 (chromato-
graphic set 3) and ACE SuperPhenylHexyl (chromatographic set 4), were tested for hepcidin-
25 analysis. Usually, phenyl-hexyl columns show remarkable selectivity for aromatic and 
amine compounds. C18 columns are virtually used for all HPLC applications, particularly for 
peptide and protein analysis. When applied to the basic mobile phases, the two columns showed 
analogous retention time of hepcidin-25. The phenylhexyl column was selected for further uti-
lization. A minor retention time drift was observed, probably due to the high volatility of am-
monia that could cause a slight long-term instability of the solvent mixture. Hence, a frequent 
exchange of the solvents was performed. 
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Figure 3.40: LC-MS/MS chromatogram of a sheep serum sample spiked with human 
hepcidin-25 (20 µg/L) using (a) basic mobile phases (0.1% NH3) and (b) acidic mobile 
phases (0.1% TFA).  
The full scan (+Q1) MS spectra of a 50 mg/L hepcidin-25 solution revealed the triply charged 
quasi-molecular ion as the most abundant ion, which was further selected for fragmentation. 
Similarly, as in the case of acidic mobile phases (0.1% TFA), the fragments b3, b4, y212+ and 
y222+ were obtained in product ion mode (MS2+). Three transitions, namely 930.3  1144.7 
(quantifier), 930.3  1218.2 (qualifier 1) and 930.3  354.0 (qualifier 2), were followed. One 
quantifier and two qualifiers were also monitored for isotope-labeled Hep-25 as follows: 937.3 
 1150.2, 937.3  1228.7 and 937.3  354.2. 
 102 
 
The developed methodology was applied to biological matrix. The LC-MS/MS chromatogram 
of a sheep serum sample, spiked with hepcidin-25 solution to a concentration of 20 µg/L, 
showed a signal-to-noise ratio (S/N) of approximately 20, compared to the method employing 
TFA-containing mobile phases, which displayed a S/N of 500 for the same sample (Figure 
3.40). This resulted in an estimated LOQ of 10 µg/L, which was not sufficient for the targeted 
dynamic range of 0.5-40 µg/L. In order to reduce the high background noise and increase the 
concentration of the analyte for signal enhancement, an additional clean-up step and a pre-con-
centration step were included in the sample preparation procedure (see Protocol II, section 
2.3.1.3.). By such, an improved sensitivity was achieved and the method was further validated 
as described in section 3.3.4.3. Hepcidin-25 quantification in the desired concentration range 
was possible with both methods employing basic and acidic mobile phases (see section 3.3.5.).  
3.3.4. Validation 
3.3.4.1. Surrogate matrix 
According to the CLSI guidelines, a surrogate matrix, also called “proxy” matrix, is usually 
required to prepare the calibration standards for endogenous analytes. The goal of surrogate 
matrixes is the generation of calibrators that: 1) are physiologically representative of the test 
matrix, thus minimizing matrix differences (matrix effects); and 2) have none or minimal con-
centration of analytes of interest and still retain as many physiological properties as possible 
[168]. 
In the absence of a source of human serum with no detectable hepcidin-25 levels, sera from 
other species were investigated as potential surrogate matrixes. To reduce the probability of 
interferences, the species were selected to offer a sufficient mass difference of hepcidin-25 as 
compared to humans (Table 3.5). Sheep and bovine serum were chosen for further investiga-
tions. However, bovine serum showed interferences with the MRM quantifier of isotope-la-
beled hepcidin-25 (data not shown). 
Table 3.5: Hepcidin-25 mass comparison in different species. 
Species Hepcidin-25 
exact mass 
Human 2787.025 
Rabbit 2776.116 
Mouse 2752.068 
Bovine 2749.062 
Sheep 2703.103 
In contrast, sheep serum did not interfere with the assay. Also, further investigations revealed 
that the produced signal suppression was lower than 35% (see section 3.3.4.2. and 3.3.4.3.), 
which was considered acceptable. Therefore, sheep serum was further used as analyte-free sur-
rogate matrix. 
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3.3.4.2. Acidic mobile phases - TFA-containing 
The methods applied for evaluating the validation parameters were described in section 2.6. 
Sheep serum calibrators and quality control (QC) samples were prepared in the dynamic range 
of 0.5-40 µg/L using Protocol I (see section 2.3.1.2.). 
Specificity 
Two MRM transitions used as qualifiers for both “light” and “heavy” hepcidin-25 were fol-
lowed for each run (sheep and human samples). The maximum permitted tolerance for relative 
ion intensities (% MRM qualifier/MRM quantifier) of > 20% to 50% as in the case of both 
“light” and “heavy” hepcidin-25 was confirmed to be within the acceptance criteria (± 25%) 
[83]. Also, the LC elution profiles of the qualifiers were monitored, by considering a retention 
time tolerance of less than 0.05 min [201]. 
Linearity 
The calibration line (7-point calibration) based on the spiked sheep serum standards (0.5, 1, 2, 
5, 10, 20, 40 µg/L) showed an r2 value of 0.999 (Figure 3.41). 
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Figure 3.41: 7-point calibration curve (y=0.862x+0.020) by LC-MS/MS analysis em-
ploying acidic mobile phases (0.1% TFA) in the dynamic range 0.5-40 µg/L. 
LOQ and LOD 
LOQ and LOD were determined at 0.5 µg/L (Figure 3.42) and 0.15 µg/L respectively (see sec-
tion 2.6). 
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Figure 3.42: LC-MS/MS chromatograms of sheep serum samples at LOQ (S/N = 10) 
using TFA-containing solvents. 
Precision and accuracy 
Hepcidin-25+21 (13C1815N3) was used as IS to minimize errors during sample preparation and to 
compensate for the instrumental variations in the MS analysis. 
Intra-assay precision and accuracy were assessed by analyzing triplicates of five sheep serum 
samples on the same day. For the evaluation of the inter-assay precision and accuracy, three 
quality control (QC) samples, for high (25 µg/L), medium (10 µg/L) and low (2 µg/L) level 
were prepared. These were then tested in five replicates on consecutive days. 
Recovery and matrix effects 
The recovery of hepcidin-25 after sample preparation was 99% using two QC samples (5, 10 
µg/L). The evaluation of matrix effect resulted in 30% signal suppression, which was calculated 
by comparing hepcidin-25 peak areas in neat solution to peak areas in sheep serum. 
Table 3.6: Analytical figures of merit of the LC-MS/MS quantification method of 
hepcidin-25 in serum using acidic mobile phases (0.1% TFA). 
Hepcidin-25 conc. (µg/L) 40 20 10 2 0.5  Acceptance criteria 
Intra-assay CV (%) 2.6 5.8 8.7 5.5 16.9  < 15% (LOQ < 20%) 
Intra-assay accuracy (%) -1.0 3.6 1.7 -7.6 -18.6  < ±15 % 
        
Hepcidin-25 conc. (µg/L) 25 10 2     
Inter-assay CV (%) 7.4 7.6 7.0    < 15%  
Inter-assay accuracy (%) -4.1 -11.5 -12.4    < ±15% 
        
Hepcidin-25 conc. (µg/L) 10 5      
Recovery (%) 99 99     > 95%  
Matrix effect - signal sup-
ression (%)  31 30     < 35% 
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Carryover 
Carryover was observed in samples with hepcidin-25 concentration >20 µg/L. A blank injection 
was applied immediately after such samples to eliminate the chances of carryover to the subse-
quent samples. Pre-verification experiments of the unknown human samples determined at 
which point carryover might occur. Blank injections were introduced at this level.  
3.3.4.3. Basic mobile phases - NH3-containing 
The validation procedures applied were described in section 2.6. The preparation of sheep se-
rum calibrators and quality control (QC) samples was performed in the concentration range of 
0.3-40 µg/L using Protocol II (see section 2.3.1.3.). 
Specificity 
Specificity was assessed as described in the previous section (see section 3.3.4.2.). The toler-
ance for relative ion intensities did not exceed ±25%. 
Linearity 
The standard curve was determined over the dynamic range of 0.3-40 µg/L (Figure 3.43). A 
linear regression was used for calibration using 8 points (0.3, 0.5, 1, 2, 5, 10, 20, 40) with an r2 
value of 0.999.  
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Figure 3.43: 8-point calibration curve (y=0.871x+0.014) by LC-MS/MS analysis em-
ploying basic mobile phases (0.1% NH3) in the dynamic range 0.3-40 µg/L. 
LOQ and LOD 
An excellent limit of quantification (0.3 µg/L) was achieved (Figure 3.44) in case of the basic 
mobile phases. Moreover, a LOD value of 0.1 µg/L was obtained. 
Precision and accuracy 
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The measurements of the spiked sheep serum samples were determined to be accurate with a 
relative error of <15%. Good precision was achieved with a coefficient of variation (CV) value 
below 15%. The recovery of hepcidin from sheep serum was 95% and matrix effects led to 30% 
of signal suppression. 
Carryover 
Carryover was assessed as described in the previous section (see section 3.3.4.2.). 
Table 3.7 compiles the validation parameters obtained for the LC-MS/MS quantification 
method using basic mobile phases (0.1% NH3) and their corresponding acceptance criteria. 
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Figure 3.44: LC-MS/MS chromatograms of sheep serum samples at LOQ (S/N = 10) 
using basic solvents (0.1% NH3). 
In conclusion, both developed LC-MS/MS methods employing acidic and basic solvents were 
carefully validated and found to comply with the acceptance criteria. The method using NH3-
based mobile phases was discovered to be less robust, perhaps due to high volatility of ammo-
nia. 
Table 3.7: Analytical figures of merit of the LC-MS/MS quantification method of 
hepcidin-25 in serum using basic mobile phases (0.1% NH3). 
Hepcidin-25 conc. (µg/L) 40 20 10 2 0.5  Acceptance criteria 
Intra-assay CV (%) 2.8 3.0 4.3 2.8 5.6  < 15% (LOQ < 20%) 
Intra-assay accuracy (%) 1.1 -3.1 -1.8 -2.4 13.4  < ±15 % 
        
Hepcidin-25 conc. (µg/L) 10 5      
Recovery (%) 95 95     > 95%  
Matrix effect - signal sup-
ression (%)  29 30     < 35% 
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3.3.5. Intra-laboratory comparison of two LC-MS/MS methods  
Previous efforts for standardization of hepcidin-25 measurements in two international round 
robin exercises employed the analysis of identical human samples with different methodologies 
[203, 204]. The obtained discrepancies between the results were partly caused by the usage of 
different calibrators and the lack of a reference material, and partly because of the fact that the 
used immunoassays cannot distinguish the different isoforms properly, while MS-based meth-
ods selectively detect the bioactive hepcidin-25 (see section 1.3.3.1.). Other publications about 
hepcidin quantification compared newly developed MS methods to commercially available im-
munoassays as reference method [198, 136]. No correlation was achieved, most likely due to 
different analytes compared. 
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Figure 3.45: Comparison of serum hepcidin-25 levels measured by LC-MS/MS using 
acidic mobile phases (LC-MS/MS 1) and basic mobile phases (LC-MS/MS 2) in healthy 
patients, n=7 (logarithmic scale). 
In the present research work, an intra-laboratory comparison of two independent MS-based 
assays for the quantification of hepcidin-25 was performed using the same calibrators to assess 
the accuracy of these methods. The two LC-MS/MS methodologies described in the previous 
sections, namely the method employing acidic (see section 3.3.3.1.) and basic mobile phases 
(see section 3.3.3.2.), were applied to nine human samples for the assessment of hepcidin-25. 
The amount of peptide in native samples was determined using a 7-point and 8-point calibration 
curve respectively, as presented in section 2.5.4.1. The serum levels of hepcidin-25 varied in a 
broad range. Therefore, a logarithmic scale seemed suitable for the comparison of the methods. 
A significant positive correlation (r2=0.999) between the two LC-MS/MS methods was found 
(Figure 3.45) and the Bland-Altman plot confirmed the commutability of these assays (Figure 
3.46). It should be noted here that the samples with concentrations lower than LOQ (n=2) were 
not considered for the correlation. 
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Figure 3.46: Comparison of serum hepcidin-25 levels measured by LC-MS/MS using 
acidic mobile phases (LC-MS/MS 1) and basic mobile phases (LC-MS/MS 2) in healthy 
patients, n=7 (Bland Altman plot). 
These results suggested that both methods are suitable for hepcidin-2 quantification, particu-
larly when a reference material is available. 
3.4. Reference method candidate for clinical assessment of hepcidin-25 in 
human serum  
3.4.1. Recommended LC-MS/MS method for hepcidin-25 quantification in rou-
tine laboratories 
Two sample preparation strategies and two chromatographic separation conditions have been 
investigated with the aim of developing a LC-MS/MS method that could serve as a reference 
method for the sensitive and reliable quantification of hepcidin-25, and could be implemented 
in routine laboratories. In order to be able to recommend a methodology in this sense, several 
clinically-relevant criteria were evaluated, including the time of the analysis, the costs involved 
and the sample volume required. These aspects were considered in addition to the analytical 
figures of merit that have been discussed previously (see section 3.3.4.). 
Due to short sample preparation time, small sample volume necessary for the analysis, rela-
tively reduced hepcidin-25 extraction costs and superior robustness (see section 3.3.4.3.), the 
LC-MS/MS method employing TFA-containing mobile phases is proposed as the methodology 
for routine analysis in the clinical field. An overview of the method parameters and a critical 
evaluation of the measurement uncertainty will be presented further. 
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Table 3.8: Correlation between quantification methods and selected criteria. 
Criteria relevant for clini-
cal use 
LC-MS/MS using TFA-
based mobile phases 
LC-MS/MS using NH3-based mobile 
phases 
Sample preparation time +++* 
(10 min centrifugation) 
+* 
(20+220 min centrifugation, overnight 
freeze-drying) 
Sample volume required +++* 
(300 µL) 
+* 
(1.2 mL) 
Sample preparation costs +++* 
(ACN, TFA) 
++* 
(ACN, TFA, Hydrosart membrane fil-
ters, liquid nitrogen) 
 * Very good +++, good ++, fair + 
3.4.1.1. Scheme of the reference method candidate for hepcidin-25 quantification 
Figure 3.47 represents a scheme comprising the three essential steps of the developed LC-
MS/MS reference method candidate. First, amino- or fluoro-silanized glass vials were em-
ployed to avoid hepcidin-25 losses due to its sticky character. Cost-effective extraction of the 
peptide from serum samples was achieved applying acetonitrile (38%)-trifluoroacetic acid 
(2%)-precipitated serum. Then, reversed phase chromatographic separation, by using a highly 
inert C18 column, was obtained. Finally, sensitive and precise MS/MS detection was achieved 
by employing a triple quadrupole mass spectrometer being operated in MRM mode. 
3.4.1.2. Uncertainty budget of the reference method candidate 
The measurement uncertainty as defined by CLSI is a non-negative parameter, which charac-
terizes the dispersion of the quantity values being attributed to the analyte, based on the infor-
mation used. This parameter may be, for example, a standard deviation called standard meas-
urement uncertainty or the half-width of an interval, having a stated coverage probability [168]. 
To determine the uncertainty of the measurement, one must determine the sources of variability 
(random error) and bias (systematic error).  
In the case of the developed LC-MS/MS methodology for the quantification of hepcidin-25, the 
main elements which influence the precision and accuracy of the method are the sample prep-
aration, the ionization process and the purity of the standards. 
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Figure 3.47: Work flow for the reference method candidate for hepcidin-25 quantification in human serum (*Reproduced with permission 
of Advanced Chromatography Technologies Ltd, UK).
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Random error - precision 
As mentioned before, “heavy” hepcidin-25 is used as IS to correct the loss of analyte during 
serum treatment (protein precipitation) and the matrix effects during analysis. Thus, the 
precision of the measurement is mainly influenced by the reproducibility of the MS signal, 
given by the standard deviation of the LC-MS/MS analysis. By measuring triplicates, this 
was determined to be <15% (<20% at 0.5 µg/L), as described in section 3.3.4.2. 
Systematic error - accuracy 
The accuracy of the method is significantly influenced by the purity and the preparation of 
the standards. In this regard, the type of calibration used determines if the “light” or “heavy” 
hepcidin-25 contributes to the accuracy. Generally, two approaches are popular for peptide 
calibration, namely single-point calibration and the use of standard curve. In the single-
point calibration, a known quantity of the IS (isotope-labeled peptide) is added to a sample 
and then the signal of the target analyte is measured relative to the internal standard, by 
taking into consideration the so-called response factor (see section 1.3.2.3.). This approach 
demands high chemical purity and isotope enrichment of the IS. By such, the internal stand-
ard influences the accuracy of the measurements [194]. However, several limitations in the 
use of a single-point calibration, such as poor day-to-day reproducibility and the inability 
to confirm that the measurements are within the linear range, restrict its application in rou-
tine analysis [194, 201]. Therefore, the standard curve approach was selected in this study. 
The CLSI guidelines indicate that calibration curves which represent ranges of up to three 
orders of magnitude should incorporate 6 to 8 standards [168]. Thus, a 7-point calibration 
curve was considered for the quantification of unknown samples in the dynamic range of 
0.5-40 µg/L. In this respect, the MRM intensity of the analyte (“light” hepcidin-25), nor-
malized to the internal standard (“heavy” hepcidin-25), was plotted against the correspond-
ing concentration ratio. A constant amount of “heavy” hepcidin-25 (10 µg/L) was added to 
several “light” hepcidin-25 standards of known quantity that spanned the selected dynamic 
range. This approach implied that the “heavy” hepcidin-25 improved the quantitative pre-
cision, while the accuracy of the results relied on the purity of “light” hepcidin-25, in con-
trast to the single-point calibration. In this regard, the standard solutions of hepcidin-25 
were prepared gravimetrically as described in section 2.3.1.1. to lower the error compared 
to pipetting [168]. 
Uncertainty budget 
To conclude, the elements contributing to the uncertainty budget are the standard deviation 
of the LC-MS instrumentation (up to 15%), the purity of hepcidin-25 as stated by the man-
ufacturer (> 95%, HPLC analysis) and the uncertainty of the balance (approximately 0.01-
0.5% in the range 20-1000 mg). Being majorly influenced by the standard deviation values, 
the measurement uncertainty can also be referred to as the standard deviation (coefficient 
of variation) of the LC-MS analysis. 
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3.4.2. Hepcidin-25 levels in healthy individuals 
The chosen LC-MS/MS methodology employing acidic mobile phases (0.1% TFA) was 
applied to determine variations in hepcidin-25 levels in healthy donors. Human sera from 
nine individual subjects, in the age ranging from 24 to 54, were analyzed. The amount of 
Hep-25 in the unknown samples was determined by using isotope-labeled hepcidin-25 for 
internal calibration and a 7-point calibration curve in the dynamic range of 0.5-40 µg/L for 
external calibration (see section 2.4.5.1.).  
The concentration of hepcidin-25 in the clinical samples ranged from <0.5 µg/L to 25.6 
µg/L. The mean (arithmetic mean) and median values were calculated by considering the 
two samples < LOQ with an assigned value of 0.25 µg/L (LOQ/2). A median of 1.9 µg/L 
and a mean value of 6.2 µg/L were obtained. The standard deviation for the mean value 
was 9.3.  
Table 3.9: Physiological level of hepcidin-25. 
Affiliation Quantification 
method 
Patient 
no 
Mean  
(µg/L) 
Median  
(µg/L) 
Concentration 
range (µg/L) 
Ref. 
Eli Lilly 
and Com-
pany 
LC-MS/MS 
(Triple Quadrupole) 10 9 3.6 <1.0 - 45.6 [195] 
Sandwich ELISA 100 
 
N/A 1.2 <0.02 - 25 
(44% < 0.9 µg/L) 
[144] 
Present 
work 
LC-MS/MS 
(Triple Quadrupole) 9 6.2 1.9 
<0.5 – 25.6 
(33% < 0.9 µg/L) [225] 
 
The physiological level of hepcidin-25 in humans seemed to vary widely, as has been ex-
tensively reported in literature [144, 136] (see section 1.3.3.3.). The results fitted the values 
established previously (physiological median level of 1-5 µg/L and mean level of 5-15 
µg/L) (see section 1.3.3.3.). Moreover, the obtained values were found to be directly in line 
with the results reported by the research group of Eli Lilly and Company (Table 3.9). 
The developed LC-MS/MS method represents a suitable reference method candidate for 
accurate hepcidin-25 quantification in human serum, particularly when a certified reference 
material (CRM) will be available. In this regard, the calibration of the method by applying 
a secondary reference material (sRM), which was developed in the frame of the ongoing 
hepcidin-25 harmonization studies (see section 1.3.3.1.), will be described in the following 
section.   
3.4.3. Participation in the international Hepcidin Harmonization Study 
(HHS2017)   
Hepcidin-25 harmonization efforts, carried out by Radboud University Nijmegen and hep-
cidinanalysis.com, identified a commutable secondary reference material (sRM), which 
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consisted of native lyophilized serum with cryolyoprotectant, to be used for hepcidin-25 
quantification [132]. In the next step, the Hepcidin Harmonization Study 2016 (HHS2016) 
aimed at the validation of commutability of this sRM and its functionality to increase the 
degree of equivalence between measurement procedures for hepcidin-25 quantification. 
The conclusion of HHS2016 was that harmonization is indeed possible with the use of the 
newly identified sRM. The commutability of the reference material was approved. Also, 
the validity of the calibrator for harmonization purposes was confirmed through mathemat-
ical simulations [214].  
Finally, Radboud University Nijmegen and hepcidinanalysis.com organized a round robin 
study in June 2017 (Hepcidin Harmonization Study HHS2017) to establish whether har-
monization could be achieved. The secondary reference material consisting of two levels 
(middle and low) and native samples of three levels (high, medium, and low) were consid-
ered for the study. The participants were asked to measure the values of the native samples 
by applying the sRM for calibration. In order to lower the bias, the organizer’s request was 
to have the samples measured in triplicate within one run. Statistical methods were applied 
at Radboud University Nijmegen to determine the proximity of data of the sample values, 
and to find out whether harmonization has been achieved. The LC-MS/MS method em-
ploying TFA-containing mobile phases developed within the present work was one of the 
ten methodologies within the HHS2017. In the next sections, investigations on the calibra-
tor set and on the native samples will be described. 
3.4.3.1. Secondary reference material determination 
The two constituents of the calibrator set (level low and medium) were quantified using the 
developed LC-MS/MS methodology based on a 7-point calibration curve (see section 
2.5.4.2.) and were consequently compared to the assigned value (Table 3.10). This assigned 
value was selected by a consensus approach, based on the guidelines of the International 
Consortium for Harmonization of Clinical Laboratory Results [214, 226], as a mean value 
of 9 validated methods worldwide, namely 5 MS-based methods and 4 immunoassays 
[214]. 
Table 3.10: Calibrator set values [214]. 
Calibrator 
level 
Mean value (SD) of 9 val-
idated methods (II) [µg/L] 
/ nM 
Obtained value (SD) by 
BAM Berlin (III) 
[µg/L] / nM 
1 (low) 6.65 (3.41) 2.38 (1.22) 
3.48 (0.22) 
1.25 (0.08) 
2 (medium) 19.64 (8.80) 7.03 (3.15) 
9.90 (0.17) 
3.55 (0.06) 
   
Although the two compared values showed differences, a constant comparative factor of 
0.5 was obtained, when expressing the value recorded in this study (BAM Berlin) relative 
to the consensus value. This shows that the deviations between aforementioned values were 
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actually most likely caused by the differences in absolute values of the calibrators, rather 
than the methodology used. 
3.4.3.2. Native samples quantification 
In the next step, three unknown human samples were determined by LC-MS/MS using two 
quantification approaches (without and with the use of sRM), applied in different analytical 
runs as described in section 2.5.4.2. (Table 3.11). 
Table 3.11: Hepcidin-25 quantification approaches. 
 Quantification without sRM Quantification with sRM 
Internal  
calibration Commercial “heavy” hepcidin (Peptide Institute) 
External  
calibration 
Commercial “light” hepcidin (Bachem) Calibrator set (hepcidinanalysis.com) 
7-point calibration curve 2-point calibration curve 
As expected, the ratio between the results of the above-mentioned quantification ap-
proaches stayed the same as the comparative factor of 0.5 obtained from the calibrator set 
determination. This confirmed that the discrepancies between the results were basically 
because of different calibrators used. At this point, it is difficult to say which material would 
be more suitable for an accurate assignment of hepcidin-25 reference levels, the commer-
cially available standard with a reported HPLC purity >95% (Bachem, Bubendorf, Swit-
zerland) or the calibrator set with a consensus value obtained as a mean of 5 MS-based 
assays and 4 immunoassays. Nevertheless, a primary reference material, also known as 
certified reference material (CRM) is required for the assignment of absolute hepcidin-25 
values, which would ensure metrological traceability to the International System of Units 
(SI). 
The performance of the LC-MS/MS method was compared to the other participating meth-
ods. Figure 3.48 shows the degree of equivalence between the results of the ten selected 
methods worldwide, expressed as the total allowable error (TEa) based on the recommen-
dations of the International Consortium for Harmonization of Clinical Laboratory Results 
[226]. These results represented the quantification values obtained for the three unknown 
samples by applying each method. Because of the absence of a true value, the x-axis rep-
resents the mean results of the samples for all methods. The y-axis shows the bias, that is 
to say the difference between results of individual samples of each method and the mean 
of all methods. The lines represent limits for optimum, desirable and minimum TEa. Under 
these conditions, the LC-MS/MS method developed within this study stayed within the 
optimal TEa. 
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Figure 3.48: Degree of equivalence between measurement results, expressed as 
total allowable error (TEa), obtained after calibration with sRM. Blue dot – LC-
MS/MS method by BAM Berlin (Figure provided by Dorine Swinkels, Radboud 
University Nijmegen). 
These findings support the notion that the developed reference method candidate, compared 
to the other existing quantification methodologies, represents an excellent choice for the 
quantification of hepcidin-25 in native samples. In this context, it is worth mentioning that 
the method developed in this research work (at BAM Berlin) was the only LC-MS/MS 
method participating in HHS2017 from Germany. 
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Conclusions and Outlook 
The main scope of this study was to develop and validate a reliable tool for the quantifica-
tion of hepcidin-25 in human serum. For this purpose, the characterization of the analyte in 
terms of its structure, solubility and copper-binding properties was achieved and different 
quantification strategies were tested. 
As a starting point, a methodology was developed for the “in house” folding of linear hep-
cidin-25, resulting in one sole folded product, as determined by HPLC. The comparison of 
its retention time and its MS isotope pattern to a commercial hepcidin-25 standard con-
firmed the identity of the folded 25-amino acid peptide with a reported disulfide connec-
tivity of Cys7-Cys23 (1-8), Cys10-Cys13 (2-4), Cys11-Cys19 (3-6) and Cys14-Cys22 (5-
7). The folding procedure showed good yields (10-50%) and was further applied to produce 
multi-milligram amount of the peptide. In future, ion mobility mass spectrometry IM-MS 
could be employed as a complementary technique able to separate isomers and for further 
investigation of partial and total oxidation of the cysteine residues. Also, the disulfide con-
nectivity should be attributed to the folded products (in different stages of the folding pro-
cess), using for example partial reductive alkylation. 
In addition, the solubility of the peptide in different solvents and at different pH values was 
tested using HPLC. The peptide was found to be most soluble in acidic solutions (1% acetic 
acid or 0.1% TFA) using polar solvents (40% ACN). This was later confirmed by LC-
MS/MS analysis. Also, the addition of methanol (20-50%) improved the solubility of hep-
cidin-25, particularly in the pH range of 7.4 to 8.5. In this regard, the synthesis of labeled 
hepcidin-25 with a fluorescent dye was achieved at a pH of 8.5 by using 50% methanol 
(v/v). 
Moreover, the first chromatographic separation of hepcidin-25 and its complexes with cop-
per(II) was achieved by employing ammonia-containing mobile phases (pH 11) and phe-
nyl-hexyl HPLC columns with extended pH stability. LC-MS/MS investigations of hep-
cidin-25 complexes with copper(II) ions using the triple quadrupole revealed two species 
at a pH of 11.2, namely hepcidin-25/Cu2+ and hepcidin-25/2Cu2+. HR-MS (FTICR-MS) 
confirmed the isotope patterns of the two compounds and established that the first copper 
ion binds the peptide with the loss of two H+, while the second copper interacts with hep-
cidin-25 without any deprotonation. Furthermore, at pH 7.4, the mono-copper(II) species 
is preferentially formed. Additional NMR structural analysis permitted the development of 
the first 3D-model of the Cu2+-bound hepcidin-25. The results of these investigations (LC-
MS/MS, FTICR-MS and NMR) clearly support the hypothesis that hepcidin-25/Cu2+ rep-
resents the native form of the iron regulator in the human body. 
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However, sample preparation techniques that preserve the metal complex (pH>5) need to 
be further developed in future for the LC-MS identification/quantification of the copper 
peptide in biological samples. Additionally, the bioactivity of hepcidin-25/Cu2+ should be 
compared to hepcidin-25, (by monitoring the internalization of ferroportin) to determine, if 
a copper(II)-assisted modulation of biological activity occurs in the case of hepcidin-25. 
Lastly, the steps required for the LC-MS/MS quantification of hepcidin-25 in human serum, 
namely sample preparation, chromatographic separation and MS/MS detection, were in-
vestigated and optimized. In this regard, it was shown that special laboratory ware is needed 
for storage and handling of the hepcidin-25 stock solutions and for the assessment of the 
peptide in human serum, because the charge of the peptide and its amphipathic character 
make it readily stick to plastic or glass surfaces. Silanized vials were developed, which 
provided inert surfaces able to reduce the adsorption of the peptide to the walls of the au-
tosampler vials (at concentrations below 1 mg/L). It was found that using glass-based 
equipment led to significant peptide losses. Applying plastic-based laboratory ware instead 
caused lower adsorption effects, however, some instability of the signal was recorded. On 
the contrary, amino- and fluoro-silanized vials showed practically no MS (MRM) signal 
instability and could be used for precise, accurate and sensitive peptide quantification. 
Amino-silanized vials were employed throughout this study for preparation and storage of 
hepcidin-25 standard solutions and fluoro-silanized vials were utilized for LC-MS/MS 
analysis of serum samples.  
Two isotope dilution (ID-)LC-MS/MS methodologies were developed and validated for the 
quantification of hepcidin-25 in human serum by applying isotope labeled hepcidin-25 
(13C18, 15N3) as an internal standard. The triple quadrupole mass spectrometer operated in 
MRM mode was successfully employed for this purpose. The first method used acidic mo-
bile phases (0.1% TFA) and a fast and cost-effective peptide extraction based on acetoni-
trile-TFA precipitated serum (38% and 2% respectively). The second method employed 
basic mobile phases (0.1% NH3) at a pH of 11 and a more complex sample preparation 
protocol, comprising protein precipitation and ultrafiltration as clean-up steps, followed by 
freeze-drying for pre-concentration purposes. The two quantification methods were vali-
dated over the dynamic range of 0.5-40 µg/L (TFA-based mobile phases) and 0.3-40 µg/L 
(ammonia-containing mobile phases) in accordance with the guidelines of the Clinical and 
Laboratory Standards Institute (CLSI). A Bland-Altman plot validated the commutability 
of the two assays, when these were applied to human serum. 
Due to quicker sample preparation and superior robustness, the LC-MS/MS method using 
acidic mobile phases was chosen as a reference method candidate for the quantification of 
hepcidin-25 in serum samples. The method presented very good analytical figures of merit 
in terms of sensitivity (LOQ 0.5 µg/L) and reproducibility (CV <15%), and was shown to 
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be suitable for routine analysis. The method was applied to assess the variability of hep-
cidin-25 in healthy subjects. A mean physiological level of approximately 6 µg/L (concen-
tration range <0.5-25 µg/L) and a median value of 2 µg/L were determined. These results 
were found comparable to previously reported values obtained by Eli Lilly and Company 
by employing two different analytical techniques (a sandwich ELISA and a LC-MS/MS 
method using a triple quadrupole system). Additionally, the recommended reference 
method candidate stayed within the optimum total allowable error as defined by the Inter-
national Consortium for Harmonization of Clinical Laboratory Results in an international 
harmonization study (HHS2017) organized by Radboud University Nijmegen and hepcidi-
nanalysis.com, which assessed the degree of equivalence between the results of ten vali-
dated quantification methods by using a secondary reference material as calibrator set. Five 
immunoassays and five MS-based techniques were compared in this study. 
In future, the assignment of the absolute levels of hepcidin-25 in healthy individuals using 
a primary reference material (or certified reference material (CRM)) is desired to reach 
hepcidin-25 standardization. A candidate, in this vein, is under development at LNR (La-
boratoire National de métrologie et d’Essais), Paris, France. Physiological and pathological 
reference ranges of hepcidin-25 should be assessed by a reference method (calibrated using 
a CRM) in order to define clinical decision limits. 
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